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ZDemographics and Healthcare System in Vietnam 
Vietnam is a country in South East Asia, with a surface area of 331,668 square kilometers. 
Geographically, it is bordered by China to the North, Cambodia and Laos to the East and the South 
China Sea to the West. The country consists of 64 provinces and four regions: the Northern, Central, 
Highlands and Southern parts. In 2010, the population was estimated at 87 million [1]. The gross 
national income (GNI) per capita was US$ 1,010 in 2009 [1]. The estimated health expenditure in 2008 
was 7.3% of the gross domestic product (GDP), with government expenditure accounting for only 38.5% 
of total expenditure for health [2]. Vietnam was ranked 113 on the Human Development Index1 with a 
life-expectancy of 75 years in 2010. The under-five mortality rate was 19 per 1,000 live births [3].  
The Vietnamese health system is a mixed public-private provider system, in which the public sector 
plays a major role in healthcare provision, policy making, research and training. The private sector has 
grown steadily since the health sector reform in 1989, but is mainly active in outpatient care while 
inpatient care is still provided through the public sector. The healthcare network is organized under state 
administrative units: central, provincial, district, commune and village levels, with the Ministry of Health 
coordinating at the central level. In the public sector, there are 774 general hospitals, 136 specialized 
hospitals and 11,576 primary health centers [4]. As of 2008, the number of doctors, nurses and 
pharmacists per 1,000 inhabitants was 0.65, 0.78 and 0.12, respectively [4]. The uniqueness of the 
Vietnamese health system is characterized by the establishment of the grassroots healthcare network, 
which provides health services at the lowest levels, (i.e. commune and district). It is the foundation for 
healthcare achievements highlighted by the attainment of national healthcare goals for the entire 
population. A milestone was the delivery of healthcare services to the people in the most remote 
regions, that are highly inaccessible and where transport is difficult. Additionally, the contribution from 
the private sector to the Vietnamese health system has increased remarkably during the past two 
decades since the health care reform, highlighted by the presence of 83 private hospitals, accounting 
for ~8.2% of the total number of hospital nationwide thus far [4].This helps to reduce the overload of 
patients in public hospitals in Vietnam. 
The goals of Vietnam’s health system is to provide curative care of diseases, preventive care through 
immunization, training and education of the healthcare workforce and developing health policies. In this 
thesis, I focus on the immunization strategies in Vietnam and explicitly on the health economics of 
immunization strategies against selected diseases, applying new and underused vaccines. 
Immunization is a very important part of the public health in Vietnam and the immunization system is 
organized from the lowest level of the health system (so-called the commune health center). In very 
remote areas where transport is cumbersome and not easily accessible, outreach posts and mobile 
services are additionally provided. Due to limited human resources for health especially in rural and 
remote regions, the majority of immunization in Vietnam is provided through fixed immunization days 
                                                          
1
 The Human Development Index (HDI) is a summary composite index that measures a country’s average 




(~2 days per month) at community health centers. However, in bigger cities, immunization services are 
provided daily. Universal vaccination against selected diseases is implemented through the Expanded 
Programme on Immunization (EPI), which is centrally run by the National Institute of Hygiene and 
Epidemiology (NIHE) [5]. Figure 1 describes the operational structure of the National Expanded 
Programme on Immunization.  
ZExpanded Programme on Immunization 
The EPI in Vietnam was established to promote and provide free universal childhood immunization. The 
program started in 1981 and is one of the most successful national priority health programs. In 1989 the 
goal of universal childhood immunization in Vietnam was achieved, with a national coverage of 87%. At 
present, there are 9 vaccines in the EPI’s immunization schedule: bacillus-calmette-guerrin (BCG), 
diphtheria-tetanus-pertussis (DTP), hepatitis B, polio, measles, tetanus, cholera, Japanese encephalitis 
(JE) and typhoid. Some are generally administered on a national level and others are administered in 
high risk areas only (Table 1).  
 
In addition, the government of Vietnam has set up several national EPI goals to be achieved by 2012, 
which include achieving universal immunization at a national coverage of 90% of children; maintaining 
the nation’s polio-free status; eliminating maternal and neonatal tetanus, eliminating measles; achieving 
hepatitis B control by 2012, and introducing new vaccines such as rotavirus vaccines [5;6]. 
 
The scope of this thesis is to focus on health economic aspects of the implementation of hepatitis B 
vaccination, which has been universallyimplemented in Vietnam since 2002, and of rotavirus 
vaccination, which ispotentially included in the EPI in the near future. In particular, the rotavirus vaccine 
has recently been recommended by the World Health Organization (WHO) on universal implementation 
worldwide. 
Hepatitis B immunization 
Epidemiology 
The hepatitis B virus (HBV) is one of the most prevalent blood borne viruses worldwide and is a major 
cause of chronic liver diseases and hepatocellular carcinoma (HCC) [7;8]. Vietnam is a high-endemic 
country of HBV infection. Several epidemiological studies carried out in Vietnam showed that the 
prevalence of chronic hepatitis B surface antigen (HBsAg) carriers is between 8.8% and 20.5% across 
different populations and regions in Vietnam [9;10]. Therefore, with the population estimated at 87 
million in 2010 [1], a large number of Vietnamese people will be at risk of premature death due to HBV 
infection. In addition to the costly antiviral therapy to treat chronic hepatitis B infection, HBV 
immunization has become one of the best preventions against the disease. Therefore, in 1992, the 
WHO recommended that all countries should include universal HBV vaccination in their national 





Figure 1 Operational structure of EPI system in Vietnam [5] 
 
Vaccine Targeted time of administration Total no. of doses Where applied 
Bacillus-calmette-guerrin (BCG) At birth 1 Nationwide 
Diptheria-Pertussi-Tetanus (DPT) 2,3,4 months 3 Nationwide 
Hepatitis B (HepB) At birth, 2, 4 months 3 Nationwide 
Oral Polio Vaccine (OPV) 2,3,4 months 3 Nationwide 
Measles 9 months, 6 years 2 Nationwide 
Tetanus Pregnant women 2 Nationwide 
Neonatal tetanus Child-bearing age women (CBAW) 15-35 3 High risk areas 
Cholera 2-5 years 2 High risk areas 
Japanese Encephalitis (JE) 1-5 years 3 High risk areas 
Typhoid 3-10 years 1 High risk areas 






Hepatitis B immunization is part of the EPI’s activities in Vietnam since 1997. Initially a locally produced 
vaccine was used, but supply constraints limited its usage to a small number of districts. Financial 
support from the Global Alliance for Vaccines and Immunization (GAVI) enabled the introduction of 
hepatitis B vaccine (produced outside of Vietnam) on a national level, covering about half of the districts 
in 44 provinces in 2002, and the remaining districts in these provinces in 2003. Locally produced 
vaccine is still used in the other 17 provinces. However, universal HBV immunization was only 
completed by mid-2003 in Vietnam. In particular, the hepatitis B third dose coverage increased from 
less than 20% in 2000 to more than 90% in 2005 [12]. In the meanwhile, the policy on hepatitis B birth 
dose was gradually changed from administration within 3 days of birth to less than 24 hours after birth, 
according to the WHO recommendation [12]. Universal hepatitis B immunization will support the 





Diarrhoea is a leading cause of child mortality and rotavirus has been identified as the most common 
cause of severe diarrhoea [14;15]. A large share of the mortality and morbidity caused by diarrhoea 
occurs in developing countries such as Vietnam [16]. Results from a sentinel surveillance network for 
rotavirus conducted in six major hospitals in four principal cities in Vietnam in 1998 showed that 
rotavirus was detected in 56% of all under five-year-old children, who were hospitalized for severe 
diarrhea [16;17]. The national data indicate that approximately 15.4% of all deaths among these 
children are due to diarrhoea. If rotavirus were associated with one quarter or one half of these 
diarrhoeal deaths, the yearly rotavirus-associated deaths among under five-year-old children would be 
between 4%-8% or, correspondingly, 1 in every 300 children would die of rotavirus-related diarrhoea 
[16;17]. With the 2010 birth cohort of more than 1,550,000 newborns, the risk for children to suffer from 
rotavirus-related morbidity and mortality would be very high. 
 
Immunization  
Currently, rotavirus vaccines have not yet been introduced in the EPI in Vietnam although two 
worldwide-approved rotavirus vaccines, RotaTeq® (Merck) and RotarixTM (Glaxo Smith Kline), have 
been available since 2006 [18;19]. These vaccines have demonstrated good protection against rotavirus 
infection and against rotavirus-related severe diarrhoea [20-22]. Studies on rotavirus immunization 
using either these vaccines have proved their effectiveness in potentially protecting the lives of nearly 2 
million children in the next decade alone [23] as well as its acceptable economic impacts to countries’ 
healthcare systems. Therefore, the WHO has expanded its recommendations to include rotavirus 
vaccines into countries’ immunization programs [24]. Importantly, the WHO and the GAVI have 
committed to provide financial support to developing countries such as Vietnam in expediting the 





ZAim and Outline of the Thesis 
The general aim of this thesis is providing an overall picture of the cost-effectiveness of the current 
universal hepatitis B immunization and the recommended universal rotavirus immunization in the 
developing world with a specific focus on Vietnam as the example. The actual analyses are carried out 
to evaluate the cost-effectiveness results using Vietnam’s epidemiological and costing data. In the 
absence of local data, data from other countries, where the epidemiology of hepatitis B and rotavirus 
are the most similar to Vietnam, have been used. All cost-effectiveness analyses are performed using 
Markov models. Based on the cost-effectiveness results on universal immunization against hepatitis B 
and rotavirus, recommendations are provided to Vietnamese health decision-making authorities in order 
to find appropriate ways for sustaining immunization, appropriate policies to support the success of the 
EPI program are proposed and evidence is provided supporting applications for external funding from 
the international health community. 
 
The thesis is structured into two parts. In Part I the epidemiology and economics of hepatitis B 
immunization in developing countries are presented, with a focus on Vietnam. In particular, chapter 2 is 
a comprehensive review of hepatitis B immunization programs in developing countries. Cost-
effectiveness results of immunization strategies in the developing world are summarized to provide 
information on the success and challenges that developing countries have achieved and encountered 
during the implementation of universal hepatitis B immunization. The chapter sets the scene for the 
original studies presented in the subsequent chapters. Chapter 3 presents a cost-of-illness study of 
chronic hepatitis B in Vietnam. The study summarizes the financial burden an average Vietnamese 
would bear when being chronically infected with hepatitis B, as well as the cost burden incurred to the 
health system of Vietnam regarding the disease in its various stages. In chapter 4 a cost-effectiveness 
analysis was performed to assess results of the current universal hepatitis B immunization in Vietnam. 
In this study, additionally a cost-effectiveness affordability curve was derived to propose different 
budgetary thresholds at which hepatitis B immunization would become both cost-effective and 
affordable for the Vietnamese government. For comparison, a contrasting picture of the hepatitis B 
situation in a developed country, the Netherlands was provided as an annex to this chapter. In this 
annex, information on drug utilization for the treatment of chronic hepatitis B was presented using 
information on drug use from pharmacy-dispensing data from community pharmacies in northern 
Netherlands. The data were obtained from the University of Groningen’s IADB.nl database 
(www.iadb.nl), which harbours information on drug utilization from 55 community pharmacies and 
covers more than 500,000 people since 1999. Additionally, the methodology for pharmacy data 
gathering was applied to Vietnam, enabling the aforementioned cost-of-illness study in chapter 3.  
 
Part II of the thesis discusses the potentials and challenges of implementing rotavirus immunization in 
developing countries, again with a focuson Vietnam. Chapter 5 provides an overview of cost-
effectiveness results of universal rotavirus immunization in the developing world once the vaccine is 
officially included in countries’ immunization programs. Cost-effectiveness results of immunization 




challenges that developing countries would achieve and encounter if the vaccine were introduced based 
on the WHO’s recommendations. The chapter also emphasizes the important role of the GAVI in 
assisting developing countries to introduce rotavirus vaccines. To resolve several challenges faced by 
developing countries in carrying out rigorous studies on cost-effectiveness of rotavirus vaccination, 
chapter 6 provides an overview of several cost-effectiveness models on rotavirus vaccination, which 
would eventually benefit middle and low-income countries in designing cost-effectiveness analyses 
using new or adapting existing models. In a more elaborated and practical fashion, chapter 7 presents 
a cost-effectiveness analysis of rotavirus vaccination in Vietnam using one of the economic models 
recommended in chapter 6. The study presents the results of rotavirus vaccination in Vietnam as well 
as challenges faced by the Vietnamese health sector if vaccination were introduced in the future.  
Finally, in chapter 8 the main findings of the studies as presented in the previous chapters are 
summarized and discussed and an outlook and future perspectives are given. In more details, 
challenges and limitations faced by developing countries in estimating the cost-effectiveness of 
preventive interventions for infectious diseases are pointed out. More importantly, suggestions on how 
to improve the quality of cost-effectiveness studies are suggested. Recommendations are also provided 
to aid health decision-making in Vietnam and other developing countries for a sustainable and good 
immunization program against infectious diseases in children in the future. 
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Economic evaluations, in particular cost-effectiveness, are important determinants for policy makers and 
stakeholders involved in decision-making for health interventions. Up until now, most evaluations of 
cost-effectiveness of hepatitis B vaccination have been performed in developed countries. Appropriate 
health-economic studies on this topic specifically targeted at the developing world are essential in order 
to justify adding another vaccine into the existing Expanded Program on Immunization in these 
countries. We present a systematic review of economic evaluations of vaccination against HBV for 
developing and less-developed countries. Vaccine price, the discount rate, incidence and prevalence of 
HBV infection were found to be major drivers of cost-effectiveness. Data accuracy and reliability were 
also major issues, with major potentials for improvement in studies of these countries. The choice 
between monovalent or combination vaccines (diphteria, tetanus and polio-hepatitis B) poses new 
challenges to cost-effectiveness analysis. It is concluded that for many developing countries 
implementation of universal immunization against HBV to reduce the level of endemicity of hepatitis B is 
an appropriate strategy, and probably cost effective in many settings. Given their limited financial 
resources, developing countries should properly plan how to achieve this. Further country-specific 
economic evaluations and related gathering of high-quality data must be conducted in developing 
countries in order to raise both public awareness of the effectiveness and economic attractiveness of 
universal immunization against HBV. 
  




HBV is one of the most prevalent blood borne viruses worldwide, responsible for liver diseases and 
hepatocellular carcinoma. It is an important public health problem in developing countries where the 
endemicity of the disease is generally high or intermediate and is less a problem in developed countries 
(Table 1). Despite the availability of effective vaccines for two decades, HBV still contributes 
substantially to global morbidity and mortality. It is estimated that over 350 million people in the world 
are currently chronically infected with HBV [101]. They are at high risk of death from liver cirrhosis and 
liver cancer diseases that kill over 1 million people each year. The epidemiology of HBV is one of the 
key factors in determining the cost-effectiveness of the vaccination program against the virus. Over 
time, thanks to universal HBV vaccination in developing countries, more and more children in these 
countries benefit from vaccination, which in turn reduces the level of endemicity in high and 
intermediate-risk countries. 
 
In 1992, the WHO recommended that all countries should include universal HBV vaccination in their 
national immunization programs. In particular, three doses of the HBV vaccine should be supplied 
regardless of the prevalence of infection. The WHO set this target for all highly endemic countries by 
1995 and two years later for all other countries [102]. However, owing to reasons such as different levels 
of endemicity and poor availability of funds for universal vaccination, strategies have not been fully 
implemented across the world. In December 2007, 171 countries had included the HBV vaccine into 
their national infant immunization programs compared to 31 countries at the start in 1992 [103].  In 
various developed countries, HBV vaccination has been limited to specific risk groups (ethnic minorities, 
healthcare workers, sexual partners of chronically infected persons, homosexual men and children of 
immigrants from high-endemic countries). In developing countries, universal HBV vaccination has mostly 
been given to newborns and infants, and not yet been extended to other groups such as adolescents 
owing to the financial limitations. However, hepatitis B continues to be an important public health 
problem in these areas because the infection is spread by maternal transmission at birth. 
Children in the poorest countries do not receive HBV vaccines because their governments cannot afford 
it (high vaccine prices compared to limited budgets given to the health sector), the poor healthcare 
infrastructure (vaccine storage facilities, delivery systems) and there is a lack of effective public health 
policies. Recently, however, with the support of the Global Alliance of Vaccines and Immunization 
(GAVI), vaccines have been made available for many developing and less-developed countries [104]. 
 
Thus far, little is known about cost-effectiveness and cost-utility of vaccination against HBV in the 
developing world as compared to the developed world. Very few such studies have assessed hepatitis 
B immunization in developing countries. This review aims to give a systematic view on HBV vaccination, 
with a focus on developing countries and economic evaluation. The paper summarizes the results and 
methodologies of the formal CEA and other economic evaluations on different HBV vaccination 
strategies. Furthermore, we analyze the current implementation of HBV immunization strategies in 




attempts to introduce HBV vaccine into their routine immunization programs. Up front, we realize that 
divergent results on cost-effectiveness ratios of various immunization strategies might sometimes be 
related to methodological issues in economic evaluations, in addition to other aspects such as 
demography, cultural characteristics and prevalence of HBV. Intuitively, for developing countries, 
vaccine price is among the most critical factors and cost-effectiveness is key in deciding upon the 
introduction of the vaccine into the national Expanded Program on Immunization (EPI). This review 
concludes with an explanation of possible options to assist health policy-makers of developing countries 
to formulate appropriate health policies in making this vaccine available to their people in a cost-
effective manner. 
 
Level of endemicity Prevalence (%) Chronic carrier Rate2 (%) Regions Recommended strategies 
High 70-95 8-20 
Tropical Africa, South America 
(Amazon Basin)South-East Asia, 
parts of China and the Pacific 
Basin 
Universal infant vaccination 
(+/- HBIG administration)  
Intermediate 20-55 2-7 
Southern Europe, Eastern 
Europe, Russia, Middle East, 
Japan, North Africa, the Indian 
Sub-continent, parts of South and 
Central America 
Universal immunization of 
infants and/or adolescents 
or immunization of high-
risk groups (all ages) 
Low 4-6 <2 North America, Western Europe 
and Australia 
Universal immunization of 
infants, adolescents or 
both  groups Immunization 
of high-risk groups 
Immunization of infants in 
subpopulations with high 
endemicity 
HBIG: Hepatitis B immunoglobin 
Data taken from [28-30] 
 
Table 1 Distinction between regional immunization strategies against HBV, based on levels of 





Relevant economic evaluations of hepatitis B vaccination were searched using the PubMed and 
Embase databases. Keywords for retrieval were ‘hepatits B’ and ‘cost(-)effectiveness’ or ‘cost’ or ‘costs’ 
or ‘economic evaluations’ and ‘vaccination’ and ‘developing countries’. In total, 202 potentially relevant 
articles published between 1993 and 31 January 2008 were retrieved. Figure 1 describes in detail the 
diagram of the literature search. 
 
Eligibility criteria 
Further eligibility criteria stipulated that: 
• Studies should be strictly classifiable in one of the formal health-economic categories of cost-
effectiveness, cost-utility, or cost-benefit analysis (CEA, CUA and CBA, respectively); 
• Studies should be written in languages that could be mastered by the authors’ team [1] 
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21 
Abstracts retrieved from the electronic databases were independently screened by two members of the 
research team (Maarten J Postma and Hong-Anh T Tu). Disagreements were resolved through 
discussion. Studies that were deemed relevant at this first screening were retrieved in full-text format 
and screened by one reviewer for further eligibility. After excluding letters and editorials, 11 different 




Detailed information was abstracted using a pre-specified data extraction form. Items of the form 
included author(s), publication year, country, approach, validation/calibration of models, type of 
sensitivity analysis, perspective and outcome.  
For our review, we specifically focus on economic modeling, the perspectives taken (societal vs. 
healthcare), discount rates, vaccine costs, epidemiology of HBV and specific immunization strategies 
(universal vs. selective). Generally, these aspects are well known to reflect important issues in the 
health-economics of vaccines 
ZResults 
General 
We found 11 relevant studies in total, focusing on the economic evaluation of HBV vaccination in 




the Western Pacific Region accounts for 50% of deaths from hepatitis B despite the fact this region only 
accounts for one third of the world’s population [5]. All countries in this region have introduced HBV 
immunization into their national vaccination programmes. The region has set 2012 as the target date for 
reducing the current level of endemicity of 8%-10% to less than 2% among children under five years old 
and to less than 1% as the final goal [106]. Three studies come from India [1, 6, 7], a country of 
intermediate endemicity of HBV.  Four out of 11 studies [8-11] are from Africa. All of African countries 
involved in these studies were eligible for GAVI fund support. In Africa, by 2000 only six countries had 
introduced the HBV vaccine into their national immunization programmes, however, 25 additional 
countries implemented vaccination in 2005. The African region has set a goal of integrating the hepatitis 
B vaccine into the national immunization programmes of all countries in the region by 2009 [12]. One 
study originated from Iran [13] in the Middle East”. 
The oldest paper that emerged from our search was from 1993 [11] dealing with an analysis of costs 
and benefits of HBV vaccination in China and the most recent one was from 2007 [8], addressing the 
economic evaluation of HBV vaccination in low-income countries, using cost-effectiveness analysis 
inclusive affordability curves. Most of the developing countries under study could be classified into 
intermediate or high endemicity (Table 1). The most relevant aspects of these studies are summarized 
in Table 2. 
Study Characteristics 
Depending on the level of endemicity of HBV across countries as well as on the fund availability for 
implementing hepatitis B immunization, the choice of the specific immunization strategy can be either 
universal or targeted (selective). Universal vaccination strategies were evaluated in 8 of the 11 studies. 
All focused on universal vaccination of newborns and infants. Targeted vaccination strategies were 
evaluated in 2 of the 11 studies (i.e. vaccination of high-risk groups). One study did not specifically 
focus on either strategy but rather performed an inventory of potential cost components. 
Specific vaccination strategies differed on details among these studies. In particular, the differences 
related to the exact comparisons made in the analyses. These aspects are summarized in Table2. 
Detailed Results on Economic Evaluations of Hepatitis B Immunization Strategies against HBV 
Universal Vaccination 
Prevention of HBV infection by universal vaccination has long been recognized as an effective means 
for reducing healthcare costs associated with the disease [14]. The effectiveness of universal HBV 
immunization programmes has been demonstrated in many countries; epidemiological data and 
economic evaluations have shown that universal HBV vaccination is potentially highly cost-effective. 
However, universal vaccination is still being postponed in many countries such as in the UK, the 
Scandinavian countries and the Netherlands [15], also due to uncertainties on the actual cost-
effectiveness of the vaccine. From a healthcare point of view, one could argue that vaccinating the 
entire population to prevent the transmission of the virus, potentially leads to reducing the burden of 
various hepatitis B-related diseases. Below, we briefly summarize all studies included in our review. 
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Kim et al.analyzed the situation in the Gambia, being the first African country in which HBV 
immunization was introduced on a routine basis to newborns, in 1990 [8]. Striking in this study was the 
use of cost-effectiveness affordability curves, which gave probabilities of a vaccination programme to be 
both cost-effective and affordable by showing different acceptability thresholds. A multivariate 
uncertainty analysis was conducted to drive the affordability curve and showed the probability of an 
affordable programme under different budget options. 
This is the only study in the review, which applied formal cost-effectiveness affordability curves.  The 
cost-effectiveness affordability curves can also provide information to decision makers for choosing a 
proper vaccine programme while facing uncertainties about the health and economic outcomes of such 
a programme, as well as of the resources required to make the programme run. The authors concluded 
that it was cost-effective for universal infant vaccination to be implemented in the Gambia when cost-
effectiveness thresholds exceeded US$ 97 per DALY averted and not cost-effective when the 
thresholds were less than US$ 25 per DALY averted (the Gambia’s per-capita GDP equals 
approximately US$ 300). With an estimated US$47 per DALY averted, from a payer’s perspective, the 
possibility of the programme being cost-effective would be 65%. 
Vimolket et al. [2] conducted a cost-effectiveness analysis of maternal HBsAg screening and 
vaccinating at-risk babies in Thailand. Four vaccination strategies were suggested: screening all 
pregnant women for HBsAg,  vaccination plus HBIG to those who have HBsAg positive (1); screening 
all pregnant women for HBsAg and HBeAg (if HBsAg+) and providing the vaccine and HBIG to those 
HBeAg+ (2); universal vaccination of all neonates (3); and no vaccination (4). Assessing these four 
strategies, the authors recommended that universal newborns vaccination to be continued, as the cost-
effectiveness per case prevented was lowest (US$ 37.76) compared to the other alternatives. The 
authors emphasized that if the funds were available, the second strategy would be additionally 
worthwhile since it both promoted universal vaccination and protected at risk newborns to HBsAg+ 
mothers with both vaccination and provision of HBIG. This will certainly increase the efficacy of the 
overall HBV prevention programme. However, this in turn raises the issue of supplying HBIG and 
equipments for HBsAg pregnant mothers, which may reflect major constraints in many developing 
countries. Different from the study in Gambia, the study did not analyze any cost-effectiveness 
thresholds to further guide decisions on funding immunization strategies against HBV. 
Griffiths et al. [22] performed the first cost-effectiveness study of a health intervention in Mozambique 
[9]. Mozambique receives support from the GAVI in the introduction of HBV vaccine. However, in the 
long run the country itself has to finance the vaccine procurement. The authors wanted to calculate the 
cost-effectiveness of introducing the HBV vaccine into the national immunization programme. A strong 
point of this study is the application of a model designed for WHO in estimating disease burden caused 
by HBV, which helps to calculate exact numbers of deaths averted by age and sex due to the 
introduction of HBV vaccine in the Mozambique. A further advantage of the model is the limited amount 
of data required for specific calculations. Cost per DALY averted and the number of deaths averted 




(DPT-Hepatitis B) and monovalent hepatitis B vaccine were calculated. The authors convincingly 
showed that the monovalent vaccine against HBV was more cost-effective than the combined vaccine 
of DPT and HBV (US$15 and US$36 per discounted DALY averted, respectively or US$178 and 
US$436 per death averted, respectively). It was also estimated that nationwide 4,000 deaths were 
averted per annum by the introduction of the vaccine.  
Aggarwal et al. elaborated on the cost-effectiveness of universal HBV immunization of newborns for 
low-income and intermediate endemic countries using a Markov model [1]. The study showed that 
universal vaccination against HBV in early childhood reduced the hepatitis B carrier rate from 4% to 
1.15%. Estimated life expectancy and QALY gains were 0.173 years (61.072 vs. 60.899) and 0.213 
QALYs (61.056 vs. 60.843 QALYs). The incremental ratios per LYG and QALY were US$16.27 and 
US$13.22, respectively. Compared to the GDP per capita in India, these figures show that universal 
immunization against HBV may be highly cost-effective. The authors also emphasized that the results 
from this study could be used for other low-income and intermediate-endemic countries that are 
comparable to India and thus help health administrators of those countries in decision making regarding 
universal HBV vaccination. However, the study also stressed some constraints in conducting this type of 
research. In particular, this concerned limited available data in low-income and intermediate-endemic 
countries on diseases progression, absence (of information on) treatment of hepatitis B complications 
and the cost components building a cost-effectiveness analysis of HBV vaccination. For example, this 
specific study had to use data from other regions such as disease progression data from high-endemic 
and low-income countries. 
In another study focusing on India, Prakash addressed a different point of view [7]. Instead of 
conducting a cost-effectiveness analysis per se, Prakash analyzed crucial parameters potentially 
affecting cost-effectiveness of universal HBV immunization. India is classified as a country of 
intermediate to high hepatitis B endemicity with a prevalence rate of 2.5-10% [16]. Costs of the vaccine 
and vaccine efficacy were important factors influencing the analysis. Vaccine price per pediatric dose 
was around US$0.75 if purchased through EPI programme. If the costs of the vaccine could be reduced 
to US$0.60, the cost per DALY averted would be reduced another approximate 5%. At the time of this 
study, India had not integrated the HBV vaccine into the national EPI due to its large population and the 
relatively high vaccine price. Also, HBV prevalence was rather intermediate than high by that time [17]. 
These sheer numbers raised the question of how to make universal hepatitis B immunization in India 
implementable and cost-effective. Targeted immunization did not seem to be a feasible option for an 
overpopulated country as India since it would not relevantly affect transmission and only achieve limited 
prevention in an at-risk subpopulation (such as newborns to hepatitis B-infected mothers).  
In contrast to the two above-mentioned Indian studies, Sahni et al. shifted the analysis towards cost-
benefit of universal immunization against HBV [6]. They compared selective vaccination against HBV 
given to newborns of HBsAg-positive mothers and universal vaccination given to all newborns. The 
authors argued that in the particular context of India - where 65% of mothers delivered at home - 
universal HBV vaccination of newborns was not cost-beneficial because the discounted cost of saving 
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each QALY (Rs 259,610 or US$ 5,192; at 3% discount rate) was  ten times higher than the per capita 
GNP (Rs 20,250 or US$ 405). It was concluded that universal immunization was not cost-beneficial if 
compared with selective immunization.  
In another cost-benefit analysis from 1995, Liu et al. concluded that universal vaccination in China 
would be cost-saving with BCRs2 between 42.41 and 48.01 [3]. The study analyzed mass vaccination of 
all newborns in Jinan City in 1990. The author analyzed three different strategies: (i) screening and 
vaccination of all newborns born to HBsAg+ mothers with 3x10µg vaccine; (ii) screening and 
vaccination of only those children born to HBsAg+ mothers with a relatively high dosage (3x30µg); and 
(iii) vaccination of all newborns with a normal dosage. The administration of vaccination to newborns 
was assumed at 0, 1 and 6 months, respectively. The second strategy appeared to be the most cost-
beneficial strategy. Yet, the other two strategies also seemed very beneficial, and the study concluded 
that if there was enough supply of HBV vaccines, all newborns should be vaccinated. 
The Gambia was one of the African countries that actively introduced the hepatitis B vaccine into its 
national immunization programme in 1986. Hall et al.calculated that adding the hepatitis B vaccine to 
the EPI in Gambia would increase the marginal cost to US$4.2 per child for three doses of vaccine [11]. 
Similar to other studies, vaccine price contributed the biggest part in the increase of the total cost of the 
EPI programme (80%). The study showed that through vaccination against HBV, the cost per averted 
death from liver cancer would be between US$150-200, which would be comparable with other EPI 
vaccines. It was obvious in the study that vaccine price per dose was the major factor which could be 
manipulated to improve cost-effectiveness. A combined vaccine against DPT and hepatitis B could 
reduce the vaccine price and improve the cost-effectiveness by hedging the cost of labeling and 
administration (for example, personnel costs, storage and supplies). At the time the Gambia’s study was 
conducted, the GAVI fund did not yet exist and the study did not clearly show if hepatitis B vaccination 
was cost-effective. However, 13 years later, when Kim at al. conducted another study in the Gambia, 
routine immunization was estimated to be very cost-effective in that country [8]. These authors 
concluded that vaccinating infants against HBV reduces the burden of HBV-related diseases by more 
than 80%. 
All universal HBV vaccination programmes discussed in this review were done on newborns and infants 
(8 studies) [1,2,5-9,11]. Universal vaccination of newborns was generally considered cost-effective and 
appropriate for the control of HBV infection in regions of medium and high endemicity, which is the case 
in most developing countries. A further common conclusion from all of the studies was that vaccine 
price was an important and critical factor influencing cost-effectiveness and the decision of health 
administrators of respective countries to introduce the vaccine in their national immunization 
programmes. Results also showed that EPI programmes could effectively facilitate the implementation 
of HBV immunization through discount procurement of the vaccine with the support from GAVI, 
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extending vaccine coverage through administration together with DPT, and using existing facilities set 
up within the EPI framework. However, the combination vaccine DPT-hepatitis B cannot be used “at 
birth”, because the pertussis component is contra-indicated until 6 weeks of age. Thus, if countries want 
to use the combined of DPT- hepatitis B vaccine, the birth dose would be monovalent hepatitis B 
vaccine, and from the second dose onwards the combined vaccine can be used. The other option would 
be to start the vaccination series from the six weeks onwards with the combined vaccine. 
Targeted Vaccination 
Two of the studies included in this review focused specifically on target groups: pre-marriage couples in 
Iran [12], and soldiers in the People’s Liberation Army in China [3].  
 
In the study from Iran, Adibi et al. were convinced that in the Iranian society, targeted vaccination of pre-
marriage couples was an effective and feasible way to prevent virus transmission [12]. The study 
underpinned that targeted immunization did help to protect this at-risk population (at the time this study 
was conducted, Iranian children of 10 years or older had not received HBV vaccination). Two strategies 
to reduce HBV infections were tested: (i) HBsAg screening to find those would-be couples that are 
HBsAg positive and provide them with HBV vaccination, single dose HBIG and condoms; and (ii) 
HBsAg screening as in the first strategy in addition to HBcAb screening in HBsAg negative spouses of 
HBsAg + persons followed by the same protocol to HBcAb negatives. The first strategy was found a bit 
more expensive than the second (US$ 202 vs. US$ 197). However, the authors yet seemed to favor the 
first strategy because it consisted of fewer steps and would be easier to manage.  
In the most recent Chinese study on HBV, Hu et al. did an assessment of the cost-effectiveness of 
vaccination against HBV targeted at soldiers serving in the People’s Liberation Army (PLA) [3]. To 
identify the optimal vaccination strategy, the authors evaluated two different strategies: (i) immediate 
vaccination; and (ii) screening and vaccination. Both were compared with no vaccination. DALYs were 
used to assess the effectiveness of the respective strategies. A hypothetical cohort of 1,000 men and 
women was monitored for 5 years and separated into four groups according to age (15-20; 20-30; 30-
40; >50). It was concluded that screening followed by vaccination was the most cost-effective scheme 
for this particular population with US$57 per DALY, compared to immediate vaccination with US$61.89 
per DALY. It was suggested that the sooner vaccination was implemented the more beneficial it would 
be for the PLA. This was the only study in the review focusing particularly on adults. 
It is clear that universal immunization against HBV in developing countries where HBV endemicity is 
high or intermediate is cost-effective and cost-beneficial on the long run. However, funding issues and 
resource mobilization are still big barriers for developing countries. Griffiths et al.came to the conclusion 
that the full benefits of a vaccination programme were only realized after some time (in the case of the 
study in Mozambique, it required 40-50 years) [9]. This concern should not distract from the importance 
and urgency of executing a universal or targeted vaccination programme in a given country. Griffiths et 
al. concluded that targeted vaccination against HBV should only be a   temporary solution as long as 
financial resources are not available to initiate a universal programme [9]. 
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One study by Edmunds et al. focused on the analysis of composition of cost components when 
introducing HBV vaccine into Ethiopia’s EPI [10]. The authors introduced a method for estimating the 
additional costs incurred of introducing a new vaccine. It was concluded that the cost of the hepatitis B 
vaccine was the majority part of the cost of introducing HBV vaccine into the EPI. The cost-
effectiveness of HBV vaccine would be most sensitive to the vaccine cost. This is the only study, which 
was not focused on either universal or targeted vaccination but on cost composition. 
General model characteristics 
Table 3 shows that the vaccine price per pediatric dose ranged from US$0.27 to US$1 for the 
monovalent hepatitis B vaccine provided that administration cost was not included in these vaccine 
costs. It was shown that through national EPI programme, the hepatitis B vaccine could be procured at 
reduced prices, which helped countries much in introducing the vaccine into their national immunization 
programmes. The adult dose, as shown in the Iran study, was much higher at US$4.8 per dose than for 
newborns. Net costs per health outcome indicator (QALY, DALY, LYG, or death averted) were very 
diverse across countries and studies. These diversities could be explained by the selection of different 
cost base years, epidemiological data, costing techniques, applied modeling techniques and varying 
discount rates. Indeed, given the potential large time span between HBV infection and hepatitis B 
disease, there was a big difference between discounted and non-discounted outcomes within and 
across studies. A Markov model was generally used for disease progression and the typical structure is 
drawn in Figure 2.  
 
Discounting 
Discounting addresses the issue of translating values obtained from one time period to another. 
Discounting makes current costs and benefits worth more than those occurring in the future because of 
an opportunity cost to spending money now and there is desire to enjoy benefits now rather than in the 
future. Cost and benefits, certainly often in case of vaccination, often occur at different point in time. 
For example, in the case of HBV vaccination benefits are not generated immediately, but obviously only 




As summarized in Table 3 three studies used the same discount rate of 3% per year for both cost and 
health effects [7-9], which is in line with the WHO guidelines on discounting [19]. Three studies 
discussed in this review only discounted costs and not health effects. They all applied the 
recommended rate of 3%. In a few studies in this review, health outcomes were both reported 
discounted and undiscounted in the base case. Two studies used 6% only for costs [10,11]. For 
example, in the Gambia’s study by Hall et al.[23]the 6% discount rate was the difference between the 
interest rate of treasury bills and the national inflation rate in mid-1988 [11]. Three studies [2-4] did not 
state any discount rate. In the case of Thailand [2], the authors only calculated costs and effects for one 




The studies reviewed in this paper mainly concerned cost-effectiveness analyses (CEA) and cost-
benefit analyses (CBA) (see Table 2). Of the 11 studies, eight were cost-effectiveness analyses (i.e. 
health gains expressed in one-dimensional natural units, infections prevented or life-years gained) 
[1,3,6-11], two were cost-benefit analyses (i.e. health gains converted into monetary terms, such as 
dollars) [2,5], and one analysis combined both techniques [12]. Some of the CEAs could be further 
classified as cost-utility analyses or CUAs (i.e. health gains expressed in integrated units adjusted for 
quality, such as quality adjusted life-years (QALYs) or DALYs) [3,5-8]. The explanation for the popularity 
of CEAs over CBAs may be that valuing health in monetary terms is quite difficult. Moreover, cost-
minimization analysis (CMA) was only applied in of the study by Edmunds et al., where CMA was 
applied next to CEA [10]. The authors mentioned CMA as an instrument to investigate reductions in 
vaccine price and to show potentials for improving cost-effectiveness of HBV vaccination in low-income 
countries. 
 
Most of the studies performed CEAs from a societal perspective except for the study conducted by Kim 
et al [24], in which a CEA was carried out from both the societal and the healthcare perspectives [8]. 
The results of the CEAs in our review were quite divergent, depending on various factors such as the 
specific vaccination strategies compared, particular populations considered, outcome measurements 
used etc. Vimolket et al. [2] and Hu et al. [4] both conducted CEAs of various strategies giving different 
results based on the specific context of HBV in Thailand and China. Different from other studies such as 
in Hall et al. [11], Griffiths et al. [9] concluded that monovalent vaccines against HBV would be more 
cost-effective than the combined DPT-Hepatitis B vaccine. The results in this study perhaps could be 
explained by the context of Mozambique and the deviation between the procured price of the 
monovalent vaccine from the combined vaccine. Our findings in this respect are similar to the 
conclusions of Beutels in an earlier review [20]. Although different methodologies and different types of 
economic analyses could lead to divergent results even for the same country on the short run (e.g. 
universal vaccination against HBV was cost-effective in India in one study [6] but not if analyzed by 
Sahni et al. [6]), all authors of studies under review came to the same conclusion that hepatitis B 
vaccination was cost-effective in the long-run. Vaccine price was identified as the most influential factor 
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affecting the cost-effectiveness of immunization against HBV and whether this vaccine was integrated 
into the national immunization programmes in several studies [6,7,9-11]. 
Modeling approaches 
Cost-effectiveness analyses in this review used different modeling approaches. Theoretically, basic 
typologies of models used in the CEAs concerns static versus dynamic and decision tree versus Markov 
model (Figure 2). 
 
Some studies explicitly used a Markov model, for example, Prakash [7] and Aggarwal et al.[1]. Some 
problems with these Markov models did emerge. For example, in the study by Aggarwal et al. acute or 
fulminant stages of the disease were not included[1]. Moreover, there were few published data on the 
disease progression rate especially for the low- and intermediate-income countries to fill the Markov 
models that were applied. Thus, the authors had to apply rates from other regions. The point of 
unreliable data on costs of treatment was raised by Griffith et al. [9] in the study for Mozambique. Four 
studies from Thailand [2], Iran [12] and China [3,4] used straightforward decision trees for calculation. 
Yet, unable to grasp all the details of more complex Markov models or even dynamic models, decision 
trees may certainly provide insights in the crude relations between costs, savings and health gains 
within the cost-effectiveness framework. 
All studies in the review applied static models (see Table 2). Dynamic transmission models were not 
applied in these studies. Typically, dynamic models take the spread of infections explicitly into account 
and generally use formal mathematics to define its structure. Oppositely, in a static model, the force of 
infection is constant over time (or changes as a function of age or other individual-based factors) [21]. In 
a dynamic model, the probability of an individual acquiring an infection is dependent on the contact 
patterns of that individual in the interactions with others, the infectiousness of the infection and the 
distribution of infections within the population over time [21]. 
Uncertainty analysis 
Uncertainty analyses have been applied in various studies (Aggawal et al.[1], Prakash et al. [7], Kim et 
al.[8], Griffiths et al. [9], Hallet al.[11]). They were used to deal with different types of uncertainties 
popular in cost-effectiveness analyses (such as parameters uncertainty, model uncertainty, and 
modeling process uncertainty). For example, in the study by Kim et al., a multivariate uncertainty 
analysis examined the affordability of a vaccination under different budget options [8]. In Aggawal et al., 
one way sensitivity analysis and Monte Carlo simulation were utilized to examine the robustness of the 
study’s results [1]. In Prakash et al., parameters uncertainty was inherent, where the epidemiology was 
the most crucial factor affecting the cost-effectiveness of the vaccination programme [7]. In Griffiths et 
al., probabilistic uncertainty analysis show how much cost-effectiveness ratios can deviate [9]. In this 
study, cost-effectiveness was found to be most sensitive to the epidemiology of HBV infection and the 
rate of clearance of HBsAg. In the study by Hall at al. [11], uncertainty analysis was applied to the 




ZDiscussion and Policy Recommendation 
Most of the existing studies on HBV immunization in high- and intermediate-endemic developing 
countries provide clear evidence that universal HBV immunization of newborns and infants is cost-
effective or even cost-saving in comparison with no vaccination. Only one study by Sahni et al. 
concluded that universal immunization against HBV was not economically attractive on the short term 
[6]. The conclusion by Sahni et al. emphasized that countries’ traditions (for example, 65% of mothers in 
India deliver babies at home) might have important impacts on the outcomes of economic evaluations of 
vaccination programmes. In terms of epidemiology, in high- and intermediate-endemic countries, 
universal immunization appears to be the most cost-effective option to combat HBV infection related 
morbidity. 
 
So far few studies on the economic evaluations of HBV vaccination were done in developing countries, 
thus, the results and conclusions summarized in this review might not be representative for the current 
situation in all these countries. Some studies in the review even date back to the early 90’s, e.g. the 
study from China [3] in 1995 and the study from Gambia in 1993 [11]. In these studies, the data might 
be out-of-date and the current HBV epidemiology in these countries might have changed. In particular, 
the determinants for designing an appropriate HBV vaccination programme depend on many time-
varying factors (e.g. epidemiology, funding, demography, cultural practices, etc).  
The studies, albeit few in number, have shown that for developing and less-developed countries, it is 
very important to design an effective and appropriate HBV vaccine policy in order to make the vaccine 
available for universal immunization against HBV. To shape such a policy, many determinants should 
be considered, including both vaccine value and health systems characteristics. Both may be of equal 
importance in this. Vaccine value characteristics include the disease burden to be prevented, safety and 
performance, and cost effectiveness. For policy makers in countries with limited health budgets, disease 
burden has been the most important factor in setting priorities for current and new vaccines to be 
integrated into the national immunization programmes. In other words, the higher the endemicity, the 
more urgent and attractive it is to introduce a new vaccine into the routine vaccination programme of the 
country [22]. The second vaccine value characteristic relates to safety and performance. One of the 
concerns for health policy makers is the safety and low rates of side effects when making a decision to 
introduce a new vaccine. Hepatitis B vaccine has been proven to be effective with duration of immunity 
up to 15 years and with an efficacy up to 75-90% [23]. All of the studies in this review also assume a 
vaccine efficacy of up to 90%. Cost-effectiveness is the final vaccine characteristic to determine whether 
a vaccine should be introduced. Economic evaluations and cost-effectiveness analyses help determine 
if vaccination is economically attractive for the society in the long run and if vaccines’ effectiveness 
outweighs the costs. Many studies in the review have concluded that vaccine price is a critical factor 
influencing the cost-effectiveness of the immunization programme. 
The second set of crucial factors considered by policy makers relates to the health-system 
characteristics. An important question is whether the health care system can support the proposed 
intervention. For example, is reliable cold storage available and can the required number of doses be 
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administered at appropriate times? In the case of the HBV vaccine, an additional important question to 
be asked is whether indeed a birth dose can effectively be implemented within 48 hours for children 
from HBV-positive mothers. Thus, introduction of a new vaccine requires a well-functioning 
infrastructure, including well-trained staff. 
HBV is moderately to highly endemic in developing and less-developed countries. However, lack of 
financial resources has prevented many countries in the region from launching universal immunization. 
Thus, all universal immunization strategies against HBV studied in this review were targeted at 
newborns and infants. Facing such constraints as financial viability, resource limitations, poor health 
infrastructure, universal vaccination against HBV for adolescents or a wider population, for example in 
catch-up settings, could not yet be achieved in these countries.  
Certain limitations have been found in the studies throughout the review. In all studies reviewed in this 
paper, static models or straightforward calculations without formal models were used for evaluating the 
cost-effectiveness of different immunization strategies against hepatitis B. Dynamic models were not 
utilized in any of the studies conducted in this review, possibly because they required a lot of input data, 
which is indeed one of the major limitations faced by developing countries. Lack of data is a striking 
disadvantage of studies conducted in developing countries if compared to studies in developed 
countries. In particular, several dynamic models were applied and developed in research for developed 
countries, such as the study by Kretzschmar et al. [24]. Further limitations refer to different 
methodologies and a variety of uncertain parameters crucially influenced the results of economic 
evaluations of the vaccination programmes. One example is the application of the same or of different 
discount rates for costs and health effects, an issue yet to be resolved but imminently influencing 
outcomes of HBV economic analyses.  
There are a lot of ongoing debates on whether health outcomes/effects and costs should be discounted 
at the same rate, which should theoretically be so if market perfection exists. Gravelle et al. argued that 
when health effects are valued in monetary terms as in a CBA, both cost and health effects should be 
discounted at the same rate [25]. However, when health effects are measured in quantities (QALYs) as 
in CEAs and the value of health effects increases over time, it was argued that health effects should be 
discounted at a lower rate than costs [25]. Literature shows that there are also other economists, who 
favor using a lower rate for health effects than for costs. Parsonage et al. recommended that health 
effects should be discounted at a lower rate than cost, which in turn was reflected by the UK 
Department of Health’s recommendations for evaluation of health interventions during the nineties and 
early 21st century [26]. This review is not intended to advise which discount rates to be used for health 
and effects, it merely describes which rates have been applied. It is useful to present both discounted 
and non-discounted cost and health effects since there are a large difference between results. It assists 
policy-makers in the judgment of a future life against a present investment and consequently makes a 
suitable decision in choosing the appropriate health interventions in a particular country. None of the 




A further limitation concerns the data. Different studies have addressed the issue of unreliable data of 
treatment costs on complications of hepatitis B. Limited data on disease progression rate is available, 
carrier rate is under reported. For example, studies also show that due to data limitations, a lot of 
assumptions were made in analysis (e.g. in Sahni et al. findings in a small part of India was generalized 
to the whole country; epidemiological data in Aggarwal et al.was gotten from other regions, etc). 
Generally, Cooper et al. also came to the same conclusion about the different sources of data, the need 
to make various assumptions on disease progression, non-transparency of identifying input data to use 
in these models [27] and even the bias created by researchers in choosing model structures and 
parameter values as inputs in models. Another problem is that none of the studies took the impact of 
herd immunity into account when estimating the long-term effects of hepatitis B vaccination. It is yet 
difficult to predict whether its inclusion would indeed drastically further improve cost-effectiveness and 
with which size.  
It is obvious that the vaccine price and the type of vaccine (monovalent or combined DTP-hepatitis B) 
chosen can be important determinants in implementing universal immunization in the developing world. 
Vaccine price has been shown as a constraint for deciding to introduce the vaccine into the national 
immunization programmes because it accounts for the larger part of the incremental cost generated due 
to the introduction. EPI programmes can effectively help to introduce the immunization against HBV and 
the vaccine procurement at a discount price. Few studies mentioned the importance of the GAVI fund 
[8,9] as a financial tool to help low-income countries to introduce the new and underused vaccines. 
Countries, which are considered to benefit from the fund, have the opportunities to vaccinate their 
newborns against HBV through their EPI programmes. Programmes costs, such as administration 
costs, costs related to keeping up the cold chain, etcetera, were mentioned in all cost-effectiveness 
evaluations. It was obvious that programme costs also contributed substantially to the total vaccination 
costs. However, EPI programmes also have advantages in this respect, for example in assisting the 
negotiations for procurement of hepatitis B vaccine at discount prices and in allowing use of existing 
facilities for the introduction of a new vaccine such as trained staff and existing cold chains. 
Developing countries need to raise cost-effectiveness issues even more than developed countries, in 
order to decide between universal and targeted vaccination strategies. Developed countries are 
currently of low endemicity due to the success of universal vaccination and/or “at-risk” strategies for 
targeted vaccination and lower baseline prevalence levels prior to vaccination implementation. In the 
developing world, where hepatitis B morbidity and mortality is the highest, cost-effectiveness of HBV 
vaccination is very attractive [28-30]. Sooner or later, such developing countries should implement 
universal vaccination for broader populations (not only for newborns and infants but also for adolescents 
and health workers). Using a combined vaccine (Hepatitis B-DPT vaccine) instead of a monovalent 
vaccine to increase the coverage and to reduce the administration costs might be an option to further 
improve cost-effectiveness.  
Some authors in the studies reviewed emphasized the contribution and benefits of the GAVI Alliance. 
GAVI Alliance is an organization, which mobilizes financial support from international donors and 
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organizations in supporting low-income countries by providing funding for new and underused vaccines 
including HBV vaccines. Thanks to the GAVI Alliance, children in many developing and less-developed 
countries in Africa and Asia have accessed to immunization against HBV, which makes the plan of 
integrating HBV vaccine into countries’ immunization programme more feasible. 
The results of the review show that immunization (either universal or targeted) against HBV is cost-
effective from the health care point of view and cost-savings for the society in the long run in terms of 
avoiding future treatment cost. Obviously, in general, immunization is a good preventive care practice. 
However, to make economic evaluations more rigorous and more properly designed, studies on cost-
effectiveness against HBV should be conducted in the developing world. Their outcome will assist 
policy-makers in designing appropriate health interventions and for planning the necessary resource 
allocation for executing HBV vaccination strategies. Universal vaccination in developing countries 
generally provides a relevant issue, in order to let policy makers know about financial needs and cost-
effectiveness in implementation. In the end this all contributes to the battle against life- threatening 
diseases caused by the HBV. 
ZConclusion and Expert Commentary 
On the basis of the available international literature on the economic evaluations of HBV immunization 
in the developing world, we conclude that it is cost-effective to implement universal immunization 
against HBV. Vaccine price is a dominant factor constraining developing countries from effectively 
implementing HBV vaccination universally. Possible options to overcome this problem include combined 
vaccines and support from the international community. Still, further high-quality economic evaluations 
are needed in the near future, for example, using dynamic models for simulating the spread of HBV in 
populations in developing countries. 
 
ZFive-Year View 
WHO has recommended that developing countries implement universal immunization against HBV. 
Each region has developed its own plan in order to achieve this goal. For example, the Western Pacific 
Region has set a goal to reduce chronic HBV infection rate to less than 2% by 2012 among children of 
five years old. Achieving this will however have high costs attached to it. On this issue and in general, 
decision makers in these countries must make choices about the best way to spend the limited 
resources available for the health of their populations. To be able to help policy makers to take evidence 
informed policy decisions on the issue, the research community must come up with convincing and 
locally relevant evidence. Therefore, high quality economic evaluations have to be done on the cost-
effectiveness of HBV immunization in different settings in the next five years. The cost-effectiveness of 
combined vaccines also deserves to be explored in the near future. Such combined vaccines may 
present options for relevant efficiency gains and cost savings. Such evidence would also be critical to 
gather financial support from international donors (e.g. GAVI fund). Countries that have more 
established infant immunization programmes, higher capacity and greater resources should consider 




years, developing countries should develop protocols or guidelines on different strategies for 
vaccination of older children (e.g. catch-up or patch-up) depending on the country context.  
ZKey Issues 
• We found evidence that developing countries with intermediate and high prevalence of HBV 
infection greatly benefit from HBV immunization. Universal immunization against HBV would have 
great impact in reducing endemicity and would be cost-effective in the long run. 
• Evidence that the high price of the HBV vaccine was the key determinant restraining developing 
countries from implementing universal immunization against HBV. Combined vaccine (DPT-
Hepatitis B) is a potentially a viable cost effective alternative. 
• We found that dynamic modeling was not applied in any cost-effectiveness analysis study reviewed 
as the needed data is not available. Dynamic modeling has been applied in research on cost-
effectiveness analysis studies from developed countries. It would be very valuable if in the future, 
when data is available, developing countries look into the possibilities of applying dynamic models in 
their economic evaluations on HBV too. This would help improve the quality and value of research 




1Immunization give to the whole general population or to all within a certain age group of the population (newborns, adolescents, adults, and so on)  
2Immunization programs selectively targeting individuals at risk of hepatitis B virus 
CBA: Cost-benefit analysis; CEA: Cost-effectiveness analysis; CUA: Cost-utility analysis; DALY: Disability-adjusted life year; DPT: Diptheria/pertussis/tetanus; HBcAb: Hepatitis B core antibody; HBIG: Hepatitis B 
immunoglobin; HBsAg: Hepatitis B surface antigen; NA: Not available  





Country Study objective Detailed analysis Types of  economic 
analysis Approach 
Kim et al, 
2007 [8] Gambia 
To identify the level of  affordability for hepatitis B vaccination 
from the payer’s perspective by using affordability and cost-
effectiveness affordability curves 
Comparison of cost-effectiveness between vaccination and 
non-vaccination CUA Universal
1 
Vimolket et al, 
2005 [2] Thailand 
To evaluate the cost-effectiveness by comparing four different 
infant vaccination strategies against HBV infection in Thailand 
Comparison of vaccination strategies depending on test 
results: 1 screening for HBsAg, and vaccination; 2 
screening for HBsAg, then HBeAg, and vaccination; 3 
universal vaccination of all neonates; and 4 no vaccination 
CEA Universal 
Griffiths et al, 
2005 [9] Mozambique 
To perform a CEA on the introduction of the HBV vaccine into 
the routine infant immunization services in Mozambique by 
calculating the costs per death and DALY averted  
Cost composition analysis of introducing the HBV vaccine 
into a country’s national immunization program and cost 
comparison between the use of monovalent HBV vaccine 
and combination vaccine (DPT-Hepatitis B) for infants 
CUA Universal 
Adibi et al, 
2004 [12] Iran 
To assess the economic aspects of HBV transmission 
prevention for pre-marriage couples in Iran (intermediate HBV 
endemicity) 
Evaluation of various strategies: 1 HBsAg screening for 
HBsAg+ person of the would-be couples followed by HBV 
vaccination, single dose HBIG and advice on condom 
protection; and 2 HBsAg screening followed by HBcAb 
screening in the HBsAg- spouses of the HBsAg+ persons 
and applying the above protocol only to HBcAb negative 
CEA  
Aggarwal et 
al, 2003 [1] India 
To assess the cost-effectiveness of universal childhood  
immunization in India 
For the analysis a specific Markov model was developed to 
grasp all the details of HBV in India CUA Universal 
Prakash, 
2003 [7] India 
To identify the cost-effectiveness of universal HBV 
immunization in India 
Specific interest was directed at identifying crucial factors 
influencing cost-effectiveness CUA Universal 
Hu et al, 2001 
[4] China 
To select an optimal vaccination approach and provide basis 
for decision-making on the control of hepatitis B infection in 
the People’s Liberation Army in China 
Comparison of vaccination strategies with different 
administration strategies depending on test results: 1 
screening for HBsAg prior to deciding on vaccination; 2 




To identify the cost-effectiveness of adding HBV vaccine into 
EPI of Ethiopia 
Cost composition analysis of introducing hepatitis B vaccine 
into a country’s national immunization program CEA, CMA N/A 
Liu et al, 1995 
[3] China 
To estimate the cost-benefit of vaccinating newborns against 
HBV 
A decision-tree model was explicitly developed to analyze 
costs and benefits CBA Universal 
Hall et al, 
1993 [11] Gambia 
To estimate cost-effectiveness of introducing the HBV vaccine 
into the national immunization program in the Gambia 
Cost composition analysis was applied using incidence of 
liver cancer and registered hepatitis B as indicators and 
specific comparison between the use of the monovalent 





year)Original price level Methods and perspective 
Disease-related 
treatment costs 
Base case discount rates 
(%) 
Costs            Effects 
Target groups 
Vaccination costs per 
vaccinated person (US$ 
2000) 
Vaccination strategies: results 
(US$ 2000) 
Kim et al. [8] (Gambia, 
2007) (2002 Dalasi) 
Static model: single birth 
cohort  Perspective : society 
and health care payer 
NA 3 3 Infants NA 
$41.45/averted DALY (societal 
perspective)                           
$24.69/averted DALY (payer’s 
perspective  Cost-saving from a 
societal perspective  
Griffiths et al.  
[9](Mozambique, 2005)              
(2001 Metical) 
Static model : single closed 
cohort followed to age 40-60 
years (time span: 40 years)    
Perspective: Society 
NA 3 0 or 5 Infants 
$0.81 (monovalent 
vaccine) 
$3.6 (DTP-Hepatitis B) 
$163.30/death averted 
($687.16/discounted death 
averted ) (monovalent vaccine)            
$13.76/averted DALY 
($17.43/discounted averted 
DALY) (monovalent vaccine) 
Sahni et al. [6] (India, 
2004) (2001, Rupee) 
Static model: single closed 
cohort monitored for 1 year. 
Time span: 45 years 
Perspective: Society 
NA 3 0 Newborns $4.2 $2,909.12/QALY ($8,893.71/discounted QALY) 
Adibi et al. [12] (Iran, 
2004) (2003, Rial) 
Static model:  Perspective: 
Society and healthcare NA 3 0 Premarriage individuals $14.4 
$202 and $197 per chronic 
infection prevented respectively 
Aggarwal et al. [1] (India, 
2003) (2002, Rupee) 
Static model : two 
hypothetical cohorts 
Perspective : Society 
NA 3 0 Newborns $3.0 $14.48/LYG and $11.76/QALY 
Prakash, [7](India, 2003) 
Static model: closed cohort. 
Time span: lifetime      
Perspective: Society 
NA 3 0 or 3 Newborns $2.25 $47.86/DALY 
Hu et al. [4] 
(China, 2001) 
Static model: closed cohort. 
Time span : 5 years        
Perspective : Society 
NA NS NS People’s Liberation Army soldiers NA 
DALY of $57.18 (screening 
followed by vaccination) 
DALY of $61.89 (immediate 
vaccination) 
Edmunds [25]10] 
(Ethiopia, 2000) (1996, 
Ethiopian Birr) 
Perspective: healthcare NA 6 NS Infants $1.5 NA 
Liu et al. [3](China, 1995) Perspective: society NA NS NS Newborns NA BCR from 42.41 to 48.01 
Hall et al. [11](Gambia, 
1993) Perspective: society NA 6 NS Infants $3 US$150-200 per death averted 
BCR: Benefit-cost ratio; DALY: Disability-adjusted life year; DPT: Diptheria/pertussis/tetanus; HBsAg: Hepatits B surface antigen; LYG: Life year gain; NA: Not available; NS: Not specified 
Table 3 Economic evaluations of HBV vaccination in developing countries.
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Objectives: To estimate the total financial burden of chronic hepatitis B (CHB) infection for Vietnam by 
quantifying the direct medical, the direct non-medical and indirect costs among patients with various 
stages of CHB infection 
 
Methods: Direct medical cost data were retrieved retrospectively from medical histories of inpatients 
and outpatients in 2008 from a large referral hospital in Hanoi, Vietnam. Direct non-medical and indirect 
costs data were obtained from face-to-face interviews of outpatients from the same hospital. The 
treatment cost per patient per CHB infection stage was multiplied by the total estimated patients in 
Vietnam to get the total cost-of-illness for the nation. 
Results: Nationally, the total cost attributable to CHB infection and its complications in 2008 was 
estimated to be approximately US$ 4.4 billion with the direct medical cost accounting for about 70% of 
that estimate. The cost of antivirals was the major cost driver in treating chronic HBV infection. The per-
patient total annual direct medical cost increased with the severity of the disease with the estimated 
costs for CHB infection and hepatocellular carcinoma as US$ 450.35 and US$ 1,883.05, respectively. 
When compared with the 2008 gross domestic product (GDP) per capita of around US$ 1,024, the 
financial burden of treating chronic HBV infection is very high in Vietnam. 
Conclusion: This study confirmed that chronic HBV infection poses a significant financial burden for the 
average patient and that lacking treatment would become a social issueis a social issue in Vietnam. 
Although vaccination against HBV has been universally implemented, more healthcare investment and 
the greater availability of affordable medications are still needed to attain equity in proper treatment for 
patients with HBV infection. 
  




Hepatitis B virus (HBV) is one of the most prevalent blood-borne viruses worldwide with chronic HBV 
infection afflicting over 350 million people [1]. Major clinical consequences of HBV infection include liver 
failure, cirrhosis and hepatocellular carcinoma (HCC) [2,3]. These complications lead to more than one 
million deaths each year [3-5]. Thus, HBV infection is an important public health problem, especially for 
developing countries where the endemicity is often either intermediate or high. 
Vietnam is one such high-endemic country for HBV infection [6]. Population surveys from the two 
biggest cities, Hanoi and Ho Chi Minh City, have shown a positive hepatitis B surface antigen (HBsAg+) 
rate of 9-14% [7,8]. High HBsAg+ prevalence in Vietnam is supported by another small survey of 
children in rural regions. In this survey, the HBsAg+ rate was 19.5% [9]. While there is very little data in 
Vietnam on the proportion of patients who were HBsAg+ and have chronic hepatitis B (CHB) infection, 
cirrhosis or HCC , the international literature has reported that 75-80% of patients with CHB, 34% of 
patients with cirrhosis, and 72% of patients with HCC were also HBsAg+ [10]. Hence, chronic HBV 
infection and the resulting liver diseases would pose a heavy burden for the Vietnamese healthcare 
system. 
For the average Vietnamese patient, whose annual income is around US$ 1,024 [11], the cost of 
treatment for diseases stemming from HBV infection is significant. Moreover, antiviral drugs remain very 
expensive. Comprehensive analyses of the financial burden of HBV infection in Vietnam, however, are 
very limited. In view of this, we conducted a cost-of-illness (COI) study of HBV infection using data from 
one major referral hospital in Vietnam and we aimed to extrapolate the results to the entire country. Our 
analyses should provide the Vietnamese decision makers some guidance on resource allocation for 
health, particularly for HBV related conditions.  
ZMaterial and Methods 
The study contains two parts: 1) quantification of the direct medical cost and 2) quantification of the 
direct non-medical cost and the indirect cost of HBV infection. The financial burden to the Vietnamese 
society is represented by the total cost (direct medical, direct non-medical, and indirect costs) multiplied 
by the estimated number of infected subjects in Vietnam. The study protocol was approved by the 
Director of Bach Mai Hospital in Hanoi, where the study was carried out. Bach Mai Hospital is one of the 
largest hospitals in Vietnam and is a highly specialized multi-disciplinary medical facility with a focus on 
internal medicine. It contains 1400 beds and is the most active in treating hepatitis B patients in Hanoi. 
In the cost analysis, the study followed the bottom up approach [12]. The direct medical costs were 
estimated from retrospective analysis whereas the direct non-medical costs and the indirect costs were 






Part 1: Measurement of direct medical cost 
Data were collected from medical and financial records of Bach Mai Hospital from 1 January to 31 
December 2008. The records for all inpatients treated at the Department of Infectious Diseases and all 
outpatients treated at the Infectious Diseases Unit of the Outpatient Department were included. 
Patients were classified into four groups: (i) chronic hepatitis B (CHB), (ii) compensated cirrhosis (CC), 
(iii) decompensated cirrhosis (DC) and (iv) hepatocellular carcinoma (HCC). Using the codes 
established by the International Classification of Diseases, 10th Revision (ICD-10), we identified and 
retrieved information on HBV patients classified under B18 (CHB patients), K74 (CC and DC patients) 
and C22 (HCC patients). Patients coded with K74 were subsequently differentiated as either CC or DC 
through clinical diagnosis from patient case notes. 
Cost consideration 
The total direct medical cost related to the treatment of chronic HBV and associated complications 
included clinic visit cost (outpatient visits and hospitalizations), investigation cost (laboratory tests and 
procedures), drug costs (antiviral drugs and other medicines) and other services (bed costs, meals, and 
so on). 
The study assessed resource utilization based on hospital charges in 2008 and is expressed in US$ at 
the exchange rate of US$ 1 = VND 17,803 [13]. Because Bach Mai Hospital is a public non-profit 
healthcare institution with most service charges based on cost recovery, the use of charge for the 
estimation of costs would be the most appropriate approach [14].  
Calculation of direct medical cost 
The total annual direct medical cost per patient from each category of chronic HBV infection was 
calculated by summing the average annual cost for inpatient admission and outpatient admission as 
described by: 
Annual cost/patient = Cost per visit x Visits per year + Cost per admission x Admissions per year 
where visits per year are the aggregated visits of observed patient cases divided by aggregated 
observed patient cases and admissions per year are the aggregated admissions of observed patient 
cases divided by aggregated observed patient cases. 
Part 2: Measurement of direct non-medical and indirect costs 
Direct non-medical costs were defined as expenses that were due to illness but did not involve the 
direct purchase of medical services (e.g. travel expenses, accommodation, meals etc.). Indirect costs 
were earnings and productivity loss that resulted from work absence, directly attributable to the illness, 
by either the patient or the caregiver.  
Estimations of direct non-medical and indirect costs were collected through interviews of patients 
treated in the Outpatient Department during the study period. Informed consents were obtained for all 
patients in the study. In the cases where no consenting subject for a particular category of clinical 
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diagnosis (described above) was available, physicians were interviewed as surrogates for their opinions 
on the likely costs to the patient. 
In the interviews patients were asked several standardized questions including socio-demographic 
characteristics, patients’ view on HBV infection as a financial burden, time spent for outpatient visits 
(including traveling time), extra expenses incurred for outpatient visits (including direct non-medical 
expenses), job loss as a result of HBV infections, and the need for informal care (caregivers quitting 
their jobs or employment of domestic help to provide care). 
Calculation of direct non-medical and indirect costs 
The direct non-medical and indirect costs for both working and non-working patients were calculated as 
described below.  
Because a significant proportion (around 70%) of patients at Bach Mai Hospital resides outside Hanoi 
city, travel time to the hospital, expenses on travels, meals and lodging were important components of 
the direct non-medical cost.  In this study, medical leave (i.e., number of day-offs) and time-off (i.e., 
number of hours taken off) were combined as one cost item in the indirect cost category while 
productivity loss was considered a separate cost item.  
For the working group, medical leave and time-off were the components for the indirect cost. The 
annual cost of day-offs for medical leave was calculated by multiplying the days taken for medical leave 
by the average daily wage rate. The annual time-off cost for outpatient visits was calculated by 
multiplying the total time-off by the average hourly earnings. For daily and hourly wage calculation, a 5-
day work week and an 8-hour work day were assumed.  
For the non-working group, productivity loss was used as the indicator of indirect cost and was 
calculated using the assumption that minimum wage was the monthly wage [15].   
Estimation of prevalence 
To extrapolate from this hospital-based study to Vietnam’s population, the values from the cost analysis 
were multiplied by the estimated prevalence of patients across various disease stages of chronic HBV 
infection. However, these prevalence data are not available in Vietnam. Consequently, data were 
extrapolated from results of studies on HBV infections and HBV-related cirrhosis in Vietnam in 2005, 
which were estimated at 10.05% and 481 per 100,000, respectively [16]. Assuming the same 
prevalence rate as in 2005 and extrapolating to the 2008 population in Vietnam of 86,084,547 [17], the 
estimated number of HBV carriers was 8,651,497 and the number with cirrhosis was 414,067. No 
official data on the ratio of CC to DC cases was available in Vietnam, but the ratio of CC to DC at Bach 
Mai Hospital was 8:1. Using this ratio as a guide, it would translate to approximately 368,059 CC and 
46,007 DC cases. 
The prevalence of HCC was estimated by multiplying the HCC incidence rate and average duration of 
HCC. Thus, with an incidence rate of 0.019% in 2005 [16] and the average survival of HCC patients of 1 




The total number of CHB cases was determined by subtracting the number of cirrhosis and HCC cases 
from total chronic HBV carriers, which was estimated to be 8,221,074. 
Sensitivity analysis 
We conducted both one-way and two-way sensitivity analyses for the cost estimates. For the direct 
medical cost, two one-way sensitivity analyses were performed. In the first sensitivity analysis, the lower 
and upper limits of the cost components (95% CI) from the direct medical cost calculation were tested 
and the number of patients was unchanged. In the second sensitivity analysis, the cost component 
remained constant and the number of patients in different chronic HBV disease stages was varied by: 
• using the prevalence rate of HBV-infected patients of 8 to 16% [7-9;21]as the lower and upper 
limits, respectively, for estimating number of chronic HBV carriers 
• using survival times from 5 months to 16 months [22-25] as the lower and upper limits, respectively, 
for estimating prevalence of HCC subjects 
• applying the base-case ratio of liver cirrhosis cases to chronic HBV carriers of 4.79% [16] to the 
lower and upper limits of chronic HBV carriers to estimate the lower and upper limits for the number 
of liver cirrhosis cases.  
For direct non-medical and indirect costs, two one-way sensitivity analyses were also performed. In the 
first analysis the 25th and 75th percentiles of the indirect cost were tested. In the second analysis the 
number of patients in each disease stage was varied as was done for the direct medical cost. 
Two-way sensitivity analyses were conducted to test the combined effects of varying both the number of 
subjects and the treatment costs. However, only the best- and worst-case scenarios were examined. 
A sensitivity analysis was performed to determine how the number of patients on antiviral treatments 
would change as a result of reducing the number of patients from all disease categories in the base-
case by 20% while the number of patients on other medications and medical services remained 
constant. We then evaluated the difference in the total direct medical cost that resulted from this 
variation. 
ZResults 
Direct medical cost 
A total of 904 patient cases (470 outpatient and 434 inpatient) were included for analysis, consisting of 
226 CHB, 203 CC, 117 DC, and 358 HCC cases. The mean age of the inpatient cases was 46.4 years 
(range: 13-83 years) and 82.8% were males. The mean age of the outpatient cases was 39.4 years 
(range: 15-61 years) and 59% were males. Virtually all of the subjects (99% for inpatients and 100% for 
outpatients) were Kinh, the most dominant ethnic group in Vietnam.  
Overall service utilization and direct medical cost analysis of chronic HBV infections by disease stages 
Annual healthcare utilization for each disease stage and the estimated average annual treatment cost 
per patient for each disease stage are listed in Table 1 and Table 2, respectively, with the lowest cost in 
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CHB patients (US$ 450.35) and the highest in HCC patients (US$ 1,883.05). On average CHB patients 
made the fewest outpatient visits (3.84 trips/year) while DC patients made the most (5.7 trips/year). 
Patients with HCC had the most hospital admissions per year and patients with DC had the longest 
hospital stay (13.54 days).  








per person per year 3.84 (3.02-4.66) 4.31 (2.65-5.97) 5.7 (3.79-7.61) 5 (3.09-6.91) 
No. hospitalizations 
per person per year 0.17 (0.12-0.22) 0.27 (0.21-0.48) 0.51 (0.37-0.65) 2.34 (2.11-4.45) 
Length of stay 
per admission (days) 2.35 (2.11-2.59) 2.50 (2.02-2.98) 13.54 (9.87-17.20) 12.76 (10.87-14.65) 
1Liver transplant program was not established at Bach Mai Hospital. 
 
Table 1 Annual outpatient visits and hospitalizations for patients with chronic HBV infection by disease 
stages in Vietnam in 20081 
 
Cost composition of chronic HBV infection 
Table 2 shows that the annual direct medical cost of the treatment increased with disease progression. 
Drug costs accounted for approximately 70% of the direct medical cost for CHB, CC and DC and 
46.81% in HCC cases. Inpatient care constituted about 63% of the direct medical cost in HCC but only 
2% for CHB and 5% for CC. Expenses on antiviral drugs were about 15% in CHB, 27% for CC and DC, 
and 2% for HCC. Expenses on laboratory tests and procedures were done extensively for HCC (~44%). 
Expenses on medications other than antivirals were extensively used in all disease stages accounting 
for more than 45% of the total direct medical cost.  
Similar to the findings from the Singaporean study (26), lamivudine was the most frequently used 
antiviral agent in our study. This finding is likely due to the fact that lamivudine is currently the only 
agent reimbursed by the health insurance of Vietnam. Based on the estimated prevalence for the 
different chronic HBV disease stages, the base-case direct medical cost associated with the different 
chronic HBV stages is shown in Table 3A. The total direct medical cost in 2008 was estimated to be 
US$ 4 billion. 
The one-way sensitivity analysis for estimating direct medical cost, where the cost components were 
varied and the number of patients was unchanged, revealed that the estimated direct medical cost in 
2008 was between US$ 2.8 and 5.5 billion. The reverse one-way sensitivity analysis, where the cost 
component remained constant and the number of patients was varied, showed the estimated direct 
medical cost in 2008 ranging between US$ 3.2 and 6.4 billion. The two-way sensitivity analyses, 




The sensitivity test, where the number of patients on antiviral treatment was reduced by 20% but the 
number of patients on other medical services was unchanged, resulted in a 3% reduction in the total 































Cost composition (%) 
Antiviral drugs2 14.85% 23.97% 27.06% 1.69% 
Other medications2 54.28% 46.59% 40.73% 45.11% 
Examination/laboratory 
tests, procedures3, other 
services4 
29.22% 28.03% 29.90% 43.97% 
Consultations 1.65% 1.41% 2.32% 9.22% 
Total 100.00% 100.00% 100.00% 100.00% 
2 Cost of medications = ∑ (Medication pricei x amounti) 3
 Cost of examinations and laboratory tests = ∑ (Unit costi x Utilization frequencyi) 
4 Other services include bed cost and meals 
 
Table 2 Average annual direct medical cost (in US$) per patient with chronic HBV infection by disease 
stages and cost compositions in Vietnam in 2008 
 
A.  Base-case estimates 
Disease 
category Number of patients Mean direct medical cost per patient  (US$) 
Total direct 
medical cost 
per year (US$) 
CHB 8,221,074.00 450.35  3,702,344,156.83 
CC 368,059.00 690.43 254,118,890.27 
DC 46,007.00 1,114.50 51,274,910.42 
HCC 16,356.00 1,883.05 30,799,174.35 
Total 8,651,497.00 4,138.33 4,038,537,131.88 
B. Sensitivity analysis 
Disease 
category 
Range of estimated 
number of patients 
Range of estimated 
direct medical cost 





CHB 6,533,015-13,058,282 319.73-599.66 2,628,542,811-4,929,838,419 2,942,130,126-5,880771,131 
CC 308,322-616,644 376.05-1,234.37 138,409,271-454,322,691 212,874,616-425,749,232 
DC 38,540-77,080 642.45-1,723.78 29,557,257-79,306,656 42,953,185-85,906,371 
HCC 6,887-21,521 1,228.03-3,870.65 20,085,706-63,308,668 12,968,124-40,525,388 
Total 6,886,764-13,773,528 2,566.26-7,428.47 2,816,595,045-5,526,776,434 3,210,926,051-6,432,952,122 
     
Disease 
category 
Range of estimated 
number of patients 
Range of estimated 
direct medical cost 
2-way sensitivity analysis (best 
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CHB 6,533,015-13,058,282 319.73-599.66 2,088,815,738  7,830,512,048  
CC 308,322-616,644 376.05-1,234.37 115,944,939  761,168,906  
DC 38,540-77,080 642.45-1,723.78 24,760,006  132,869,790  
HCC 6,887-21,521 1,228.03-3,870.65 8,457,139  83,300,879  
Total 6,886,764-13,773,528 2,566.26-7,428.47 2,237,977,823  8,807,851,623  
CHB- Chronic hepatitis B, CC- Compensated cirrhosis, DC- Decompensated cirrhosis, HCC- Hepatocellular carcinoma 
5
 Lower and upper limits of the cost components (95% CI) from the direct medical cost calculation were tested and the number of patients 
was unchanged  
6 Cost components remained constant and the number of patients per disease stage was varied  
 
Table 3 (A) Base-case estimates and (B) sensitivity analyses of total direct medical cost of chronic HBV 
infection by disease stages in Vietnam in 2008 
Direct non-medical and indirect costs 
Financial burden of illness survey 
A total of 51 chronic HBV patients participated in the study. The mean age of the patients was 36.12 
years (range: 16-59 years) and 64.7% were males. All participants considered chronic HBV infection as 
a financial burden that heavily influenced the household's income.  
Indirect cost components of caregivers and loss of job 
None of the participants in the financial survey reported job loss, the need to employ caregivers, or 
family members giving up employment to provide care as consequences of chronic HBV infections. The 
study results showed these elements had minimal impact on indirect costs for chronic HBV carriers in 
Vietnam.  
Direct non-medical cost and indirect cost 
Because the cost distribution was skewed, the median rather than mean values were used to calculate 
indirect costs. Many patients were from the surrounding provinces to the hospital and their travel time 
often consisted of a whole working day. Thus, expenses on transportations, meals and lodging were 
higher than medical leave, time-off and productivity loss. The cost item representing medical leave and 
time-off was the second largest cost component of the direct non-medical and indirect costs (Table 4).   








CHB 1.04  15.32  22.62  38.98  
CC 1.73  25.53  148.85  176.11  
DC 17.63  71.49  154.11  243.23  
HCC 76.19  80.27  153.12  309.58  
Total 96.59  192.61  478.70  767.90 
7Monthly cost of reduced productivity = Reported loss of productivity x monthly wage rate where:  
Reported loss of productivity = number of sick days due to HBV/total number working days of a month. 
  
Table 4 Annual direct non-medical and indirect costs (US$) of chronic HBV infection by disease stages 




From our study, the base-case estimation for total direct non-medical and indirect costs for all the 
different chronic HBV disease stages in Vietnam was roughly US$ 375 million (Table 5A). Results of 
one-way sensitivity analyses for estimating direct non-medical and indirect costs are summarized in 
Table 6B. Varying the cost components while keeping the number of patients in various stages 
unchanged resulted in a wider impact (US$ 153 million-929 million) than the reverse situation where the 
costs were unchanged and the number of patients was varied (US$ 299 million-600 million). In two-way 
sensitivity analyses where both the number of patients and the non-direct medical costs (direct non-
medical and indirect costs) were varied, the total cost was between US$ 122 million and US$ 1.5 billion 
(Table 5B). 
Cost-of-illness for chronic HBV infection estimation 
When the total cost-of-illness for chronic HBV infection in Vietnam was compared for the various 
disease stages, chronic HBV infection was the most costly condition, estimated at US$ 4 billion. 
Furthermore, the ratio of direct to indirect cost increased with progression of disease severity (Table 6). 
Direct medical cost was the major component of the total treatment cost of HBV infection patients, 
accounting for approximately 70% of the expenses. 
A.  Base-case estimates 
Disease 
category Number of patients 
Mean direct non-medical and indirect cost per 
patient  (US$) 
Total direct non-medical  
and indirect cost per year 
(US$) 
CHB 8,221,074.00 38.98  320,429,256  
CC 368,059.00 176.11  44,846,050  
DC 46,007.00 243.23  7,756,533  
HCC 16,356.00 309.58  2,417,703  
Total 8,651,497.00 767.90  375,449,542  
B. Sensitivity analysis 
Disease 
category 
Range of estimated 
number of patients 
Range of estimated 
direct non-medical & 
indirect cost 
1st one-way sensitivity 
analysis (US$) 
2nd one-way sensitivity 
analysis (US$) 
CHB 6,533,015-13,058,282 15.01 – 100.15 123,363,341-823,309,245 254,634,496-508,967,017 
CC 308,322-616,644 62.30 – 244.91 22,931,607-90,141,550 37,567,371-75,134,743 
DC 38,540-77,080 113.90 – 250.86 5,240,034-11,541,475 6,497,619-12,995,238 
HCC 6,887-21,521 130.25 – 238.14 2,130,329-3,894,954 1,017,980-3,181,189 
Total 6,886,764 -13,773,528 321.45 - 834.05 153,665,312-928,887,224 299,717,467-600,278,186 
     
Disease 
category 
Range of estimated 
number of patients 
Range of estimated 
direct non-medical & 
indirect cost 
2-way sensitivity 
analysis (best case 
scenario) (US$) 
2-way sensitivity analysis 
(worst case scenario) 
(US$) 
CHB 6,533,015-13,058,282 15.01 – 100.15 98,032,753  1,307,737,174  
CC 308,322-616,644 62.30 – 244.91 19,209,723  151,022,492  
DC 38,540-77,080 113.90 – 250.86 4,389,558  19,336,503  
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HCC 6,887-21,521 130.25 – 238.14 896,981  5,124,939  
Total 6,886,764-13,773,528 321.45-834.05 122,529,015 1,483,221,108 
CHB- Chronic hepatitis B, CC- Compensated cirrhosis, DC- Decompensated cirrhosis, HCC- Hepatocellular carcinoma 
 
Table 5 (A) Base-case estimates and (B) sensitivity analyses of total direct non-medical and indirect 
costs of chronic HBV infection by disease stages in Vietnam in 2008 
 
 
Disease category Direct medical cost Direct non-medical 
and indirect costs Cost-of-illness 
Ratio of direct medical cost to 
direct non-medical and 
indirect costs 
CHB 3,702,344,157  320,429,256  4,022,773,413  11.6:1 
CC 254,118,890  44,846,050  298,964,940  5.7:1 
DC 51,274,910  7,756,533  59,031,443  6.6:1 
HCC 30,799,174  2,417,703  33,216,878  12.7:1 
Total 4,038,537,132  375,449,542  4,413,986,674   
CHB- Chronic hepatitis B, CC- Compensated cirrhosis, DC- Decompensated cirrhosis, HCC- Hepatocellular carcinoma 
Table 6 Direct medical cost, direct non-medical and indirect costs, total cost-of-illness for different 
stages of chronic HBV infection in Vietnam in 2008 (US$)` 
 
ZDiscussion 
To the best of our knowledge, this is the first cost-of-illness study for chronic HBV infections in Vietnam. 
Our results clearly showed that CHB infection and its complications impose a significant financial 
burden on the Vietnamese society and healthcare system. If all patients with CHB and its various 
disease stages were treated in hospitals, the total annual cost would amount to approximately US$ 4.4 
billion, which is approximately 5% of the GDP of Vietnam in 2008. 
In reality the Vietnamese government’s expenditure on health accounted for only a quarter of the total 
national health expenditure with the remainder coming from patients’ out-of-pocket payment (27-29). 
Even if the individual patient is responsible for only part of the treatment costs of chronic HBV infections, 
the current low Vietnamese GDP per capita of US$ 1,024 (11) would still make the partial cost a 
significant financial burden for the average Vietnamese patient. Furthermore, as 80% of the population 
works in the agricultural sector with low wages, the number of HBV patients who cannot bear these 
costs would be substantial and therefore many may be under-treated or untreated.  
As a consequence of these costs, many patients turned to traditional medicines as an alternative. From 
interviews with physicians from Bach Mai Hospital, it appeared that only 1% of patients with CHB 
infection and other complications received hospital treatment. One suggested solution to alleviate the 
financial burden for individual patients seeking chronic HBV treatment is to continue and upgrade the 





In our study, expenses on medications were the largest cost driver for the direct treatment cost for CHB, 
CC and DD. These costs accounted for more than 70% of the total direct medical cost. However, this 
finding differs from another published study in which laboratories tests were extensively conducted (26).  
The difference may be explained by the high drug prices in Vietnam.  
While the prices of nucleosides are becoming less expensive, they are still very costly in Vietnam. As a 
result, antiviral therapy is affordable for only a small proportion of HBV infected patients. This problem is 
exacerbated by the higher drug prices in public pharmacies (30), where many patients with chronic HBV 
infections would purchase their medications. In fact, prices for drugs in general and branded drugs in 
particular are many times higher in the Vietnamese market than in many of the other countries in the 
region (31). For chronic diseases, one-month treatment cost might be equivalent to 22 days’ minimum 
wages for generic drug and up to 50 days’ wages for an innovator brand (30).  Contributing factors to 
the high drug prices in Vietnam include an inefficient procurement process and a lack of sound 
regulations on mark-ups. Thus, if more generic drugs could either be manufactured domestically at a 
lower cost or be allowed to enter the Vietnamese market at a lower price, then affordability of chronic 
HBV treatment would increase as a result of the lowered drug prices. The one-way sensitivity analysis 
investigating the number of patients on antiviral treatment also showed that a decrease in the number of 
patients would result in a small reduction in the total direct medical cost. Resource utilization pattern for 
the direct medical costs in this study was consistent with other published studies; direct medical costs 
increase with disease progression (26, 32-34). 
Direct non-medical and indirect cost accounted for approximately 6% of the total treatment cost for CC 
and DC and 12% for CHB and HCC. This study differs from other studies on the same subject in that 
the direct non-medical costs resulting from lodging, transportation and meals were considered. Because 
many chronic HBV patients reside outside of Hanoi, these costs could be quite high and even exceed 
the total indirect cost. This naturally would lead to the suggestion of establishing more healthcare 
institutions in rural areas. Improved health care access in rural areas where approximately 80% of the 
Vietnamese population resides would also ameliorate the common problem of patient overloading of 
hospitals in major Vietnamese cities. 
While other studies on this topic used health insurance data [26-28], our study used medical records of 
Bach Mai Hospital. A study using data from the medical and financial records would not only provide a 
more detailed breakdown but also more accurately capture resource utilization compared to studies 
using health insurance data. Furthermore, hospital records allow for the identification of items not 
covered by health insurance and information on patients without health insurance, which represent a 
large proportion of the Vietnamese population.  
Our study also has several limitations. One limitation is the issue of representativeness of the patient 
sample.  Many inpatients after discharge do not return to outpatient clinics for follow-up. Ideally, they 
would have to go back for post-discharge assessment and therapy. However, in reality this does not 
happen in Vietnam for a number of reasons. Many chronic HBV patients live in provinces distant from 
Hanoi and are agricultural workers with very low income. Thus, it is not easy for them to travel to the 
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hospital for regular outpatient visits. Hence, our outpatient samples were from those who attended the 
outpatient clinic and may not be truly representative as evident that formal care was not required by any 
of the participants.  
In addition, our study was confined to the northern area of Vietnam and we only collected data from one 
central hospital albeit the biggest in the North and not in other two regions of the country (Central and 
the South). However, as medications accounted for ~70% of the total cost in our study and there is little 
variation in drug prices across Vietnam, this would allow an extrapolation to the whole country. 
Likewise, minimum wage was applied in estimating medical leave and time-off for the indirect cost, and 
there would not be much deviation of direct non-medical and indirect cost when our results are 
extrapolated to different regions in Vietnam.  
However, extrapolation of treatment cost collected from one hospital to the national level could be prone 
to overestimating the treatment cost of chronic HBV infection in Vietnam. Nonetheless, in lieu of any 
cost information in Vietnam, our results could be viewed as a potential scenario that provides an 
estimation of what the “might be” quantum of the cost to fill in an existing information gap. 
Finally, we were unable to retrieve the expenditure data on traditional medicines in treatment of chronic 
HBV infections either; thus underestimating the total treatment costs. In Vietnam, there is a fairly large 
population seeking care from traditional medicines rather than western medicines despite a lack of 
published studies on their efficacy and safety. Besides cultural and traditional belief in traditional 
medicines, there is also the benefit of easier access and lower costs.  Although patients may still need 
to travel far to access to traditional medicine, they will not need to do it regularly as traditional healers 
can prescribe medicines for several months if financial conditions of patients disallow frequent travels. 
Even with these potential limitations, this study, as the first and only COI study on chronic HBV infection 
in Vietnam, still provides valuable information for health care decision makers in resource allocation and 
planning. The heavy financial burden presented here suggests that the continuation of universal 
immunization against HBV is the optimal long-term solution to minimize HBV-associated costs. 
Universal infant immunization against HBV in Vietnam started later than other countries in the Asia-
Pacific region, however, the coverage has now reached more than 90% nationwide [29]. To reduce the 
prevalence of chronic HBV cases in Vietnam, catch-up HBV vaccination will also be required. Another 
suggestion is the implementation of universal health insurance that would at least partially subsidize the 
treatment cost of chronic HBV infection. However, universal health insurance would definitely require 
additional financial resources, which likely require support from international organizations. 
ZConclusion 
We showed that chronic HBV infection potentially imposes a heavy financial burden on Vietnam, and 
patients with chronic HBV infection clearly face many difficulties in attaining the appropriate treatment. 
Our results showed that prices of antivirals were still very high making the chronic HBV treatment very 




those in need, at the least the costs of drugs must either be reduced or be subsidized for the poor. 
Beside the direct medical cost, direct non-medical cost was for the first time taken into consideration 
and appeared to be a substantial component of the indirect cost in Vietnam.  
Given the high prevalence of HBV infection in Vietnam, it is imperative that steps be taken at various 
levels to address the problem. In addition to universal vaccination of newborns against HBV, a re-
consideration of Vietnamese policies on drug pricing, treatment of chronic HBV infections, and other 
initiatives for the prevention of infection are required.  
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Objectives: To perform a cost-effectiveness analysis and to identify the cost-effectiveness affordability 
levels for a newborn universal vaccination program against hepatitis B virus (HBV) in Vietnam 
Methods: Using a Markov model, we simulated a birth cohort using 1,639,000 newborns in Vietnam in 
2002 and estimated the incremental cost-effectiveness ratios (ICERs) for quality-adjusted-life-year 
(QALY) gained following universal newborn vaccination against HBV. Two types of analyses were 
performed, including and excluding expenditures on the treatment of chronic hepatitis B and its 
complications. In addition, we used Monte Carlo simulations to examine cost-effectiveness acceptability 
and affordability from the payer’s perspective and constructed a cost-effectiveness affordability curve to 
assess the costs and health effects of the program.  
Results: In the base-case analysis, newborn universal vaccination against HBV reduced the carrier rate 
by 58% at a cost of US$ 42 per carrier averted. From the payer’s perspective, ICER per QALY gained 
was US$ 3.77 which is much lower than the 2002 Gross Domestic Product (GDP) per capita estimate of 
US$ 440. Vaccination could potentially be affordable starting at a budget of US$ 2.1 million. At the cost-
effectiveness threshold of US$ 3.77 per QALY and an annual budget of US$ 5.9 million, the probability 
that vaccination will be both cost-effective and affordable was 21 percent. 
Conclusions: Universal newborn vaccination against HBV is highly cost-effective in Vietnam. In low-
income, high-endemic countries, where funds are limited and the economic results are uncertain, our 
findings on the cost-effectiveness affordability options may assist decision-makers in proper health 
investments. 




The hepatitis B virus (HBV) is one of the most prevalent blood borne viruses worldwide and is a major 
cause of chronic liver diseases and hepatocellular carcinoma (HCC) [1,2]. It is an important public 
health problem for developing countries where the endemicity is generally high. Currently, it is estimated 
that 350 million people in the world are chronic HBV carriers, as demonstrated by the presence of the 
surface antigen of HBV (HBsAg) for more than 6 months [3]. These individuals are at much higher risk 
of liver damage;15-40% of the infected patients eventually develop cirrhosis, liver failure or HCC, 
contributing to more than 1 million deaths annually [1,4,5]. Epidemiological studies have reported that 
the prevalence of chronic HBsAg carriers is between 8.8% and 20.5% across different populations and 
regions in Vietnam [6,7]. Therefore, with a population of 86 million in 2010, Vietnam would have more 
than 7.5 million people who are at risk of premature death as a result of HBV infection. 
For high-endemic regions of chronic HBV infections, universal vaccination of newborns against HBV 
could be a feasible and effective solution for the prevention of HBV infection [8]. Studies have shown 
that vaccination against HBV is cost-effective in the developing world [9]. In Vietnam, a locally produced 
hepatitis B vaccine was first introduced into the Expanded Program of Immunization (EPI) in 1997, but 
its use was limited because of supply constraints [10]. Universal vaccination against HBV was not 
completed until mid-2003 with the support from the Global Alliance for Vaccines and Immunizations 
(GAVI) starting in 2002 [10]. To date, data is lacking regarding the impact of universal vaccination of 
newborns in Vietnam from a health-economic perspective. While cost-effectiveness analyses of 
universal vaccination against HBV have been extensively performed for many developed countries, 
such analyses are still scarce for the developing world [9]. However, economic studies, specific for 
developing countries, suggested that HBV vaccination is cost-effective and may even be cost-saving [9]. 
In order to aid decisions on the allocation of scarce healthcare resources, it is important to assess the 
cost-effectiveness of any large scale prevention programs, which require substantial resource inputs. 
Properly conducted economic analyses can also identify the programs that would provide the best value. 
In this paper we estimated the cost-effectiveness of the current HBV vaccination program for the 
Vietnamese situation. Additionally, cost-effectiveness affordability curves were constructed to estimate 
the impact of the budget on the vaccination program. 
ZMethods 
Modeling approach 
We designed a decision analytic model to estimate the cost-effectiveness of universal vaccination 
against HBV compared with no vaccination. A Markov model simulating disease progression was linked 
to a decision tree (figure 1). The analyses were performed using the simulation software TreeAge Pro, 
version 2009 (Treeage Software Inc., Williamstown, MA, USA).  
In the model we focused only on chronic hepatitis B infections because chronic infections comprise the 




lacking for Vietnam. The Vietnamese birth cohort of 2002 was selected because universal vaccination 
against HBV was completed in mid-2003; thus, we can compare the impacts before and after universal 
HBV vaccination. Type 1 mortality was assumed (i.e., everyone lives to the life expectancy, which is 75 
years in Vietnam). Each Markov cycle was defined as 1 year. The Markov health states used in the 
model were: (1) alive, (2) immunity, (3) chronic hepatitis B, (4) compensated cirrhosis, (5) 
decompensated cirrhosis, (6) HCC and (7) death.  
Parameters 
Probabilities 
The transition probabilities used in the model represent the natural course of chronic hepatitis B 
infections and were obtained from international literature(through PuBMed), particularly from studies in 
high-endemic Asian countries where the epidemiology of hepatitis B infections is more similar to that of 
the Vietnamese situation (Table 1). In the cases where there were two or more studies reporting 
estimates for a particular transition probability, we combined the outcomes of the studies using a 
random effect model to account for possible heterogeneity [11]. 
In Vietnam the reported prevalence of HBsAg carriers was between 8.8% and 20.5% in 2002 (6;7). For 
the purpose of our study, we took the mean of the two values (14.7%) as the base-case prevalence of 
HBsAg carriers. Other parameters such as vaccine coverage, vaccine efficacy, vaccine wastage were 
also taken from published literature (Table 1). The vaccine coverage for newborns in Vietnam was 
reported to be 70% (range of 45%-94%) [12]. The efficacy of the monovalent vaccine against HBV from 
a 3-dose schedule (0, 2 and 4 months) was approximately 84% (range of 65%-95%) [13-15]. In Vietnam, 
the hepatitis B vaccine was provided in the form of two-dose vials. Thus, the vaccine wastage was 
estimated at 12.5% (range of 5-25%) [12,16]. Vaccine wastage was calculated by the following formula: 
Vaccine wastage = [(Amount of vaccines purchased-Amount of vaccines used)/Amount of vaccines 
purchased]*100 
Cost estimates 
The cost-effectiveness analysis was performed from societal, healthcare, and payer’s perspectives. The 
affordability analysis was conducted from the payer’s perspective only. For the societal perspective, we 
included the direct medical costs (vaccination cost and the averted costs of treatment for chronic 
hepatitis B infections and hepatitis B-related cases), the direct non-medical costs (travel, meals and 
lodging), and the indirect costs (productivity loss). For the healthcare perspective, vaccination cost and 
direct medical costs were included. For the payer’s perspective, where the Vietnamese government or 
international organizations are the main payers for vaccination programs,we included only the 
vaccination cost because we explicitly wanted to assess the affordability of implementing a vaccination 
program.  
Treatment cost of chronic hepatitis B and its related progressions were taken from a previous cost-of-
illness study we conducted for Vietnam (data is available upon request). However, the costs in that 
study were calculated for year 2008. To convert the costs back to year 2002 levels (matching the birth 
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cohort used in this study), we used the country’s gross domestic product deflators. All costs were 
reported in US$ based on a conversion rate of 1 US$ = 17,803 Vietnamese Dong [18]. 
 
1CHB = Chronic hepatitis B; CC = Compensated cirrhosis; DC = Decompensated cirrhosis; HCC = Hepatocellular carcinoma; HBsAg = 
Hepatitis B surface antigen 
Figure 1 Decision analytic model for estimating the cost-effectiveness of universal hepatitis B 
vaccination in Vietnam1 
 
The hepatitis B vaccine used for newborns in Vietnam was Euvax-B and it was purchased through 
GAVI’s financial support from 2002-2008. The cost of the vaccine alone was approximately US$ 1 
[19,20]. Including the administration costs, the full cost per dose was estimated to be US$ 1.50 (range 
of US$ 0.5-3.5) [19,20]. In this study, we did not take into account indirect costs such as time and 
money spent by parents to bring the child for immunization. However, we included the direct non-
medical costs and the indirect costs that resulted from complications of chronic hepatitis B infections 





Quality of life (QOL) 
Due to a lack of data on specific QOL estimates for Vietnam, we used QOL estimates based on various 
international sources (Table 1). The utility values range from 0 (death) to 1 (perfect health). 
Other assumptions 
In the model we made several assumptions: (i) all chronic hepatitis B infections occurred in the first year 
of life; (ii) the mortality and losses of QALY and LYGs that were due to acute hepatitis B infections were 
ignored; (iii) the simulation continued until 99.9% of the cohort had deceased; and (iv) the hepatitis B 
unrelated death rate was based on the age-specificity mortality of the Vietnamese population (19). In 
the absence of age-specific mortality rates for 2002, we used the rates from 2006 under the assumption 
that mortality rates remained constant between 2002 and 2006. 
Sensitivity analysis 
To evaluate the uncertainties associated with cost-effectiveness outcomes, we performed probabilistic 
sensitivity analyses for all three perspectives. The model input parameter values and the associated 
distributions are shown in Table 1 [21]. For each scenario we conducted 5000 Monte Carlo simulations. 
The results were subsequently presented in cost-effectiveness acceptability and cost-effectiveness 
affordability curves from the payer’s perspective only. We then evaluated affordability based on the joint 
distribution of simulated incremental costs and health gains of HBV vaccination. Affordability analysis 
was done with the assumption that vaccination programs for infants were indivisible, which means it 
cannot be done for only a fraction of infants because in Vietnam universal hepatitis B vaccination is for 
every child. Using the theory and methodology described by Sendi and Briggs [22], we generated a 
cost-effectiveness affordability curve by capturing the points in the cost-effectiveness (C-E) plane under 
the horizontal lines representing different budget levels.  
Several univariate analyses were performed to assess the effects of uncertainties surrounding input 
parameters on the outcomes. However, only the analyses from the payer’s perspective are shown. The 
parameters included in the univariate analyses were vaccine coverage, vaccine wastage, vaccine price, 
vaccine efficacy, and HBV prevalence rate. 
Outcome measurement 
The two effectiveness outcomes investigated in the model were life-years-gained (LYG) and quality-
adjusted-life-year (QALY). In addition, we calculated the ICER per LYG and per QALY for different 
scenarios (vaccination vs. no vaccination). 
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Parameter Base-case estimates Range Distribution References 
HBV prevalence (%) 14.70 8.80-20.50 Triangular [6,7] 
Vaccine coverage (%) 70.00 45.00-94.00 Triangular [12] 
Vaccine efficacy (%) 84.00 65.00-95.00 Triangular [13-15] 
Vaccine wastage (%) 12.50 5.00-25.00 Triangular [12;16] 
Immunization cost/child (US$) 4.50 1.50-10.50 Triangular [19;20] 
Disease progression        
Outcome from chronic 
hepatitis B      
Resolution 0.006183  Gamma (26.56, 4295.75) [24-26] 
Chronic hepatitis B #1    
Compensated cirrhosis 0.022989  Gamma (32.98, 11434.66) [27-31] 
Hepatocellular carcinoma 0.009100  Gamma (10.27, 1128.91) [24,26-28,30,32-35] 
Disease non-related deaths Life-table  Beta [23] 
Outcome from compensated 
cirrhosis     
Compensated cirrhosis #    
Decompensated cirrhosis 0.069139  Gamma (58.66, 848.48) [37,38] 
Hepatocellular carcinoma 0.016121  Gamma (5.72, 354.72) [37] 
Disease-related death 0.033146  Gamma (11.04, 333.05) [3,29,39] 
Disease non-related deaths Life-table  Beta [23] 
Outcome from decompensated 
cirrhosis     
Decompensated cirrhosis #    
Hepatocellular carcinoma 0.05  None [40] 
Disease-related deaths 0.245262  Gamma (39.29, 160.21) [41] 
Outcome from hepatocellular 








Disease-related death #    
Cost estimates (US$) 
       
Treatment cost (Healthcare 
perspective)     
Chronic hepatitis B 270  Gamma (535.2326; 1.98155) 
Data available 
upon request  
Compensated cirrhosis 564  Gamma (348.5901; 0.61709) 
Decompensated cirrhosis 1559  Gamma (10515.865; 6.74428) 
Hepatocellular carcinoma 1901  Gamma (13148.086; 6.91638) 
Treatment cost (Societal 




Chronic hepatitis B 347  Gamma (885.83; 2.55)  
Compensated cirrhosis 746  Gamma (607.98; 0.81)  
Decompensated cirrhosis 1774  Gamma (13615.48; 7.67)  
Hepatocellular carcinoma 2111  Gamma (16222.215; 7.68)  
Discount rate (%) 0 or 3    
Quality of life (QoL) 
       
Chronic hepatitis B 0.92 0.90-0.98 Triangular [44-46] 
Compensated cirrhosis 0.82 0.75-0.95 Triangular  
Decompensated cirrhosis 0.55 0.25-0.75 Triangular  
Hepatocellular carcinoma 0.55 0.25-0.75 Triangular  
1The hash mark (#) is used in place of the probability expression for one branch, in order to have TreeAge Pro automatically calculate the 
complement during calculations. 
 





The results of the base-caseanalyses comparing universal hepatitis B vaccination with no vaccination 
are presented in Table 2. Under the framework of the model, implementing universal vaccination of 
newborns reduced HBV prevalence by 8.66% (a change of 58%) from 14.70% to 6.04% and increased 
the expected LYG and the QALY gained per person by 0.80 years and 0.95 years, respectively. The 
cost incurred to prevent one HBV infection case was estimated to be US$ 41.79. From the payer’s 
perspective the ICER per LYG and QALY gained were estimated at US$ 4.52 and US$ 3.77, 
respectively. From the societal and healthcare perspectives, universal vaccination of newborns against 
HBV dominated no-vaccination (i.e., more effective and cost-saving).  
Parameter Unvaccinated cohort Vaccinated cohort Change with 
vaccination 
HBV carrier rate (%) 14.70% 6.04% -8.66% 
Discountedexpect life-years/person 27.21 28.01 0.80 
Discounted QALY gained per person 26.94 27.90 0.95 
No. of new infections for the cohort 240,114 98,927 -141,187 
No. of  primary liver cancer cases 2,185 900 -1,285 
No. of  premature deaths 2,366 975 - 1,391 
Life-time cost incurred from societal perspective 
(US$) per person 1,151.52 478.03 - 673.49 
Life-time cost incurred from healthcare perspective 
(US$) per person 910.00 378.00 -532.00 
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Cost incurred from payer’s perspective (US$) per 
person  3.60  
ICER per LYG (US$) from payer’s perspective  4.52  
ICER per QALY gained (US$) from payer’s 
perspective  3.77  
Cost of preventing a HBV carrier   41.79  
Total vaccination cost of birth cohort (US$)  5,900,400  
 
Table 2 Base-case results for vaccination vs. no vaccination strategies against HBV for newborns 
where HBV carrier rate is 14.7%, vaccine coverage is 70%, vaccine efficacy is 84%, vaccine wastage is 
12.5% and discount rate is 3% 
 
Results of one-way sensitivity analyses 
The results of univariate sensitivity analyses from the payer’s perspective are presented in a 
tornadogram, showing the ranges of ICERs for routine universal HBV vaccination compared to no 
vaccination (figure 2). The results revealed that ICER values were most sensitive to vaccine price and 
HBV prevalence rate, moderately sensitive to vaccine efficacy, and less sensitive to vaccine wastage. 
Because the applied model in the study was a static design, sensitive analysis on vaccine coverage did 
not affect the results of the ICER per LYG and per QALY (data not shown). 
 
Figure 2 Results of univariate sensitivity analyses showing the ranges of ICERs for universal newborns 
HBV vaccination compared to no vaccination in Vietnam (payer’s perspective) 
Results of probabilistic sensitivity analysis 
 
Cost-effectiveness (C-E) plane 
The cost-effect pairs from 5000 Monte Carlo simulations, which accounted for the uncertainties 
surrounding all input parameters, are shown on C-E planes for the societal, healthcare, and payer’s 
perspectives (figure 3). Under the societal and healthcare perspectives, all points lied in the southeast 









quadrant (lower cost and greater effectiveness), confirming that from these perspectives universal 





Figure 3 5000 Monte Carlo simulations of incremental cost-effectiveness ratios plotted on a C-E plane 
comparing vaccination vs. no-vaccination 
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Cost-effectiveness acceptability curve 
We further presented the uncertainty of the C-E plane on a cost-effectiveness acceptability curve 
(CEAC) for the payer’s perspective (figure 4). The CEAC reports the probability that infant universal 
vaccination against HBV would be cost-effective for a range of WTP thresholds. For the base-case 
threshold of US$ 3.77 per QALY, the probability of cost-effectiveness for the vaccination program was 
51%. At the WTP threshold of US$ 18 per QALY, the probability of cost-effectiveness reached 100%, 
but decreased to 0% when the WTP threshold was less than US$1 per QALY. 
 
Figure 4 Cost-effectiveness (C-E) acceptability curve for universal newborn vaccination against HBV in 
Vietnam (payer’s perspective 
Affordability curve 
To overcome the above limitation of the cost-effectiveness acceptability curves, affordability curves 
were generated to explain the impacts of financial resources on the vaccination program. Accounting for 
the uncertainties of all parameters, the curve visualizes the probabilities of affordability for a vaccination 
program given different budgetary levels. 
The focus of this study was to assess the impact of the budget on vaccination alone. Thus, all 
affordability and subsequent cost-effectiveness affordability analyses were explicitly evaluated from the 
payer’s perspective. The results indicated that the vaccination program would not be affordable when 
the budget is less than US$ 2 million. In contrast, vaccination would always be implementable when the 
budget exceeds US$ 13 million. Thus, the implementation of infant HBV vaccination in Vietnam would 
require between US$ 2 and 13 million. For the base-case scenario with a vaccination budget of US$ 5.9 
million per year (Table 2), the probability that the program would be affordable was only 26% because 





Figure 5 Affordability curve to explain the impacts of financial resources on the universal newborn HBV 
vaccination program in Vietnam (payer’s perspective) 
 
Cost-effectiveness affordability curve 
The ideal situation is for the vaccination program to be both cost-effective and affordable. Combining 
the cost-effectiveness acceptability curve and the affordability curve, the cost-effectiveness affordability 
curve presented various scenarios for a vaccination program to be both cost-effective and affordable at 
different cost-effective threshold values and budgets (figure 6). The analyses showed that if the budget 
is less than US$ 2 million, the probability for the vaccination program to be cost-effective and affordable 
is 0%, regardless of the WTP threshold. In the base-case scenario with a cost-effective threshold of 
US$ 3.77 per QALY and a budget of US$ 5.9 million, the probability for the vaccination program to be 
both cost-effective and affordable was 21 percent. If the budget was increased to US$ 10 million, the 
program would have a 65% probability of being cost-effective and affordable at a WTP threshold of 
US$ 6.5 per QALY. Under the most ideal situation where the budget reaches US$ 13 million and the 
WTP threshold reaches US$ 18 per QALY, the vaccination program would be 100% cost-effective and 
affordable.  





Figure 6 Cost-effectiveness (C-E) and affordability curve presenting various scenarios for universal 
newborn vaccination against HBV in Vietnam to be both cost-effective and affordable at different cost-
effective threshold values and budgets (payer’s perspective) 
ZDiscussion 
The results from the baseline analyses showed that universal newborn vaccination against HBV could 
reduce the HBV carrier rate by approximately 60 percent. Using the World Health Organization’s criteria 
for cost-effectiveness [47], our analyses suggest that vaccination against HBV in Vietnam is highly cost-
effective from the payer’s perspective. The incremental cost-effectiveness ratio was only US$ 3.77 per 
QALY, which is much lower than three times the GDP per-capita in Vietnam for 2002 [48]. One-way 
sensitivity analyses showed that vaccine efficacy and vaccine wastage had little impact on cost-
effectiveness whereas changes to vaccine price and HBV prevalence rate markedly influenced the cost-
effectiveness of the program.  
From the societal perspective, when the treatment costs of complications were included, universal 
newborn vaccination not only dominated no-vaccination but also was a cost-saving strategy. 
Vaccinating Vietnamese newborns against HBV could potentially save US$ 1 billion by averting the 
treatment costs of chronic hepatitis B infections and associated complications such as compensated 




Considering that the country’s GDP per-capita was approximately US$ 440 in 2002 [48] and assuming 
that the cost for a fully-immunized child was US$ 4.5 as was done in this study, vaccination remained 
quite an acceptable and affordable option even for a Vietnamese household to pay out-of-pocket. 
However, with an annual birth cohort of 1,639,000 in 2002, universal vaccination against HBV for 
newborns could amount to a very large investment for the Vietnamese government. As investment in 
health is still limited in Vietnam and resource allocation among health interventions is quite competitive, 
the cost of universal vaccination poses a heavy financial burden when the GAVI’s support for Vietnam in 
the EPI program is terminated. This financial implication should prompt the Vietnamese health decision 
makers to access the processes involved in setting priorities and allocating limited resources among 
different childhood vaccination programs. In this context, the importance of examining affordability and 
cost-effectiveness should be taken in consideration. Furthermore, our results may aid the Vietnamese 
government in the application for further financial support from the GAVI. 
The results from probabilistic sensitivity analyses in our study partly addressed concerns regarding a 
number of uncertainties surrounding a universal vaccination program against HBV. By constructing the 
cost-effectiveness acceptability curve, this study reported the probabilities that a vaccination program is 
cost-effective over a range of willingness-to-pay thresholds. However, cost-effectiveness does not imply 
affordability. Application of the affordability curve showed that the newborn vaccination program against 
HBV in Vietnam could start as low as US$ 2,100,000 but becomes 100% cost-effective and affordable 
with an annual budget of at least US$ 13 million (figure 5). Even at this maximum level of investment, 
the program cost is extremely modest in comparison to the treatment costs of chronic HBV infections in 
Vietnam that could amount to more than US$ 1 billion. In addition, a vaccination program will gradually 
reduce HBV prevalence in Vietnam. Therefore, continuing the vaccination program appears to be a wise 
health investment. 
Our study confirms that vaccination is absolutely cost-effective in Vietnam from the payer’s perspective 
and is a cost-saving intervention from the societal and healthcare perspectives. These results are in 
agreement with other studies in high-endemic and intermediate-endemic countries. Because Vietnam is 
a high-endemic country regarding HBV infection, a universal newborn vaccination program is a “must-
do” strategy.  
However, this study has a few limitations. First, we applied a simple static Markov model of the disease 
instead of a dynamic model. Because of the lack of data and information, we opted to focus only on the 
chronic part of the hepatitis B infection and ignored the acute and fulminant stages of hepatitis B 
infection. However, morbidity from these clinical presentations was short-lasting and mortality 
constituted only a small proportion of hepatitis B related deaths. Therefore, the inclusion of these factors 
in our model would likely result in the vaccination strategy being even more cost-effective. Second, 
there is an absence of published epidemiological data on hepatitis B in Vietnam. As a result, we used 
published data from other countries in the region where extensive research on the disease had been 
conducted [25,31,34,35,40], and in the cases where no data were available at all, we used data from 
the western world. This is justified because disease progression rates appear to be stable across 
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populations. Third, we did not have age-specific disease progression rate and we assumed the same 
prevalence rate for all age groups. This might underestimate the number of infections that would occur 
in this birth cohort and that current prevalence is a rough estimate for infections that might occur to the 
population. Fourth, the study did not take into account the indirect herd-immunity effects; doing so would 
likely result in a more favorable cost-effectiveness for the vaccination strategy.  
As the first cost-effectiveness study on universal newborn vaccination in Vietnam, the outcomes are 
very encouraging and informative. The results will assist policy makers in evaluating the continued 
support for universal vaccination against HBV infection. Our findings will also be informative for health-
policy decisions in other highly endemic countries of HBV prevalence. In addition, our study 
demonstrated how the application of cost-effectiveness affordability curve could be used for resource 
planning of other health interventions, especially for new and underused vaccines. To fully evaluate 
impacts of HBV vaccination in Vietnam, future studies applyingdynamic models of HBV infection to 
account herd immunity and acute fulminant stages of the disease are recommended.  
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Objectives: The main aims of this work were to describe patterns of medication use in the treatment of 
chronic hepatitis B virus (HBV) infection in patients in the northern part of the Netherlands and to 
compare these practices with established guidelines. In addition, the duration of use and the costs of 
these treatments were investigated. 
Methods: We selected subjects from the University of Groningen’s IADB.nl database; by 2006, the 
database provided information about drug utilization from 55 community pharmacies in the northern 
Netherlands and included a population of 528,911 individuals, of which 49% were male. Eligible 
subjects had received ≥1 prescription for drugs used to treat chronic HBV infection (ie, lamivudine, 
pegylated interferon-α2a, pegylated interferon-α2b, adefovir, tenofovir, and entecavir) between the 
years 2000 and 2006. The annual prevalence and cumulative incidence of HBV treatment per 1000 
people covered in the database were calculated and stratified by sex. Kaplan-Meier survival analysis 
was used to analyze the duration of use. Drug costs in the treatment were calculated for all patients or 
per patient, and by drugs used per subperiod (2000–2003 and 2004–2006). Treatments for hepatitis C 
virus and HIV were excluded from the analyses. 
Results: From the database, we identified 59 patients (46 male, 13 female), aged 25 to 60 years, who 
received ≥1 prescription for a medication to treat chronic HBV infection between 2000 and 2006. The 
overall prevalence of people using chronic treatments for HBV was between 0.03 and 0.06 per 1000 
during the years of the study. The cumulative incidence of treatment was ~0.01 per 1000 per year 
(ranging from a high of 0.021 in 2000 to a low of 0.009 in 2006). When stratified by sex, there were 
more male than female subjects who received medications for HBV. Lamivudine was the most 
commonly prescribed drug, followed by adefovir and pegylated interferon-α2b. In 2000 and 2001, 
lamivudine was the only medication prescribed for the treatment of chronic HBV. From 2002 to 2006, 
the prescription rate for lamivudine dropped from 90% to 61%. In contrast, the prescription rate for 
adefovir increased from 4% in 2003 to 36% in 2006. Pegylated interferon-α2b remained stable at 8% to 
11% between 2002 and 2006. Twenty-five percent of patients had stopped HBV treatment by the end of 
1 year. Fifty-five percent had stopped by 3 years. Seventy-seven percent of patients received their first 
HBV prescription from a medical specialist. Per patient, the cost of drug therapy was highest with 
adefovir. From 2004 to 2006, the cost of adefovir therapy accounted for 49% of total expenditures for 
the treatment of chronic HBV (equivalent to €128,037; as of January 2010, €1.00 = US $1.43). The 
second and third most expensive drugs were tenofovir and pegylated interferon-α2b (€33,700 and 
€33,250, respectively). Costs incurred per patient increased over the years of the study period. 
Conclusions: The overall prevalence and cumulative incidence of patients with treatments for chronic 
HBV were relatively low in the northern part of the Netherlands between 2000 and 2006. The 
prescribing and utilization patterns were in agreement with international and Dutch guidelines. Given the 
low numbers of prescriptions, the costs also remained relatively low. 




Hepatitis B virus (HBV) is one of the most prevalent blood-borne viruses worldwide, causing chronic 
liver diseases and hepatocellular carcinoma (HCC). It is an important public health problem for 
developing countries, where the endemicity is generally high or intermediate, as well as in developed 
countries. It is currently estimated that >350 million people in the world are chronically infected with 
HBV. They are at risk of death from liver cirrhosis and HCC, which cause the deaths of >1 million 
people worldwide each year [1].  
In the Netherlands and in Scandinavian countries, the carrier rates for HBV are estimated to be <2% [2–
4]. In the Netherlands, the estimated seroprevalence of hepatitis B surface antigen and hepatitis B core 
antigen antibodies are ~0.2% and ~2.1%, respectively [5]. Notified new cases of chronic hepatitis B 
were estimated at 1443 (0.01%) in 2005 [6].Despite relatively low endemicity, the Dutch health 
authorities have begun considering nationwide universal infant vaccination against HBV [7, 8]. Until 
now, only infants from ethnic minorities and specific risk groups (such as those whose biological parents 
are drug users or men who have sex with men) are provided with targeted vaccination against HBV. 
Cost-effectiveness is one of many issues that must be considered in the decision about whether to 
implement universal HBV vaccination. In addition, there may be regional differences in the occurrence 
of HBV infection within the Netherlands; for example, it is possible that the occurrence of HBV might be 
relatively low outside the major urban areas in the western Netherlands.  
The availability of antiviral drug treatment of chronicHBV infection has largely improved treatment over 
the last decade, but such treatment has also becomes more complicated, creating the need for 
treatment guidelines for chronic HBV. Existing guidelines include the European Association for the 
Study of the Liver (EASL) [9], the Asian-Pacific consensus statement [10], and the guidelines of the 
American Association for the Study of Liver Diseases (AASLD) [11].  
In the EASL guidelines of 2009, interferon-α (IFN-α), pegylated IFN-α (PEG-IFN-α), lamivudine, 
adefovir, tenofovir, entecavir, and telbivudine are now all suggested drugs for treatment of chronic HBV 
infection in Europe [9]. The Asian-Pacific consensus statement of 2008 provides recommendations on 
the treatment of chronic HBV infection using the following drugs approved in Asia: IFN-α, PEG-IFN-α2a, 
lamivudine, adefovir, entecavir, and telbivudine. In addition, clevudine has been approved in Korea and 
thymosin-α1 has been approved in several countries in Asia [8]. In the AASLD guidelines of 2007, IFN-
α, PEG-IFN-α2a, lamivudine, adefovir, entecavir, and telbivudine are the recommended drugs for the 
treatment of chronic HBV infection [9]. The list of recommended drugs differs depending on the time 
when these guidelines were published. The Dutch guidelines published in July 2008 for the treatment of 
chronic HBV infection were based on these international guidelines [7–9]. Table I shows the drugs 
recommended for the treatment of chronic HBV infection according to the Dutch guidelines.  
The main objectives of the current study of information from a claims database were to describe the 




chronic HBV infection in patients in the northern Netherlands, and to compare our findings with national 
and international treatment guidelines [7–10]. 




Interferons Interferon alfa-2a 24-08-1999 L03AB04 
 Interferon alfa-2b 09-03-2000 L03AB05 
 Peginterferon alfa -2a 20-06-2002 L03AB11 
Antiviral Drugs Adefovir Dipivoxil 06-03-2003 J05AF08 
 Entecavir 26-06-2006 J05AF10 
 Lamivudine 29-07-1999 J05AF05 
The approval date by College ter Beoordeling van Geneesmiddelen (CBG) or Medicines Evaluation Board (MEB); ATC-code: Anatomical 
Therapeutic Chemical classification code [30] 
Table 1 List of drugs for the treatment of chronic hepatitis B included in the Dutch guidelines of 2008 
 
ZMethods 
Setting and Population 
Information on drug use and related costs from pharmacy-dispensing data from community pharmacies 
in the northern Netherlands was obtained from the University of Groningen’s IADB.nl database (formerly 
called the InterAction DataBase). Dutch patients typically register at a single community pharmacy; 
therefore, this pharmacy can provide an almost complete listing of the subject’s prescribed drugs [15]. 
By 2006, the database provided information about drug utilization from 55 community pharmacies in the 
northern Netherlands and included a population of 528,911 individuals, of which 49% were male. The 
database’s pharmacy information includes, among other data, the name of the drug dispensed, 
anatomic–therapeutic–chemical (ATC) classification, date of prescription, number of days covered by 
the prescription, and the number of defined daily doses based on the definition of the World Health 
Organization [14]. However, over-the-counter (OTC) drugs and in-hospital prescriptions are not 
included. Cumulatively, the database includes data for nearly 1 million people, dating back to 1999 
(~6% of the total population of the Netherlands) [16, 17]. In this study, we retrospectively reviewed 
patients’ data from 2000 to 2006. 
Internal Review Board and Human Rights Issues 
Because this was a retrospective analysis of information from a single database, internal review board 
approval was not necessary, and human-rights protocols were not required. The information in the 








We selected, from the IADB.nl database, all patients who received ≥1 prescription between 2000 and 
2006 for the treatment of chronic HBV infection. Such prescriptions were identified by the ATC codes 
listed in Table I, as well as those for tenofovir (ATC code J05AF07) and PEG-IFN-α2b (ATC code 
L03AB10), which are also used in daily practice and recommended by international guidelines for the 
treatment of chronic HBV infection [9–11]. Because some of the drugs used to treat patients with 
chronic HBV infection may also be used for other infections and diseases, such as HIV or hepatitis C 
virus (HCV), some patients were excluded to limit the sample to the patients who were most likely to 
have been treated for chronic HBV infection. We aimed to identify patients using drugs for HBV 
treatment alone, rather than combination treatment for other and/or concomitant viral infections. The 
strategy applied for selecting patients who were most likely to have chronic HBV infections is depicted in 
Figure 1. 
 
The first step was to discriminate between groups of patients in the data obtained from the database. 
The drugs listed in box 1 of Figure 1 were used as the first inputs to discriminate for HBV, but may also 
have been used for HIV and HCV infection treatment. The second step was to exclude HIV-infected 
patients, whom we defined as those who received ≥1 prescription per month of a combination of ≥2 
drugs from the list of HIV drugs or to receive combined antiviral drug therapy (box 2). The third step was 
to exclude HCV-infected patients, identified as those who received drugs listed in box 3; for chronic 
HBV infection, PEG-IFN-α treatment should last >40 weeks and not be combined with ribavirin.18 
Patients using IFN-α were also excluded because this drug is used in the treatment of other diseases, 
such as multiple sclerosis [19–22]. In the IADB.nl database, it was impossible to distinguish between 
patients who were using IFN-α to treat chronic HBV and those using the drug for other reasons; the 
information in the database is related to individual prescriptions and not to the complete medical history. 
Thus, to avoid the possibility of including patients who were not infected with chronic HBV, we excluded 
all patients, and instead considered only patients who used other drugs approved for the treatment of 
chronic HBV infection: lamivudine, PEG-IFN-α2a, PEG-IFN-α2b, adefovir, entecavir, and tenofovir. 
(Thus, IFN-α was not a criterion we considered for screening our patients and was not included in the 
filters shown in Figure 1.) Ultimately, the remaining patients were considered to have chronic HBV 
infections. 
To validate the filters applied in this selection of subjects from the database, clinicians who specialize in 
the treatment of infectious diseases reviewed the lists of drugs used to treat HIV, HCV, and HBV. After 
we identified HBV-infected patients from the IADB.nl database, we randomly selected subsets of 
included and excluded subjects and the lists of drugs they had used. The clinicians identified the 
disease of these patients based on the list of prescribed drugs given to such patients. All patients in the 
subset were correctly identified as being infected with HBV or were correctly excluded. This validated 






Figure 1 Flow scheme used to select chronic HBV-infected patients from the IADB.nl database 
Data Analyses 
The annual prevalence of chronic HBV infections per 1000 people was calculated by counting the 
number of patients receiving ≥1 prescription for a medication for chronic HBV infection in a given year, 
divided by the total population covered in the database in that year and then multiplied by 1000. We 
stratified prevalence by sex. Cumulative incidence was calculated by counting the number of patients 
who were identified as receiving new prescriptions for medications to treat chronic HBV infection, 
divided by the total population covered in the database in that year, multiplied by 1000. The continuity 
correction method, which is used for very small proportions, was used to calculate the 95% CI values 
[23].A Kaplan-Meier survival curve was constructed to examine the duration of drug use in the treatment 
of chronic HBV infection for treatment initiators using the standard methodology.  
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A treatment initiator was defined as someone who existed in the database for ≥180 days before the 
initial prescription of anti-HBV treatment. We defined 180 days as the lag time between a prescription 
and the subsequent prescription, as is typically done in this type of drug utilization analysis. If a subject 
stopped using the drug for >180 days, he or she would be counted as a treatment initiator when 
treatment was resumed. (The 180-day threshold for defining treatment cessation was used because it is 
a standard in pharmacoepidemiology research and because patients with chronic HBV infection are 
typically seen every 3–6 months.) The starting date was defined as the date on which a patient received 
his or her initial prescription of drugs for the treatment of chronic HBV. To identify the date when therapy 
ended, we calculated the number of days of duration for every prescription, based on the daily dosage 
and the prescribed number of units (eg, tablets, capsules) for each patient. The number of days 
between the starting date and the end date was subsequently calculated. Duration of drug use was 
considered to be censored if the last recorded prescription was within 180 days.  
Additionally, data regarding the cost of drugs used in the treatment of chronic HBV infection were 
retrieved from the IADB.nl database. We calculated the total cost of the drugs for either all patients or 
per individual for the period from 2000 through 2006, based on the Dutch pharmacists’ official price list 
[24].For this purpose, prescriptions of drugs for the treatment of chronic HBV infection were linked to the 
Z index,the official price index for all drugs and their specific formulations registered for the Dutch 
market. Total costs were calculated for 2 subperiods (2000–2003 and 2004–2006) to visualize the cost 
effects of differences in the patterns of drug prescriptions. In particular, 2003 was chosen as the cutoff 
because several new antiviral drugs for chronic HBV treatment were introduced to the Dutch market that 
year (eg, adefovir, tenofovir, entecavir) [14].We calculated the annual total drug cost per subject for 
chronic HBV treatment by dividing the total cost of drugs per year for all patients by the number of 
patients who received ≥1 prescription for the treatment of chronic HBV infection in a given year. 
ZResults 
Overall Utilization 
From the IADB.nl database, we identified 59 subjects (46 men and 13 women), ranging in age from 25 
to 60 years, who had received ≥1 prescription for the treatment of chronic HBV infection in the period 
from 2000 through 2006. The total number of prescriptions for chronic HBV medications during this 
period was 716 (a mean of 12.1 prescriptions per subject). The number of patients increased from 15 in 
2000 to 33 in 2006 (P < 0.001).  
Figure 2 shows the overall prevalence of patients who were treated for HBV infection, stratified by sex 
and year. The overall prevalence increased every year during the study period from 0.03 to 0.06 per 
1000 people in the database. Prevalence among women was considerably lower than among men. 
Female prevalence remained stable from 2000 to 2002 at 0.01 per 1000 women in the database, 
slightly increased from 2002 to the end of 2003, but decreased from 2004 to 2006. The prevalence for 





Figure 2. Prevalence of hepatitis B virus (HBV) infection per 1000 people in the IADB.nl database in a 
retrospective analysis of prescription claims for drugs to treat HBV infection, dispensed from 2000 to 
2006, in the northern Netherland. Patients with suspected coinfection with hepatitis C virus or HIV were 
excluded. 
The total number of patients in the population covered by the IADB.nl database is shown in Table II, 
along with annual cumulative incidence. The cumulative incidence was stable at ~0.01 per 1000 people 
between 2001 and 2006, ranging from an overall high of 0.021 in 2000 to an overall low of 0.009 in 
2006. 
Year Population (n) Initial patients Cumulative incidence 95% Confidence interval1 
2000 486,138 10 0.021 0.011-0.037 
2001 489,871 5 0.010 0.004-0.024 
2002 495,551 5 0.010 0.004-0.023 
2003 502,146 6 0.012 0.005-0.026 
2004 511,475 7 0.014 0.007-0.028 
2005 518,219 5 0.010 0.004-0.022 
2006 528,911 5 0.009 0.004-0.022 
1
 95% confidence interval (CI) were calculated using the ‘Score with CC-method’, which is applied for very small proportions [31] 
Table 2 Population included in the IADB.nl database and cumulative incidence of chronic HBV infected 
patients per 1,000 persons per year, in a retrospective analysis of prescription claims for drugs to treat 
HBV infection in the northern Netherlands from 2000 through 2006. 
 
Per-Year Utilization Patterns 
Figure 3 shows changes in drug use over the study period (2000–2006). Lamivudine was the most 
prescribed anti-HBV drug overall. In 2000 and 2001, it was the only drug prescribed for the treatment of 
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patients with chronic HBV infections. In 2002, 90% of patients used lamivudine. From 2003 to 2006, the 
proportion of prescriptions for lamivudine among all anti-HBV drugs remained fairly stable (61%–70%). 
The proportionate use of PEG-IFN-α2b remained relatively constant from 2002 to 2006 (8%–11%). In 
the era of the new antiviral drugs (eg, adefovir, tenofovir, entecavir) being introduced to the Dutch 
market, adefovir became the second most prescribed drug for chronic HBV infection; the proportionate 
use of adefovir substantially increased from 4% to 36% between 2003 and 2006. The use of tenofovir 
remained stable following its introduction to the Dutch market in 2002. However, with the introduction of 
the other new antiviral drugs, there appeared to be a switch from monotherapy (2000, 2001, and 2003) 
to combined drug therapy (2002 and 2004–2006); switching patients to newer antiviral medications also 
appeared to be common. Based on the information from the IADB.nl database, it appeared that the only 
combination therapy used was lamivudine plus adefovir. 
Prescribers’ characteristics were analyzed for treatment initiators. In particular, 43 subjects initiated 
treatment during the study period. Of these patients, 10 (23%) received their first prescriptions from a 
general practitioner and 33 (77%) received their first prescriptions from a medical specialist. Individual 
drug choices were quite similar between general practitioners and specialists; for example, all initial 
prescriptions were for monotherapy. 
We divided the study period into 2 subperiods (2000–2003 and 2004–2006) to further investigate 
differences in the patterns of initial prescriptions. It became obvious that the proportion of lamivudine 
use among treatment initiators dropped by 21% from the first to the second subperiod (from 80% to 
59%). During the second subperiod (2004–2006), adefovir became the second most prescribed drug, 





Duration of Use 
After 3 years, 55% of users were still taking medication for chronic HBV infection (Figure 4). The 
respective proportions of patients who still used the drug after 1 and 2 years were estimated at 75% and 
68%, respectively, suggesting relatively good persistence. 
 
Figure 4. Kaplan-Meier survival curve showing duration of drug use in a retrospective analysis of 
prescription claims for drugs to treat hepatitis B virus infection, dispensed from 2000 to 2006, in the 
northern Netherlands, based on a retrospective analysis of the IADB.nl database. Patients with 
suspected coinfection with hepatitis B or HIV were excluded. 
 
Cost Incurred by Drug Use 
Figure 5 shows the cost of drugs to treat chronic HBV infection in relation to total expenses for chronic 
HBV treatment. No costs were incurred for entecavir and PEG-IFN-α2a in the period from 2000 to 2003 
because they were not used for the treatment of chronic HBV infection until 2004, based on information 
in the IADB.nl database. Costs for adefovir therapy increased substantially from subperiod 1 (2000– 
2003) to subperiod 2 (2004–2006); in subperiod 2, they amounted to €128,037 (as of January 2010, 
€1.00 = US $1.43)25 and represented 49% of all expenditures for chronic HBV therapy. Although the 
purchase price for lamivudine was almost the same in the 2 subperiods, the proportion of overall anti-
HBV treatment that was attributable to lamivudine therapy decreased from 62% in subperiod 1 to 19% 
in subperiod 2. Thus, expenditures for novel drugs increased over time. Expenditures for PEG-IFN-α2b 
remained constant between subperiod 1 and subperiod 2. The annual costs per patient for anti-HBV 
drugs increase from subperiod 1 (2000–2003) to subperiod 2 (2004–2006), from €950 to €2947 (Figure 
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6). In 2006, these per-patient costs were €171 per 1000 people in the general population, or €0.18 per 
capita. 
 
Figure 6. Annual per-patient costs (in 2 subperiods: 2000-2003 and 2004-2006) for drugs to treat 
chronic hepatitis B virus infection in the northern Netherlands, based on a retrospective analysis of 
prescription claims in the IADB.nl database. Patients with suspected coinfection with hepatitis C virus or 
HIV were excluded. 
ZDiscussion 
Principal Findings 
During the study period from 2000 to 2006, the annual prevalence of chronic HBV infection appeared to 
increase steadily, based on database information regarding prescriptions for anti-HBV medications. 
Lamivudine was the most frequently prescribed drug, followed by adefovir, as recommended by 
international and Dutch guidelines [9–12]. Lamivudine was the only drug prescribed from 2000 to 2001, 
as it was the first nucleoside analogue approved in the Netherlands for the treatment of chronic HBV 
infection. From 2000 to 2001, no other antiviral drugs were available on the Dutch market [14]. When 
more antiviral drugs were introduced to the Dutch market, the prescription rate for the older drugs (ie, 
lamivudine) decreased, and the prescription rate of newer drugs (e.g., tenofovir, adefovir) increased. 
Our results also indicated that combined therapy seemed to be more popular from 2004 to 2006; the 
combination of lamivudine and adefovir was the only one used. PEG-IFN-α was used for a very small 
and stable number of patients over the years. PEG-IFN-α2b and tenofovir were not recommended for 
the treatment of chronic HBV infection in the Dutch guidelines [12]. However, the utilization of these 2 
drugs was stable among the population investigated in this retrospective database analysis. Prescription 
patterns for drugs to treat chronic HBV infections in the Netherlands were generally consistent with the 





In terms of duration of drug use, 25% of patients (n = 9) stopped using drugs for treatment of chronic 
HBV infection within 1 year after initiation; 68% (36 patients) were treated for >2 years. Fifty-five percent 
(34 patients) continued the therapy for >3 years. This illustrates the chronicity of the disease and related 
drug use; clinical guidelines call for patients to receive therapy for chronic HBV infection for an extended 
period, or even for the rest of their lives. In addition, most of the patients in the IADB.nl database used 
nucleoside or nucleotide analogues (e.g., lamivudine, adefovir, tenofovir, entecavir) rather than PEG-
IFN. A disadvantage of using nucleoside or nucleotide analogues is that they typically require prolonged 
or indefinite therapy because the sustainability of their response after treatment discontinuation is 
limited [26].  
In this retrospective analysis of Dutch prescription data, more men than women were treated for chronic 
HBV infection; the between-sex difference in infection prevalence increased over the course of the 
study period. This is unsurprising, given that men who have sex with men are considered to be at 
particularly high risk of HBV infection, which might have been increasingly detected with the risk-group–
based approach to vaccination in the Netherlands in recent years [27]. Other populations at high risk for 
HBV infection include persons who have multiple sexual contacts, immigrants from areas of moderate 
or high endemic HBV prevalence, and intravenous drug users. Although the database used in the 
present study included information about sex, it did not include information about subjects’ ethnicity. The 
patients identified in the IADB.nl database were in the age range of 25 to 60 years.  
Adefovir, which was introduced to the Dutch market in early 2003, appeared to be the most costly drug 
for the treatment of chronic HBV infection. Lamivudine was the most prescribed drug; expenditures for 
this drug remained steady over the period investigated. Annual mean per-subject expenditures for anti-
HBV drugs increased from 2000 to 2006. This may have been partly the result of higher prices for 
newer drugs. 
Study Strengths and Weaknesses 
As noted previously, this study was conducted with the IADB.nl database, which contains information 
about prescriptions dispensed in the Netherlands. The IADB.nl database has several strengths. It 
includes information about 528,911 people for a large period of time (from 1999 to the present), 
providing detailed dispensing records. Moreover, it also provides information about costs incurred for 
the purchase of drugs to treat chronic HBV infection over the course of a given year. 
However, the database could not provide information about the actual use of dispensed medicines. 
Therefore, the present study describes patterns of drug dispensing, rather than drug use; it is possible 
that the 2 may differ. Furthermore, the database does not contain medical records; thus, diagnoses 
must be inferred from the drugs dispensed, rather than determined more directly. By trying to filter out 
patients who might have received antiviral medications for other diseases, we may have underestimated 
the number of patients with chronic HBV infection. For example, we excluded users of IFN-α because 
this medication may be used to treat other diseases, even though it was the first medication used to 
treat HBV infection. Also, no information about drugs obtained OTC or in hospitals was available; 
however, the role of such drugs in the treatment of chronic HBV may be minor. Despite these 
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limitations, the IADB.nl database makes it possible to retrospectively evaluate drug use in a relatively 
large and well-defined population. Further work should seek to link the IADB.nl prescription database 
with other databases comprising medical, diagnostic, and virologic information.  
According to Dutch treatment guidelines [12], the recommended duration of therapy with PEG-IFN-α is 1 
year for all patients, and the required duration of therapy with nucleoside or nucleotide analogues is 
longer. Our results suggest that prescriptions forchronic HBV infection in the Netherlands conform to 
this recommendation. The primary difference between actual practice and the Dutch guidelines was that 
tenofovir and PEG-IFN-α2b were prescribed for the treatment of chronic HBV infection in practice, even 
though the guidelines do not yet recommend such use in the Netherlands. However, the Dutch 
guidelines were published relatively recently, so patients who were treated for chronic HBV infection 
before their publication may have received therapy that did not conform to the current 
recommendations.  
The results of the present analysis indicate relatively low prevalence and incidence of HBV infection in 
the Netherlands during the study period, which supports previously published findings.6 In fact, the 
prevalence we observed (0.03–0.06 per 1000) is low compared with the overall prevalence of chronic 
HBV infection in the Netherlands (0.2%) [12]. However, it should be noted that the present analysis 
included only patients who received pharmacotherapy, and excluded those who were likely to have 
been coinfected with HCV or HIV. The general prevalence of 0.2% includes patients who do not receive 
pharmacotherapy, as well as those with coinfections. 
Our results also indicate that switching to newer antiviral drugs and prescribing combined therapy 
(particularly lamivudine plus adefovir) have become more common since 2004. A previously published 
study reported that combination therapy with lamivudine and adefovir was associated with higher rates 
of response and lower rates of resistant mutations than lamivudine monotherapy [28]. The combination 
of IFN-α or PEG-IFN-α with lamivudine is also associated with higher rates of treatment response than 
lamivudine monotherapy [11]. 
Despite the relatively low prevalence of HBV infection in the Netherlands, the Dutch health authorities 
are currently considering a nationwide universal infant vaccination against HBV [7,8].It should be noted 
that the occurrence of HBV infection might be greater in urban areas, and the epidemiology of HBV in 
the Netherlands may be influenced by populations originally from regions where HBV infection is more 
common [23,27,29,30]; more immigrants live in the large cities in the western Netherlands (e.g., 
Amsterdam, Rotterdam, the Hague). The IADB.nl database covers the population of the northern part of 
the Netherlands, where considerably fewer immigrants live. However, the low rate of treatment and 
modest expenditures for anti-HBV therapy in the northern Netherlands do not support the inception of a 
national HBV vaccination program. 
ZConclusions 
The results of this retrospective analysis of information from the IADB.nl database indicate that the 




based on the numbers of prescriptions for and the expenditures for pharmacotherapy to treat the 
disease during the study period. 
To our knowledge, this is the first study of drug utilization and costs for the treatment of chronic HBV 
infection in the Netherlands. Patients with chronic HBV infections may be coinfected with either HIV or 
HCV, but patients taking pharmacotherapy that suggested such coinfections were excluded from the 
present analysis. Further research is needed to explore drug utilization in HIV–HBV or HBV–HCV 
coinfected patients. 
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Diarrhoea is a leading cause of mortality for children under-five-years old, and rotavirus is identified as 
the main cause of severe diarrhoea worldwide. Since 2006, two rotavirus vaccines, Rotarix and Rotateq, 
have been available in the market. These vaccines have proved to have high efficacy in developed 
countries. Clinical trials are being undertaken in Asia and Africa, and early clinical results find that the 
vaccine significantly reduces severe diarrhoea episodes due to rotavirus (48.3% for Asia and 30.2% for 
Africa). The World Health Organization (WHO) recommended that rotavirus immunization be included 
into all national immunization programs. Based on WHO’s recommendations, the Global Alliance for 
Vaccines and Immunization (GAVI) decided to provide financial support of rotavirus immunization in the 
developing world. In this review, we attempted to ascertain the cost-effectiveness of universal rotavirus 
immunization in developing countries.  After an extensive literature search, we identified and evaluated 
15 cost-effectiveness studies conducted in the developing world. The results from these studies showed 
that rotavirus immunization is a cost-effective strategy and the “best hope” for prevention of rotavirus-
related diarrheal disease. However, rotavirus vaccines are expensive and the vaccine price appears as 
the most challenging and crucial factor to decision-makers regarding whether to introduce this vaccine 
into developing countries’ immunization. All the studies concluded that rotavirus immunization is cost-
effective but it might not be affordable for the developing world at present. Developing countries will 
definitely rely on the financial support from international organizations to introduce rotavirus vaccination. 
It is recommended that more cost-effective research with updated data be conducted and new rotavirus 
vaccine candidates be developed at cheaper price to speed up the introduction of rotavirus 
immunization in the developing world. 
  




Globally diarrhoea is a leading cause of child mortality. Annually, worldwide, around 1.8 million children 
under the age of five die from diarrhoeal diseases and rotavirus is identified as the most common cause 
of severe diarrhea [1-3]. Rotavirus infection has been reported to be responsible for more than 2 million 
hospitalizations and roughly 527,000 deaths [4]. The burden of disease of rotavirus infection is 
considered high in both developed and developing countries. However, the disease mortality caused by 
rotavirus is a more serious public health concern in the developing world as more than 85% of the 
rotavirus-related deaths occur in Africa and Asia [5]. Correspondingly, rotavirus infection and its 
consequences have become a heavy economic burden to both national healthcare systems and 
families in many low-income countries. 
In addressing high rotavirus-related diarrhoeal hospitalizations and mortality rates among young 
children, immunization against this virus appears to be the most promising prevention strategy. This is 
particularly so for regions in Asia and Africa, where living conditions are poor and medical services are 
limited thus enhancing potentials for rotavirus infections to develop into more severe complications.  
Since 2006, two approved rotavirus vaccines, Rotateq (Merck) and Rotarix (Glaxo SmithKline), are 
available worldwide. These vaccines have demonstrated good protection against rotavirus infection and 
as such a good preventive agent against rotavirus-related severe diarrhoea and hospitalizations [6-11]. 
Therefore, the World Health Organization (WHO) recommends the inclusion of rotavirus vaccination into 
countries’ immunization programs [12]. However, the costs of current generations of rotavirus vaccines 
are high in comparison to the current budgets spending for vaccines for prevention of childhood 
illnesses in many developing countries [13,14].  
The decision to incorporate rotavirus vaccination into national immunization programs must be based on 
evidence including evidence on cost-effectiveness of such a strategy. At the global level as rotavirus 
vaccines is introduced into national immunization programs of developing countries, often with financial 
support from global initiatives, monitoring the implementation of these strategies is very important to 
ensure that the public fund is not being used suboptimally. Part of the assessment should include 
conducting cost-effectiveness analyses of rotavirus immunization in developed and developing 
countries, both prior and after potential introduction.  
In this review, we systematically summarize the international peer reviewed literature on economics and 
cost-effectiveness of rotavirus immunization with a focus on studies performed in the developing world. 
This focus is justifiable on the ground that it is in the developing world where the burden of rotavirus-
related disease is the highest and the challenge of assuring vaccine performance the greatest when 
introducing rotavirus vaccination into countries’ national immunization programs most urgent. This paper 
shows the results and methodologies of formal cost-effectiveness analyses, different vaccine pricing 
scenarios, under which rotavirus immunization might be affordable and acceptable, and challenges 
faced by governments of developing and low-income countries when considering to introduce rotavirus 





Criteria for cost-effectiveness evaluation of healthcare interventions 
All cost-effectiveness studies included in this review used one of the following standards set by either 
the WHO or the World Bank to assess the cost-effectiveness of rotavirus immunization in countries 
where studies were carried out.  
WHO Commission on Macroeconomics and Health 
There is no formal threshold for cost-effectiveness evaluations of healthcare interventions in developing 
countries. The WHO’s Commission on Macroeconomics and Health suggests that interventions are 
considered “very cost-effective”, “cost-effective” and “not cost-effective” when their costs are less than 
the Gross Domestic Product (GDP) per capita per disability-adjusted life year (DALY), three times GDP 
per capita per DALY and higher than three times GDP per capita per DALY, respectively (102).  
The World Bank 
For developing countries (a country of low- or middle-level of GDP per capita is labeled a developing 
country [World Bank definition] [103]), an intervention is defined as highly cost-effective if an 
incremental cost effectiveness ratio (ICER) is ≤ US$ 227 per DALY averted [15]. For low-income 
countries (a low-income country is a country with 2008 gross national income per capita at US$975 or 
less [World Bank definition] [103]), an intervention is defined as highly cost-effective if an ICER is ≤ 
US$ 166 per DALY averted (15).  
Search strategies 
Economic evaluations of rotavirus vaccination were searched using PubMed and Embase databases. 
Keywords for retrieval were “rotavirus” or “rotavirus gastroenteritis” and “cost-effectiveness” or “cost-
benefit” or “cost-utility” or  “economic cost” or “cost” or “costs” or “economic evaluation” and “vaccination” 
or “immunization” and “developing countries” or “low-income countries”. We decided to select studies 
between 2000 and August 2010 because rotavirus vaccines are very new vaccines, which have been 
available in the market only since 2006.  
Eligible criteria 
Further eligibility criteria stipulated that: 
• Studies should be strictly classifiable in one of the formal health-economic categories of cost-
effectiveness, cost-utility or cost-benefit analysis (CEA, CUA and CBA, respectively). 
• Studies should be written in English and only peer-reviewed journals were considered. 
• Studies were strictly conducted in developing or low-income countries.  
All abstracts retrieved from the electronic databases were independently screened and reviewed by two 
team members (MJ Postma and HA Tu). Disagreements were resolved through discussions. Eligible 
abstracts were later retrieved in the full-text format and screened by another reviewer (HJ Woerdenbag) 
for confirming eligibility. Reference sections of the retrieved articles were manually searched for any 
potential missing studies. 





Detailed information was abstracted using a pre-specified data extraction form. Items in the form 
included author(s), publication year, country, approach, validation/calibration of models, type of 
sensitivity analysis, perspectives taken and outcomes included.  
In this review, we specifically focus on economic modeling, perspectives taken (societal, healthcare, 
payer), and discount rate as they are important factors for cost-effectiveness analyses. Generally, these 
aspects are well known to reflect important issues in the health economics of vaccines, especially for 
new and underused vaccines. 
ZResults 
General 
In total, 138 potentially relevant articles published between 2000 and August 2010 were retrieved. 
Figure 1 describes the flow chart of the literature search. After culling according to the eligibility criteria, 




rotavirus immunization between 2000 and August 2010. Of these, 8 studies took place in Asia [14,16-
21]; 3 came from Africa [22,23] and 4 were done in Central and Latin America [24-27]. Eight studies 
were conducted in GAVI Alliance-eligible countries [13,14,17-20,23]. The search result and culling 
process are shown as per Figure 1. 
The oldest study emerging from the search was from 2005 [16] and the most recent study was 
published in 2010 [13]. The most relevant aspects of these studies are summarized in Table 1. 
Study characteristics 
Most studies being review evaluated the cost-effectiveness of universal rotavirus immunization 
[13,14,16-21,23,24-28] except for the study by Ortega et al. [22], being a cost-benefit analysis. In all 
studies, universal rotavirus immunization was evaluated and no study was found for targeted 
immunization. This is not surprising given the general notion that no clear risk factors for rotavirus 
infections can be identified. Thirteen studies modeled impacts of universal rotavirus immunization on 
children under 5 years of age [14,16-24,26-28], while two studies [13,25] modeled impacts of universal 
immunization of children up to only two years old. Details are provided in Table 1.  
Perspectives taken in evaluation rotavirus immunization 
All studies under review followed the WHO’s generic protocol for monitoring the impact of rotavirus 
immunization [29]. All cost-effectiveness analyses were conducted from either the societal perspective 
(e.g., including direct medical cost, direct non-medical cost and indirect cost, n = 14) or/and the 
healthcare perspective (e.g., including direct medical cost and direct non-medical cost, n = 15). In other 
words, there is only one study, which was conducted solely from the healthcare perspective.  
 
Detailed results on economic evaluations of rotavirus immunization 
Cost-effectiveness analysis 
Cost-effectiveness analyses (CEAs) were carried out in two countries in Africa [32;33]. In Malawi 
rotavirus infection is very common in children. The country is eligible for the highest support from the 
GAVI Alliance for co-financing new vaccines. Berry et al.conducted a CEA of universal rotavirus 
immunization in Malawi [13]. This study differs from others because impacts of rotavirus immunization 
were evaluated in children under two years old only, which can be considered as a conservative 
approach. Importantly, the study considered impacts of both the GAVI Alliance subsided vaccine price 
and the marketed vaccine price on the cost-effectiveness result. The study shows that at both the GAVI-
subsided and the marketed vaccine price, universal rotavirus immunization in Malawi is cost-effective, 
with ICERs per DALY of US$ 5.07 and US$ 74.73, respectively. Sensitivity analyses revealed that 
under both vaccine pricing schemes, the cost-effectiveness was most sensitive to vaccine efficacy, 
vaccine price and rotavirus-related mortality of under-two-year-old children. The authors also noted that 
even at a relatively low preliminary estimate of vaccine efficacy of 49%, the vaccine still presents a very 
good value for money. Adding rotavirus vaccination to Malawi’s immunization program was 
recommended as very advantageous to public health. 
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In a study conducted in Kenya it was shown that universal rotavirus immunization could prevent 55% of 
deaths, 65% of hospitalizations and 59% of clinic visits, all related to rotavirus infection [23]. The 
program would be cost-saving if the vaccine price was less than or equal to US$ 1.03 per dose 
(including administration). The study revealed that outpatient cost was a major part in the treatment 
costs (and potential savings) of rotavirus infection in Kenya. The authors concluded that when vaccine 
price was below US$ 7.35, 9.26, and 20.31 per dose based on thresholds of the WHO, World Bank and 
the Kenyan GDP per capita in 2006, which was US$ 580, respectively, rotavirus immunization would be 
cost-effective. However, these pricing thresholds are much higher than the GAVI-subsidized price of 
US$ 0.30 per dose that is offered to developing and low-income countries, thus making immunization 
cost-saving only if Kenya receives financial support from the GAVI Alliance. The authors also 
emphasized that the GAVI’s additional financial support is only available for the first 5 years of vaccines 
implementation. After that, Kenya will have to finance rotavirus immunization by itself with the risk of 
becoming unaffordable to Kenyan government in the long run, although mentioned threshold prices do 
provide some room for still being cost-effective at higher pricing. It is notable that at the time the study 
was carried out, only early results of rotavirus vaccine trials were available in Africa. The authors 
considered it very important to continue surveillance on the impact of immunization on the disease 
burden in Kenya.  
 
Several economic evaluations on rotavirus vaccination have been performed in Asia to assess the 
potential cost-effectiveness of the vaccine. The most recent CEA comes from Thailand. Similar to many 
studies in the developing world, the authors wanted to explore the feasibility if rotavirus immunization 
were introduced to Thailand [28]. The study highlighted that universal rotavirus immunization could be 
cost-effective in that country, saving 109,918 outpatient visits and preventing 419 deaths per year. The 
break-even price calculated from the healthcare perspective was quite high (US$ 6.2 per dose), which 
almost equals the current market price of available rotavirus vaccines in Thailand. Yet, for rotavirus 
immunization to be affordable in Thailand, the vaccine price should be lower than the current market 
price of US$ 7 per dose. In addition, Thailand is not a GAVI-Alliance eligible country; therefore, it will not 
receive concessional purchase price for rotavirus vaccines. This indicates that implementing rotavirus 
immunization in Thailand could be a financial challenge for the government.  
Two CEAs were carried out in Vietnam. The first study, being the oldest one included in this review, 
explored the impact of universal rotavirus immunization from both the societal and healthcare 
perspectives [16]. Cost data were collected and compared for urban and rural areas. Direct medical 
costs were about 1.5 times higher in urban areas than in rural areas. In contrast, the total cost per 
outpatient visit was higher in rural than in urban areas. Hospitalizations accounted for 75% of the total 
direct medical cost. The authors concluded that introducing rotavirus immunization might potentially 
reduce 70% of related outpatient visits, 84% of hospitalizations and 83% of deaths and probably 
become a cost-effective strategy in Vietnam. The cost-effectiveness of the program would be most 
sensitive to rotavirus-related mortality rate and vaccine price. The medical break-even point occurred 
when the vaccine price was estimated at US$ 1.04 for a two-dose vaccination regime (Rotateq). It was 




vaccine into the Vietnamese routine immunization. At the time the study was conducted in 2005, the 
GAVI Alliance did not provide financial support for rotavirus vaccination yet.  
The second Vietnamese study by Kim et al. was the first to conduct a cost-effectiveness analysis of 
universal rotavirus immunization in a developing and low-income country by applying a complex Markov 
model [19]. Many comparable studies only used a simple static model with the assumption that each 
child would be infected with rotavirus only once in his or her life-time. However, these authors embarked 
in exploring the impact of rotavirus immunization by developing a Markov model, which captured the key 
features of rotavirus infections such as allowing a child to get up to four infections during the child’s 
lifetime. The model also took into account partial immunity by wild type infection that varies depending 
on the number of past infections. Another difference of this study compared to almost all studies in this 
review was the inclusion of vaccine wastage in the model and the use of a probabilistic sensitivity 
analysis to test the robustness of the results including parameters’ uncertainty. The study revealed that 
cost-effectiveness was most sensitive to vaccine price, vaccine efficacy against severe diarrhoea and 
discount rate. In summary, the study showed that rotavirus immunization would reduce the incidence of 
severe cases of rotavirus gastroenteritis by 67%. Vaccination appeared to be a cost-effective strategy, 
as the ICER per DALY was US$ 540 and US$ 550 from societal and healthcare perspectives, 
respectively, values that were lower than GDP per capita in 2009 [15]. However, the authors argued that 
for a developing and low-income country like Vietnam, favorable cost-effectiveness of an immunization 
program does not necessarily implies affordability for the country’s healthcare system when the 
resource is limited. Obviously, rotavirus vaccine is still quite expensive, thus posing a financial hurdle for 
its introduction into the national immunization. Nonetheless, both the studies by Fischer et al. [16] and 
Kim et al. confirmed the cost-effectiveness of rotavirus immunization in Vietnam [19].  
In China, the Lanzhou lamb rotavirus vaccine has already been developed and licensed since 1998, but 
rotavirus immunization has not yet been integrated into the EPI. Wang et al. conducted a cost-
effectiveness study to assess potential benefits of universal rotavirus immunization by using this vaccine 
[21]. The authors concluded that in China rotavirus immunization was cost-effective, especially in 
remote rural areas. In contrast to other studies, the analysis was performed from the patient’s 
perspective where all out-of-pocket payments were considered. It was clear that in the absence of 
health insurance in rural areas in China, treatment cost are borne by the patient’s family and thus, the 
patient’s out-of-pocket expenditures would be the major hurdle for the introduction of rotavirus 
immunization. The strength of this study compared to other studies is that it did not rely heavily on many 
assumptions. Much data was derived empirically from a prospective, population-based diarrhoeal 
surveillance. The authors themselves also conducted a cost-of-illness study to collect the cost incurred 
due to rotavirus infection. Univariate and probabilistic sensitivity analyses showed that the cost-
effectiveness of rotavirus immunization was most sensitive to vaccine price. The authors concluded that 
in China where 80% of people live in the rural areas, rotavirus immunization should be considered as a 
potential, cost-effective measure against rotavirus infection. 
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Wilopo et al. in a study in Indonesia confirmed that rotavirus immunization can effectively reduce the 
disease burden and rotavirus-associated healthcare cost [14]. The study evaluated the possibility to 
introduce rotavirus vaccine in the Indonesian national immunization program. It showed that immunizing 
children of less than 5 years old reduced deaths, hospitalizations, outpatient visits by 76.5%, 84%, and 
70%, respectively. Immunization would become cost-saving with the vaccine price less than US$ 2.7 
per dose from the healthcare perspective. Vaccine cost was the main driver influencing the program’s 
cost-effectiveness. Similar to all other studies under review, rotavirus immunization in Indonesia was 
considered a cost-effective intervention. However, affordability of a rotavirus immunization program is 
uncertain to the government despite its obvious cost-effectiveness results. This is congruent with 
findings from the studies by Kim et al[19] and Tate et al [23]. Indeed, available rotavirus vaccines have 
been argued as costly vaccines and they face likely competition by other childhood vaccines for gaining 
the limited budget allocation. The authors emphasized the need for external financial support from 
international organizations and less-costly produced rotavirus vaccines in Indonesia in order to make 
universal rotavirus immunization affordable.  
Two studies were carried out in the Central Asia. With a set-up comparable to other cost-effectiveness 
studies on rotavirus immunization, Flem et al performed their research in Kyrgyzstan [17], a GAVI 
Alliance-eligible country [105]. The authors analyzed the disease cost in terms of direct medical, direct 
non-medical and indirect costs due to rotavirus infection and estimated the future savings from 
immunization against the disease. A detailed cost composition showed that medical costs accounted for 
52% of the total cost-per-episode of rotavirus admission, while the remaining 48% were generated from 
the direct non-medical and indirect cost. Out-of-pocket payment to take care of inpatients and 
outpatients contributed substantially to the total treatment cost. From a detailed sub-analysis, it 
appeared that families of children with diarrhea used almost 62% of their savings, which in turn reduced 
household expenses by 31% in order to shift funds to cover illness expenses. Through the cost-
effectiveness analysis, it was calculated that rotavirus immunization for children under five years old 
would reduce 63% of direct medical costs or 66% of the total cost of treatment. Rotavirus immunization 
would be cost-effective at a vaccine price per child of less than US$ 9.41 per dose. The program would 
become cost-saving for the Kyrgyz government at the GAVI-subsided price of US$ 0.3 per dose and 
also in the range of US$ 0.5-1 per dose if the societal perspective is taken. Sensitivity analyses 
revealed that the program’s cost-effectiveness was most sensitive to mortality rate, vaccine efficacy 
against mortality and vaccine price. The study was carried out at the time Kyrgyzstan received GAVI’s 
financial support for rotavirus immunization. However, the future possibility for immunization being 
affordable is still questionable when the country would eventually rely on its own funding in sustaining 
immunization. The study’s strength lies in applying the same methods for economic evaluation, which 
has been applied in similar studies in Eastern Europe region. This enables comparisons within the same 
region and income strata. However, it also encountered several similar limitations as other studies in 
terms of calculation of the disease costs, which are of often difficult to measure and estimated with 




The second study carried out in Central Asia came from Uzbekistan [18]. Like Kyrgyzstan, Uzbekistan is 
a GAVI Alliance-eligible country. In general, the country has high vaccine coverage and a well-
established infrastructure for vaccines delivery. The authors conducted a cost-effectiveness analysis on 
universal rotavirus immunization in Uzbekistan using both the national and international data on 
mortality. Based on the national data, rotavirus immunization would be cost-effective at vaccine prices 
up to US$ 8 per dose. In contrast, using the international data, rotavirus immunization could be cost-
effective at the vaccine price up to US$ 25 per dose. It was concluded that the cost-effectiveness results 
were most sensitive to mortality rate and vaccine price were most crucial in determining the cost-
effectiveness results. Rotavirus immunization could prevent 91% of hospitalization cost, of which direct 
medical costs accounted for 89% (equivalent to US$ 328,154 for the healthcare system). The authors 
also estimated out-of-pocket expenses spent by families on hospitalizations, which was around 37% of 
families’ incomes. This figure clearly supported that rotavirus infection is a heavy financial burden for 
Uzbek individuals due to the long hospitalization in the rotavirus treatment protocol in Uzbekistan. The 
authors suggested to shorten the hospitalization stay in order to save costs incurred by these individuals 
beyond healthcare insurance cover. The study also faced several limitations. The cost incurred by 
outpatient visits was neglected and the reported indirect cost was low as the data was collected only by 
interviewing women, who traditionally do not work in Uzbekistan. However, this was the first study in a 
former Soviet Union’s country, which aimed to quantify the financial burden caused by rotavirus 
infection. It would definitely support health decision makers in such countries to develop a proper 
rotavirus immunization plan. 
The most recent cost-effectiveness study on rotavirus immunization in Latin America comes from 
Columbia and was done by De la Hozet al [25]. Different from all other studies, the authors measured 
the impact of using the two available vaccines (Rotarix vs. Rotateq) by comparing immunization against 
“no vaccination” for three hypothetical cohorts (immunization using Rotarix, immunization using Rotateq 
and no immunization). This approach could capture costs and effects from all possible immunization 
scenarios using available vaccines in the market. The results showed that rotavirus immunization could 
be highly cost-effective in Columbia, with the average cost-effectiveness ratio (ACER) of approximately 
US$ 1,063 per DALY if comparing vaccination with no vaccination. Compared to no immunization,it 
would bring a 27% and 25% reduction in hospitalization and death averted for Rotarix and a 30% and 
28% reduction in hospitalization and death averted for Rotateq. Rotavirus immunization would become 
cost-saving at the vaccine price of US$ 3 per dose. Sensitivity analyses also revealed that vaccine price 
and vaccine efficacy are the critical variables to the cost-effectiveness results. The authors emphasized 
that although both vaccines have high potentials of being beneficial to the Expanded Program on 
Immunization (EPI) program in Columbia and could potentially reduce the mortality rate in the country, 
the final choice on vaccination still has to be made by the health decision makers. Using Rotateq 
resulted in a higher reduction rate of hospital admissions and deaths, but the three-dose course for 
children requires more logistics and investment. In contrast, Rotarix requires only two doses, and thus 
reducing a lot of direct non-medical and indirect cost of caregivers as well as the cost of the health 
system. The authors further suggested that selecting appropriate immunization strategies depends on 
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the choice of vaccines. To do that, surveillance and identification of the rotavirus strains related to the 
disease are needed.  
Rose et al evaluated the cost-effectiveness of mass immunization in India using one specific rotavirus 
vaccine [20]. In contrast to comparable studies conducted in other developing countries where the 
complexity of the disease epidemiology was ignored, the authors of this Indian study took a different 
approach in their economic evaluation. In the model, the simulations of sequential events, from infection 
to symptoms development, use of health services, disease outcomes, recovery and re-infection for a 
heterogeneous birth cohort were explicitly taken into account. Similar to Kim et al [19], the model in this 
study shared some key features of rotavirus infection such as incorporating partial immunity from 
previous infections and the possibility of being re-infected. However, the major strength of this model is 
that it simulates clinical events and health services while accounting the effects of each individual’s age, 
infection and vaccination history. Vaccine efficacy was also adjusted to account for specific rotavirus 
strain distributions in India. Methodologically, the Markov model used in this study was the most 
sophisticated and most complex compared to other CEAs included in this review. The authors also 
concluded that universal rotavirus immunization was cost-effective in India and the results were 
reconfirmed by one and two-way sensitivity analyses. An interesting finding emerging from this study 
was the sensitivity of ICERs to the probability of using outpatient services. This in fact was the only 
parameter that could plausibly increase the ICERs to a value greater than one time GDP per capita 
while being varied.  
In the most recent study from Brazil, de Soarez et al conducted a cost-effectiveness analysis of 
universal rotavirus vaccination in that country [26]. Brazil is one of the first countries, that has 
implemented universal rotavirus immunization using the Rotarix vaccine since 2006. The study was 
performed from both the societal and healthcare perspectives. In the healthcare approach, only costs 
incurred from public health facilities were calculated, although 30% of healthcare services in Brazil 
come from the private sector. The authors developed a decision tree model to simulate the disease 
progression in the case of rotavirus infection. The disadvantage of this model was that it only allowed 
each child to get one rotavirus infection during his or her lifetime. The study concluded that universal 
rotavirus immunization in Brazil was proven very cost-effective from both societal and healthcare 
perspectives. The authors argued that if the model were allowed to capture rotavirus re-infections, 
rotavirus immunization would become even more cost-effective. Results from sensitivity analyses 
showed that cost-effectiveness of immunization would be the most sensitive to rotavirus incidence, 
proportion of severe, moderate and mild diarrhea episodes, vaccine coverage and vaccine prices. Cost-
effectiveness results were not sensitive to treatment cost or discount rate. The break-even point for 
immunization would be US$ 9.98 and US$ 4.24 per dose from the societal and healthcare perspective, 
respectively. The authors also emphasized that in a populous country like Brazil, where there is a huge 
regional and socio-economic difference, using only local data on costs to represent the national values 
might undermine the accuracy of the results. Like all other CEA studies, indirect effects of herd 
immunity were not considered as no data was yet available from the literature. Despite these 




rotavirus vaccination in Brazilian National Immunization Program in 2006 was justifiable from the 
economic point of view. 
In an earlier study from Brazil, Constenla et al performed a cost-effectiveness analysis of rotavirus 
vaccination in the country [24]. The authors explored the benefits of mass rotavirus immunization by 
calculating the savings from the medical treatment of gastroenteritis, number of averted hospitalizations, 
outpatient visits, deaths and DALYs. The outcome measures of this study were different from the study 
by de Soarez et al, where the authors aimed to calculate the number of life-years saved and deaths 
averted [26]. It was shown that rotavirus vaccination possibly saved Brazil’s healthcare system 
US$ 19.3 million of direct medical costs. Cost-effectiveness results were most sensitive to vaccine price, 
vaccine efficacy and rotavirus-associated mortality rate. The authors argued that at US$ 7-8 per dose, 
the program would be cost-effective according to the WHO’s definition. However, it might not be 
affordable in Brazil if the government eventually had to fully finance the entire immunization program. As 
calculated, if the vaccine price was estimated at US$ 2.17 per dose, immunization would be considered 
cost-saving. In all cases, rotavirus immunization reduced outpatient visits, hospitalizations and deaths 
averted by 77%, 76% and 73%, respectively. The authors also recommended the herd immunity be 
considered to better estimate the full benefits of rotavirus immunization.  
Valencia-Mendoza et al evaluated the cost-effectiveness of universal rotavirus immunization using the 
pentavalent vaccine, Rotateq, in Mexico [27]. The authors measured the cost-effectiveness outcomes in 
various dimensions: incremental cost per case prevented, death averted and life-year gained. By 
conducting sensitivity analyses, it was shown that the leading determinants of the cost-effectiveness 
results were case fatality, vaccine price, vaccine efficacy, serotype prevalence, and annual waning of 
efficacy. More specifically, the cost-effectiveness of vaccination was very sensitive to the number of 
case fatalities, which implies that the vaccine might contribute significantly more to public health in the 
poorer areas and where access to prompt medical care is limited, both enhancing case-fatality rates. 
When vaccine price was less than US$ 15 per dose, immunization would be very cost-effective. 
Interestingly, cost-effectiveness was insensitive to the medical cost of the disease, which is different 
from the findings by Rose et al [20]. However, the model was based on the healthcare perspective 
where only direct medical cost was considered. Direct non-medical cost on transportation, foods etc and 
indirect cost of productivity loss of caregivers were ignored but might contribute substantially if 
considered. Similar to the analysis in Kenya [23], affordability of immunization was again debated in 
spite of its potentially favorable cost-effectiveness.  
Cost-benefit analysis 
This review locates only one cost-benefit analysis (CBA), a study carried out in Egypt [22]. The authors 
aimed to calculate benefit-cost ratios (BCRs) based on various vaccine prices (worst-case, base-case, 
and best-case scenarios). In the base-case scenario, the BCR was 0.0726:1, which implied that 
introducing rotavirus immunization in Egypt would not be a cost-saving strategy explicitly from the 
Ministry of Health’s perspective. However, rotavirus vaccination could reduce outpatient visits, 
hospitalizations and mortality by 91%, 90% and 88%, respectively. Rotavirus immunization also 
Economic evaluations of rotavirus immunization for developing countries 
 
105 
contributed to 63% reduction in the morbidity. Sensitivity analyses showed that vaccine price was the 
most critical parameter followed by the rotavirus incidence, and the frequency of outpatient visits. This 
study looked at the financial burden of the disease only from the Ministry of Health’s perspective, in 
which only the direct medical cost was considered. Despite its preliminary results, the study proved that 
immunization was clearly beneficial to the Egyptian society in terms of the health and economic gains 
related to reduced morbidity and mortality as well as the saved treatment cost incurred from rotavirus 
infection. The study’s results revealed that vaccine price is a crucial factor influencing the cost-saving of 
the program. The authors suggested more in-depth similar research be carried out in that country.   
Methodological Issues 
General model characteristics 
Almost all studies included in this review used simple decision tree models of rotavirus infections. 
Consequently, they encountered several limitations. The model applied in these studies only allows a 
child to be infected once with rotavirus during his/her life-time [14,17,18,21,23,24,26,27], and hence 
could not fully incorporate all key features of rotavirus infection (e.g., allowing more than one rotavirus 
infection during the life of a child). This creates some uncertainties in the ICERs as the potential impact 
of these key features that were not incorporated remained unexplored. To overcome these issues, Kim 
el al  in the study in Vietnam developed a Markov model which allowed up to four re-infections per child 
[19]. In addition, their Markov model also considered partial immunity by wild type infections. In a similar 
analysis Rose et al  in the study in India developed a Markov model, which additionally captured the 
shifts in the mix of inpatient and  outpatient care that might result from decreased severity of symptoms 
among vaccinated children who became infected [20]. However, a common limitation that all reviewed 
studies encountered is the exclusion of the herd immunity in the analysis. This issue has been 
acknowledged and discussed in several papers[14,20,24,26,30]. Had herd immunity been considered in 
the analyses, the effects of universal immunization might be enormous. However, to do this, there 
should be data available on the magnitude of herd immunity. Partial immunization has also been 
reflected in the modeling across several studies [22,24,26]. For example, in the study by de Soarez et al, 
effects of immunization with one dose versus two doses of the Rotarix vaccine was considered [26]. 
Regarding the effect due to the type of vaccines, most of the studies modeled on the use of the 
monovalent two-dose vaccine (Rotarix) [14,17-20,23,24,26]. One study made a cost-effectiveness 
analysis by comparing the two available vaccines (Rotarix and Rotateq) [27] whereas another focused 
on the cost-effectiveness of Rotateq vaccine alone [34]. The study from China conducted a CEA using a 
Chinese-manufactured vaccine [21]. 
In terms of the methodology, all studies are quite similar in the way they carried out cost-effectiveness 
analyses. All CEAs were performed from either healthcare (only direct medical cost) or societal 
perspectives (including direct non-medical cost and indirect cost) or both. Only one study under review 
conducted a CBA [22]. The studies being review differ in the way cost items were collected and cost 
categories were defined. This happens because countries have different healthcare structures and the 
way costs collected would depend on the country-base context. Nevertheless, no study collected 




collected in one region (urban vs. rural) or from hospitals (central vs. regional vs. district) and then 
extrapolated nationally. Hence, the treatment cost might not represent the true treatment cost in a 
country. However, these limitations were discussed in all studies.  
Basic typologies of models used in the CEAs are static versus dynamic or decision tree versus Markov 
models. Fourteen studies in this review were CEAs with twelve studies of these CEAs used decision 
trees in modeling [13,14,16-21,25-28]. The similarity of these decision tree models was that they only 
captured one rotavirus infection per child during the first 5 years of their life. A few studies tried to 
develop a more complex decision tree model in an attempt to incorporate as many possible health 
outcomes from rotavirus infection [13,26,27]. In contrast to very simple decision tree models, Markov 
models would enable capturing more than one infection per child during his or her life. It is notable that 
two Markov models developed are quite comprehensive and sophisticated [19,20]. These models 
indeed could capture many additional features of rotavirus infections such as allowing multiple rotavirus 
infections, factoring in acquisition of partial immunity from previous infections, the changing effects of 
individual’s age, the impacts of vaccine efficacy due to different strains, and the timing of clinical events 
(e.g., time interval corresponds to episodes of rotavirus infection). Nevertheless, none of the studies 
tried to apply dynamic modeling in conducting CEAs. This could be due to the lack of available data on 
rotavirus epidemiology. Herd immunity was also not taken into account in any of the studies due to the 
same reasons.  
Discounting 
Discounting refers to the translation of values obtained from one time period in future to the present 
value. Discounting makes current costs and benefits worth more than those occurring in the future 
owing to an opportunity cost to spend money now and a desire to enjoy the benefits now rather than in 
the future. As summarized in Table 1, in the study by de Soarez et al the cost and health effects were 
discounted at the highest discount rate of 6% [26]. The authors argued that it was considered as the 
most appropriate discount rate for developing countries. The remaining 14 studies in the review applied 
a 3% discount rate per year for both cost and health outcomes [13,14,16-25,27,28], which is in line with 
the WHO’s guidelines on discounting [31].  
Study types 
Cost-effectiveness analyses (i.e., health gains expressed in integrated units adjusted for quality or 
infections prevented or life-years gained) were conducted in 14 studies [13,14,16-21,23-28].  Only one 
study [22] focused on a cost-benefit analysis (CBA). The effectiveness outcomes investigated in CEAs 
were life-year gained (LYG) and DALY, and quality-adjusted-life-year (QALY) was not utilized in any of 
the studies. Possible reasons are that it was difficult to measure quality of life of a child under 5 years 
old and published literature on QALYs for rotavirus-related diarrhoea is not available. 
All studies being review followed the WHO’s generic protocol for research on rotavirus immunization 
[32]. As described in Table 2, in addition to calculating ICERs in monetary value per DALY as the most 
common health outcome indicator, cost-effectiveness results of rotavirus immunization were also 
expressed in terms of reduction of hospitalizations, outpatient visits, number of deaths averted, number 
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of reduced severe cases, and the direct medical cost saved when comparing immunization vs. no-
immunization.  
Model parameters 
It appeared from all analyses that the cost-effectiveness results were most sensitive to variation in 
vaccine price. Although cost-effectiveness results revealed that rotavirus immunization was either cost-
effective or very cost-effective in developing countries, vaccine price appeared to be unaffordable to 
governments of developing countries where the rotavirus vaccines have to compete with other less 
expensive childhood vaccines (e.g. hepatitis B or polio) for the limited resources.Hence, vaccine price 
has become one of the most important factors in decision making of whether to include this vaccine into 
the country’s routine immunization program. Mortality rate and vaccine efficacy are other two factors 
having substantial impacts on cost-effectiveness results. So far, clinical trials of vaccine efficacy are 
being conducted in several developing countries and results will soon be released. Therefore, many 
studies in this review have to use vaccine efficacy data from developed countries where clinical data is 
available. Rotavirus-related mortality rate is not available in any of the studies being review, thus all 
studies had to use diarrhoea-related mortality rate, which is naturally higher.  
Uncertainty analyses 
Due to the fact that results of rotavirus vaccination depends largely on many parameters like vaccine 
price, vaccine wastage, vaccine efficacy, diarrhea incidence, case-fatality rate, severity of, diarrhea, 
hospitalization costs, mortality, and morbidity, there is a huge uncertainty surrounding the cost-
effectiveness results of rotavirus immunization. Therefore, in all studies, sensitivity analyses were 
conducted to test the robustness of the results. Several studies even conducted probability sensitivity 
analysesto test the effects of multiple parameters simultaneously [19,20].  
ZDiscussion 
All reviewed studies on rotavirus immunization in developing and low-income countries provide clear 
evidence that universal rotavirus immunization of children under 5 years old is either cost-effective or 
very cost-effective, but the vaccine price is still expensive and not yet affordable by the healthcare 
system of these countries. However, sensitivity analyses have shown that even at a vaccine price as 
high as US$ 25/dose [35], rotavirus immunization would still be cost-effective. Since all studies included 
in this review explored the possibility of introducing universal rotavirus vaccination into countries’ 
national EPI rather than evaluated an actual ongoing immunization, almost all studies have provided 
several scenarios under which immunization would be breaking-even, cost-effective, very cost-effective 
or cost-saving. By evaluating these scenarios, it helps vaccine manufacturers, the GAVI Alliance and 
various national governments to seriously consider the feasibility and affordability to introduce rotavirus 
vaccination into countries’ routine immunization programs by either providing rotavirus vaccines at a 
much cheaper price or developing new generations of vaccines at lower costs. 
All studies followed the WHO’s generic protocol in evaluating diarrhea [33], and therefore, the cost-




sophisticated and complex Markov models rather than applying decision tree models to capture all 
manifestation of rotavirus infections (i.e., allowing re-infections in the disease transitional model or to 
consider partial immunization vs. fully immunization) [19,20], all studies came to the same conclusion 
that universal rotavirus immunization is cost-effective. This is in spite of the fact that cost data were 
collected in different way. The perspectives (i.e., either societal or health care), in which CEAs were 
carried out would be appropriate based on the objectives of the studies.  
Studies’ results showed that for developing countries, where access to medical services, especially 
when urgent care is limited, rotavirus immunization appears as the best prevention against severe 
diarrhea caused by rotavirus. Rotavirus immunization might reduce greatly the number of 
hospitalizations, outpatient visits, deaths as well as a significant amount of treatment cost incurred from 
rotavirus infection per year. It is notable that though rotavirus related diarrhoea is one of the most 
deadly diseases in children in the developing world, it is also the most preventable disease. Rotavirus 
immunization takes effect immediately. This is different from other infectious diseases such as hepatitis 
B for which the benefits of immunization only become apparent in 30-40 years.  Hence, rotavirus 
vaccination is a worthwhile healthcare investment and the best prevention against rotavirus-related 
diarrhoea. However, rotavirus immunization is still a costly intervention for developing and low-income 
countries where the cost of the vaccine is a major challenge for its introduction. All studies in this review 
concluded that without the financial support from international health organizations, developing 
countries would not be able to implement universal rotavirus immunization at least at present or in the 
near future. Finally, concerns on inefficiencies in the delivery of a complete course and getting 
vaccinations on time to all children were raised, and these concerns should be considered and 
addressed. 
The cost-effectiveness analyses included in this review were undertaken while many clinical trials were 
still ongoing in Asia and Africa. Therefore, one issue needing exploration was vaccine efficacy. While 
rotavirus vaccine efficacy was shown to be very high in industrialized countries, it seemed to have much 
variation in developing countries and heavily depending on country-wide situations. One of many 
features of the rotavirus is that it has various genotypes and these genotypes differ from country to 
country. Kim et al also mentioned that the genotype distributions differed widely across studies and 
even within Vietnam, leading to a wide range of adjusted vaccine efficacy ranging between 46% and   
81% [19]. 
Furthermore, even though the incidence of rotavirus infection is similar between developed and 
developing countries [20,24], the severity of the disease manifestation differs greatly across countries.  
It has been shown that the local case fatality is one of the most influential parameters to cost-
effectiveness results of the immunization program [26]. This is explainable because the quality, 
accessibility and availability of healthcare services differ across and within countries. It is worthwhile to 
recommend that, in addition to implement rotavirus immunization, developing healthcare infrastructure, 
nutrition improvements, education for oral rehydration therapy should be considered as a combined 
prevention and treatment strategy to enhance the control of diarrhoeal disease.  
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In all studies, vaccine price was the dominant parameter influencing the cost-effectiveness results and 
hence the decisions of health policy makers. Even confirmed to be cost-effective, this does not imply 
rotavirus immunization is affordable by developing countries. For low-income countries, this would 
require the heavy financial support from international organizations such as the GAVI Alliance’s fund. 
Economic evaluations can provide useful information for the GAVI Alliance in making plans to help 
eligible countries in introducing rotavirus vaccination. The results of these studies also help 
governments and GAVI to negotiate with vaccine producers to obtain a cheaper vaccine price. Another 
suggestion is the possibility to develop less expensive rotavirus vaccines. Many reviewed studies 
showed that if the vaccine price were US$ 2-3/dose, immunization would become cost-saving and 
affordable by the countries’ healthcare systems. This translates in a 50-60% reduction of the current 
vaccine price. At the moment, the GAVI Alliance is accepting applications from its eligible countries for 
rotavirus vaccines financing. The subsidized price given by GAVI is budgeted at US$ 0.30 per dose 
[13,34], which is much lower than the current market price of US$ 7 per dose [26]. If developing 
countries are to benefit from the GAVI subsidized vaccine price, rotavirus immunization might become 
affordable in the developing world.  
The review points to several limitations faced by the various studies. First is the lack of epidemiological 
data. Many studies in this review had to use data instead from developed countries in the modeling 
[18,23,28,34]. Thus, the authors suggested more surveillance studies on rotavirus epidemiology in 
countries around the world. Second is the application of disease transitional models. Many studies used 
simple static decision tree models, allowing only one infection of rotavirus-related diarrhoea. However, 
in reality, nearly every child under 5 years of age gets more than one rotavirus infection in his or her life 
time[12]. Herd immunity was not considered in any reviewed study partly because no published data is 
available. In the same manner, dynamic models were not utilized in any study though a few studies had 
developed more complex disease progression models to capture different genotypes, more infections 
per child, results of partial immunization against rotavirus [13,19,20]. Another limitation is the lack of 
data on rotavirus vaccine efficacy in developing countries. Rotavirus vaccines have been available only 
since 2006, thus many clinical trials are still being conducted. This leads to the applying of data from a 
developed country to a developing country, which might over-estimate the results of cost-effectiveness 
analyses.   
Despite various concerns faced by developing countries in introducing rotavirus vaccination in their 
national immunization program, it is obvious that rotavirus immunization is a “worth-to-do” intervention 
from the healthcare point-of-view. Eventually, developing countries have to implement rotavirus 
immunization as it saves many lives of young children, especially in the most marginalized and 
impoverished regions where living conditions and quality of healthcare are still under-developed. To 
prepare the developing world in introducing rotavirus vaccination into routine immunization, substantial 





ZConclusion & Expert Commentary 
Based on the available international peer reviewed literature on the economic evaluations of rotavirus 
immunization in the developing world, we conclude that it is cost-effective to implement universal 
rotavirus immunization. So far, vaccine price is the most crucial factor hindering developing countries 
from introducing rotavirus vaccination into their routine immunization programs. Despite the cost-
effectiveness of rotavirus vaccination, the vaccine price appears to be too expensive and unaffordable 
to all developing countries. It is evident that without the support from international organizations like the 
GAVI Alliance or World Health Organization (WHO), implementation of universal rotavirus immunization 
will be very difficult. In addition, post-marketing surveillance and clinical trials on the efficacy of rotavirus 
vaccines should be strengthened to ensure maintenance of acceptable cost-effectiveness of the 
program. 
ZFive-Year View 
In 2006, the WHO has recommended that all countries in the world implement universal rotavirus 
immunization. This is the reason for the GAVI Alliance to decide on expansion of financial support for 
rotavirus immunization introduction in Asia and African and is now reviewing applications from eligible 
countries. If rotavirus vaccines were used in the most impoverished and poorest regions in the world, 
they would potentially prevent roughly 225,000 deaths per year and save 2.5 million lives in children 
between 2007 and 2025 [35]. It is obvious that with the GAVI’s financial support, more countries in Asia 
and Africa will be able to implement rotavirus vaccination in the next 5 years. At present, rotavirus 
vaccines are still too expensive for developing countries to introduce into their national immunization 
program. However, several vaccine manufacturers in India, China and Brazil are working to develop 
promising new rotavirus vaccines candidates at a lower production cost, making rotavirus vaccines 
potentially affordable and available in the market in the near future. If this happens, it will expedite the 
implementation of universal rotavirus immunization in the developing world. Furthermore, more clinical 
trials on vaccine efficacy and high-quality cost-effectiveness studies on rotavirus immunization will be 
accomplished in developing countries in the next five years to confirm the cost-effective of such 
programs.  
ZKey Issues 
• Disease burden of rotavirus infection is highest in Asia and Africa where vaccines preventing 
rotavirus are not yet widely available and still very costly 
• Rotavirus vaccination appears to be the “best hope” for prevention of rotavirus-related diarrhoeal 
disease, a major cause of mortality for children under five years age 
• The price of rotavirus vaccines is the main factor restraining developing countries from 
implementing universal rotavirus immunization 
• Cost-effectiveness studies in the developing world reveal that universal rotavirus immunization is 
cost-effective but not always affordable  (continued on page 114) 
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et al. (2010) Thailand 
To estimate rotavirus disease burden, impacts of 
vaccination and evaluate the cost-effectiveness of 
introducing rotavirus vaccination into the national 
immunization. 
To use international disease burden data and local 
costing data to estimate the cost-effectiveness of 
rotavirus vaccination in Thailand 
CEA 3 Universal 
Berry et al. (2010) Malawi To examine cost-effectiveness of rotavirus vaccination 
using both GAVI-subsidized price and the market price 
To use published data on disease burden, vaccine 
efficacy and healthcare costs to perform a cost-
effectiveness analysis 
CEA 3 Universal 
De la Hoz et al 
(2010) Columbia 
To estimate the disease burden caused by rotavirus and to 
perform cost-effectiveness against rotavirus using Rotarix 
and Rotateq vaccines 
Results of three vaccination strategies were compared 
among three hypothetical cohorts: no vaccination, 
vaccinated with two doses of Rotarix and vaccinated 
with three doses of Rotateq. Simulations were run  in a 
Markov model for 24 months 
CEA  3 Universal 1 
Kim et al. (2009) Vietnam 
To evaluate cost-effectiveness by reflecting additional 
uncertainties like re-infection, different degrees of partial 
immunity from natural infection 
To develop a Markov model of rotavirus transmission 
to evaluate cost-effectiveness of vaccination against 
the disease and without vaccination 
CEA  3 Universal  
Rose et al. (2009) India 
To estimate cost-effectiveness of universal vaccination 
with live attenuated human rotavirus vaccine and the 
affordability of a program 
To evaluate impacts of vaccination against rotavirus 
from both healthcare and societal perspectives in 
comparison without vaccination based on a Markov 
transitional model 
CEA  3 Universal 
Wang et al. (2009) China 
To assess the incidence and economic burden of rotavirus 
diarrhea and the potential cost-effectiveness of vaccination 
in a rural province in China 
To apply a decision-analytic model in evaluating the 
cost-effectiveness of vaccination in rural China using 
real epidemiological and cost data from payer and 
societal perspectives 
CEA  3 Universal 
Wilopo et al. (2009) Indonesia 
To perform an economic evaluation of potentially 
integrating rotavirus vaccination into Indonesian national 
immunization program 
To compare results of universal vaccination against 
rotavirus with no vaccination and identify the break-
even point of the vaccination  
CEA  3 Universal 
Ortega et al. (2009) Arab Republic 
of Egypt 
To conduct cost-benefit and cost-effectiveness analyses of 
the national rotavirus vaccination from Ministry of Health 
and societal perspectives, respectively 
To perform evaluation for three different strategies: no 
vaccination, partial and full vaccination and compare 
the results from these three vaccination strategies 
CBA 3 Universal 
Tate et al. (2009) Kenya 
To estimate disease burden among children <5 years, 
direct and indirect cost and potential impact of cost-
effectiveness of vaccination against rotavirus in a Kenyan 
province 
To perform a comparison of impacts between 
vaccination and no-vaccination against rotavirus and to 
conduct a cost-effectiveness analysis of the 
vaccination strategy 
CEA 3 Universal 
Flem et al. (2009) Kyrgyzstan To conduct a cost-effective analysis of introducing 
rotavirus vaccination 
To estimate the cost burden due to rotavirus infection 
and based on this data a CEA of vaccination against 
rotavirus infection was performed 
CEA  3 Universal 
Constenla et al. 
(2008) Brazil 
To perform a cost-effectiveness analysis of the national 
rotavirus vaccination against rotavirus from the healthcare 
perspective 
To compare between vaccination and no-vaccination 
strategies against rotavirus infection based on the 
reduction of hospitalizations, outpatient visits and 
averted death and to identify a reasonable price of 
vaccine in Brazil 
CEA 3 Universal 
  
de Soarez et al. 
(2008) Brazil 
To conduct a cost-effectiveness analysis of a universal 
rotavirus immunization for children < 5 years in Brazil 
To use local data to evaluate cost-effectiveness of a 
rotavirus vaccination program CEA 6 Universal 
Valencia-Mendoza et 
al. (2008) Mexico 
To assess the cost-effectiveness of integrating pentavalent 
rotavirus vaccine into the national immunization program 
To use a Markov model for modeling the vaccination of 
a birth cohort and to compare the cost and disease 
burden of rotavirus between vaccination and no-
vaccination using Rotateq vaccine 
CEA  3 Universal 
Isakbaeva et al. 
(2006) Uzbekistan 
To perform cost-effectiveness of rotavirus vaccination from 
both healthcare and societal perspectives 
To compare the cost and effects of vaccination and no-
vaccination against rotavirus. To identify parameters 
influencing the cost-effectiveness results 
CEA  3 Universal  
Fisher et al. (2005) Vietnam 
To pilot test WHO generic protocol by assessing the 
country’s rotavirus disease burden in terms of costing 
based on the actual data. 
To assess the national rotavirus disease burden using 
the local data in a cost-effective analysis CEA  3 Universal  
1
 Immunization given to the children <= 5 years of age 
CEA: Cost-effectiveness analysis; CBA: Cost-benefit analysis; DALY: Disability-adjusted life year; GAVI: Global Alliance for Vaccines and Immunization 
Table 1 Economic evaluations on rotavirus vaccination in developing and low-income countries as published in the international literature between January 
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akorn et al, 
2010, 
Thailand  
Rotarix 7 932,000 (2007) 0-5 85% 
0.93-1.35 / 
person-year 419 46,542 109,918  370/DALY (h) 
BE @US$ 
6.2/dose 6,351,366 5,715,118 
Berry et al, 




(2008) 0-2 49.5%   2,582  11,354  28,590  74.73/DALY  80,748  













300 (25%) for 
Rotarix or 350 
(28%) for Rotateq 
35,012 (27%) 














Kim et al, 
2009, 
Vietnam  




   
  
Rose et al, 
2009, India  Rotarix 7 
25,000,00
0 (2007) 0-5 80.4%  41,000 203,000 1,794,500 134/DALY  $9/person  
Wang et al, 
2009, China   5 
5,000 
(2004) 0-5 75%     
0.08/case 
averted    
Wilopo et al, 
2009, 
Indonesia  
Rotarix 7 4,200,000 (2007) 0-5 70-80% 
1,400/10,000 
for boys & 
$1,300/10,00
0 for girls 
8,148 (76.5%) 176,375 (84%) 488,547 (70%) 120.5/DALY 
2.70 (h) or 3.79 
(s) 11.67 million 1.779 mil 
Ortega et al, 











2,873 (88%) 47,508 (90%) 438,395 (91%) 363/DALY 
CS if a course 
≤ US$1.34 2,481,792  
Tate et al, 
2009, Kenya  Rotarix 0.5-10 NA 0-5 78%  2,467 (55%) 5,724 (65%) 
852,589 
(59%)  
CS if a course 
≤ US$ 2.07   
Flem et al, 
2009, 
Kyrgyzstan  
Rotarix 0.3¹ 116,000 (2009) 0-5 63%-85%   2,921 (75%) 
17,449 
(56%)  









Rotarix 7.0-8.0 3,471,000 (2003) 0-5 85%  1,317 (73%) 69,256 (76%) 
423,652 
(77%) 643/DALY (h) 
CS if a course 
≤ US$ 2.17 (h) 14.67 million  
de Soarez et 
al, 2008   7 
3,300,000 





   
cost/life-year 
saved = US$ 
1,028(s) or 
US$ 1,713(h) 
BE @  US$ 





al, 2008  




saved = US$ 
4,283.75 




Rotarix 1-12.5 538,128 (2004) 0-5 93% 
Mortality rate 




 328,154 40,667 
Fisher et al, 
2005, 
Vietnam  





5,001 (83%) 105,393 (84%)   
BE @ US$ 





 rotavirus incidence for under-5 children 
2
 GAVI Alliance-subsided price 
³ Rotarix: vaccine efficacy is 40% & 85% after first & second doses, respectively; Rotateq: 40%-60%-95% after first, second and third doses, respectively. 
BE = Direct medical break-even; CS = cost-saving; CS: Cost-saving; DALY: Disability-adjusted life year; GAVI: Global Alliance for Vaccines and Immunization; h: Healthcare perspective; ICER: Incremental cost-
effectiveness ratio; IP: Inpatient; NA: Not applicable; OP: Outpatient; s: Social perspective 




• Developing countries will have to depend on external financial support (e.g., GAVI, WHO) in order 
to expedite rotavirus immunization program 
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Background: This study aims to critically review available cost-effectiveness models for rotavirus 
vaccination, compare their designs using a standardized approach and compare similarities and 
differences in cost-effectiveness outcomes using a uniform set of input parameters.  
 
Methods: We identified various models used to estimate the cost-effectiveness of rotavirus vaccination. 
From these, results using a standardized dataset for four regions in the world could be obtained for 
three specific applications.  
 
Results: Despite differences in the approaches and individual constituting elements including costs, 
QALYs and deaths, cost-effectiveness results of the models were quite similar. Differences between the 
models on the individual components of cost-effectiveness could be related to some specific features of 
the respective models. Sensitivity analysis revealed that cost-effectiveness of rotavirus vaccination is 
highly sensitive to vaccine prices, rotavirus-associated mortality and discount rates, in particular that for 
QALYs. 
 
Conclusions: The comparative approach followed here is helpful in understanding the various models 
selected and will thus benefit (low-income) countries in designing their own cost-effectiveness analyses 
using new or adapted existing models. Potential users of the models in low and middle income countries 
need to consider results from existing studies and reviews. There will be a need for contextualisation 
including the use of country specific data inputs. However, given that the underlying biological and 
epidemiological mechanisms do not change between countries, users are likely to be able to adapt 
existing model designs rather than developing completely new approaches. Also, the communication 
established between the individual researchers involved in the three models is helpful in the further 
development of these individual models. Therefore, we recommend that this kind of comparative study 
be extended to other areas of vaccination and even other infectious disease interventions. 




Various countries are currently in the process of evaluating whether or not to include rotavirus 
vaccination in their national immunization programs. Two rotavirus vaccines are currently available: 
Rotarix® and Rotateq™, marketed by GlaxoSmithKline (GSK) and Sanofi Pasteur MSD (SPMSD), 
respectively. Rotavirus vaccines have proven to be efficacious in preventing rotavirus-related disease, 
gastrointestinal disease and health-care use (GP-visits and hospitalizations) in infants and toddlers [1-
3]. 
Health-economic properties of these new vaccines present one characteristic to be analysed with 
respect to their inclusion in National Immunization Programs (NIPs). Numerous health-economic 
analyses already exist regarding rotavirus vaccination, mostly in high-income country settings, some 
being single-country analyses but a few multi-country analyses [4-6]. Also, one critical review of these 
existing models has already been performed [7]. Recently, some studies have become available 
targeted at situations in low- and middle-income countries, involving all regions in the world (for 
example, Vietnam, China, Kenya and Colombia [8-11]). A review of these studies in Asia, Africa and 
South-America is in preparation [12]. Based on the favourable cost-effectiveness profile of many of the 
models applied in low- and middle-income countries, the World Health Organisation (WHO) advises 
inclusion of rotavirus vaccines in the NIPs [13]. However, in general, it is still not always clear which 
aspects these individual models differ on, what impact such differences have on the cost-effectiveness 
outcomes and which model might be preferred over the others in continental, regional or country-
specific situations [14]. 
This study aims to critically review some of these available cost-effectiveness models for rotavirus 
vaccination, compare their designs using a standardized approach and compare similarities and 
differences in cost-effectiveness outcomes using a uniform set of input parameters. WHO has initiated 
this study to enable providing guidance to low- and middle-income countries if requested, on the 
strengths and weaknesses of existing health-economic models for rotavirus vaccination as a basis for 
decisions about whether or not to build their own models or to adapt existing models to local situations. 
In particular, our study intends to help WHO to guide individual countries on rotavirus modelling, 
specifically national decision makers who may have the interest, research capacity and resources to 
conduct their own cost-effectiveness analyses in generating evidence for decision making on whether or 
not to introduce rotavirus vaccination. Therefore, our analysis might be most suited for lower middle 
income countries that have some capacity to attract global partners for model adaptation, whereas most 
low income countries may not have sufficient technical capacity for building or adapting existing models. 
Notably, our goal is neither to advocate the use of specific models nor to recommend individual 
modelling groups over others.  
ZMethods 
Review of Models 
Initially, we searched for existing health-economic models in the literature using PubMed, Embase and 




emerged from the initial search and crude selection were all in English. A further selection was made for 
those models to be included in the detailed comparison based on various criteria, related to our goals of 
achieving diversity in terms of provenance (public versus private), methods (single-cohort models, multi-
cohort models and so on) and specific vaccines to be incorporated by the model (that is, two individual 
vaccines exist that are slightly different). Modelling groups were selected and contacted, explicitly based 
on these criteria.  However, availability, ease of access, complexity and time investment of the individual 
research groups appeared to be the strongest criteria in practice for inclusion in the final comparison. In 
particular for those models with a high degree of complexity, the time investment required appeared to 
prevent the groups from becoming involved in our comparison. Also, for these complex models resource 
requirements for this analysis presented a strong limitation, which could not easily be overcome given 
the limited funds available by WHO for the endeavour.  
Comparative Framework 
As described, various cost-effectiveness models were identified by the process described above. Their 
developers were contacted by a WHO officer (RH) to invite them to participate in the model comparison. 
Subsequently, the model inclusion was co-ordinated by 2 authors (RH & MP), while 1 author (MP) 
included his own group’s model into the comparison. The process resulted in three models provided to 
us, including analyses using the standardized dataset specified below (Table 1). From all modelling 
groups at least one co-author was included in the author list of this paper. These models represented a 
balanced public-private mix involving one designed by the pharmaceutical industry (Roxanne RotarixTM 
Analyses of Economics from GSK), one developed by public financing within a European-Union project 
(POLYMOD) and one privately financed (Sanofi Pasteur MSD) but developed by the University of 
Groningen within the context of an unrestricted grant (CoRoVa Consensus Rotavirus model 
Vaccination). Models included could be applied to modelling use of either vaccine (Rotarix or RotaTeq), 
hence ensuring that the unique features of the two vaccines were adequately represented in our 
analysis. In addition, both manufacturers were directly (Roxanne) or indirectly (CoRoVa) involved in the 
models. Only static models were compared; this posed both a disadvantage and an advantage. In 
particular, comparison with a dynamic model, which could explicitly analyze the effect of vaccination on 
the spread of rotavirus infection using mathematical modelling, would be extremely valuable. However, 
our selection of only static models for comparison enhances comparability of the individual models and 
facilitates understanding the differences that still remain between the models’ outcomes. 
 
 POLYMOD Roxanne CoRoVa 
Developers HPA GSK University of Groningen 
Funding EU GSK SPMSD 
Software platform Excel Excel Excel 
Dynamic vs. Static Static Statistic Static 
Deterministic vs. stochastic Deterministic Deterministic Deterministic 
Open vs. closed Open Closed Closed 




based Multi-cohort Cohort Cohort 
Special features Stepwise waning Breastfeeding effects modeled In-between dose efficacies 
modeled 
Table 1 Basic characteristics of the models investigateda 
aSpecific questions regarding the three models should be attended to Dr. Raymond Hutubessy (email address: hutubessyr@who.int) 
The owners of the models provided access to their models through physical transfer of the software – 
accompanied with user guides and/or publications - and explained various concepts and characteristics 
of these models face-to-face, through e-mail contacts and telephone calls during 2009. Additionally, 
during a one-day consultation in 2009 at the WHO headquarters in Geneva, concepts and draft results 
were discussed with a large group of experts in epidemiology, immunology, vaccinology, political 
sciences and health economics. In the end, final calculations were performed by the modellers 
themselves using the most current model versions at the end of 2010 and extensively discussed during 
the winter of 2010/11. To summarize the way the three models were included in this analysis, we note 
that all the software for the models was physically available to the coordinating team (MP and RH), at 
least 2 face-to-face meetings between member(s) of the coordinating team and each research group 
were organized and final calculations were checked by the coordinating team and cross-checked for 
face validity by all the 3 individual research groups.  
The standardized approach in comparing these models involved stepwise analysis of the structure, the 
input parameters required and specific assumptions underlying the models. 
Details on Available Models 
As mentioned, during the model selection process three models with corresponding results for the 
standardized input parameters became available to us. These were the POLYMOD-model [4,15,16], 
Roxanne [17-20], and CoRoVa [21-23]. 
 
The POLYMOD-model was developed in the context of an EU-funded project with the same acronym 
[4]. RVGE Rotavirus GastroEnteritis was modelled using an age-structured cohort model that followed 
cohorts of vaccinated and unvaccinated individuals (Table 1). For the first year of life, the cohort was 
stratified into monthly age groups, with one-year age bands applied beyond (one to five years old). The 
model was initially a single-cohort model; however, it was adapted to a multi-cohort model for the 
purpose of this exercise to allow a step-up in vaccination coverage. RVGE was stratified into mild 
disease with home treatment only, moderate disease with primary care visits (GP and/or hospital 
outpatient), severe disease with hospital ER-visits and/or admissions, nosocomial infections and death. 
QALY losses were incurred both by the index infants and their care givers. QALYs were taken from one 
specific study on the topic [23], which were quite comparable to those used in some other health-
economic studies [5]. The model was designed by modellers based in England’s Health Protection 
Agency (HPA) with input from modellers based in public health institutions in Belgium, Finland, France 
and the Netherlands and applied to model rotavirus epidemiology and cost-effectiveness of vaccination 
in the five countries of Belgium, England & Wales, Finland, France and the Netherlands. Unlike most 




Further country-specific models – based on this multi-cohort, multi-country model – have been 
published, for example, for the Netherlands [16]. 
Roxanne was developed as a Markov cohort process tree [17]. It is programmed in Microsoft Excel 
2007 using Visual Basic and contains both cost-effectiveness and budget impact modules. The model 
was initially parameterized with data from France [18], but allows data from any country to be used [19]. 
A precursor of the model has been used to estimate the cost-effectiveness of Rotarix® in the 
Netherlands [20]. Besides a comparison of vaccination versus no vaccination, the model was designed 
to additionally allow explicit comparison of two- and three-dose vaccination strategies. Obviously, 
outcomes in such analyses crucially depend on the exact characteristics and properties applied to the 
two- and three-dose vaccination schedules. Finally, Roxanne allows extensive probabilistic sensitivity 
analysis, using the At Risk add-in for Excel. A special feature of Roxanne involves the explicit inclusion 
of the modelling of maternal protection from (severe) infection through breastfeeding. 
CoRoVa was initially developed for the specific Dutch situation and aimed at achieving consensus 
among various Dutch modelling groups that had previously worked on the cost-effectiveness of 
rotavirus vaccination [16, 20]. An age-structured cohort model was developed in Excel applying a time 
horizon of 5 years with time cycles of one month for children less than one year of age and annual 
thereafter [21-23].  Outcomes in the model were classified by severity and included home-treated 
community-acquired diarrhoea and rotavirus infection leading to GP consultations and/or hospital 
admissions (including emergency department visits), nosocomial infections and death. Specific 
characteristics of the model are the ability to take waning immunity, maternal protection against infection 
through breastfeeding, and herd protection into account. However, the model is not a transmission 
dynamic model because herd protection is incorporated by straightforward calculus only, using a static 
approximation based on a fixed fraction of the direct effects. In the base-case analysis for the 
Netherlands, QALY losses of caregivers were not included and the QALY decrement for children was 
based on a combination of two published studies performed in the Canada and the UK [24, 25]. Similar 
to the Roxanne-model CoRoVa also used the At Risk software for (probabilistic) sensitivity analyses. 
Standardized Input Parameters 
For this study, analyses of the models were provided regarding their structure and outcomes for 4 
hypothetical countries, representative of different continents and income levels (low, middle or high), 
respectively classified into the WHO geographical regions and mortality strata [14]. In particular, sets of 
standardized input parameters were provided to the modellers and analysed for a hypothetical Afr E 
country representing the African region with high child and very high infant mortality; a hypothetical Sear 
D country representing the South-east Asian region with high child and adult mortality; a hypothetical 
Amr D country representing the South and Middle American regions with again high child and adult 
mortality; and a hypothetical Eur A country representing developed countries in the European setting. 
Tables 2, 3, 4 and 5 summarize the set of standardized input parameters. Rectangular age distributions 
were assumed, implying that life expectancy decreases with one year exactly for every one-year 
increase in the age of infants and toddlers considered. (For example, if life expectancy is 70 at birth, it 
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would be 69 at the age of 1, 68 at the age of 2 and so on). Simplifying assumptions were justified as our 
interest concerned the comparison between models rather than the exact representation of country-
specific demographic, epidemiological and economic impacts. 
Although the time horizon in the single- and multi-cohort models was lifetime, this effectively produced a 
time horizon of 5 years after the birth of the last cohort, since it is assumed that no rotavirus 
gastroenteritis occurs beyond the age of 5 years and vaccination is only investigated in infants in their 
first year of life. Various sources were utilised for parameter estimates as indicated in Tables 2, 3, 4 and 
5 [1-5, 7, 14, 15, 20, 26-31]. However as the objective was comparative rather than to exactly mimic the 
situations of specific countries often plausible assumptions were made rather than exact replications of 
individual sources. Plausibility of assumptions was primarily based on the expert opinions of two of the 
authors (MP and MJ) 
 Afr Sear Ams Eur Notes 
Total # of life births 1,496,200 3,427,800 140,110  190,000  
Life expectancy at birth in 
years 54 66 73 80 
average men & 
women 
Population 34,255,722 141,822,276 5,486,685 16,500,000  
% of population < 5 years 16.75% 16.75% 16.75% 6.1%  
% urban 42% 23% 62% 100%  
Infant mortality (< 1 year of 
age) 64 45 21 4 
per 1000 life 
births 
Mortality < 5 years 104 57 26 0.5 per 1000 life births /yr 
Population < 5 years 5,736,373 17,399,197 730,913 1,000,000  
Incidence mild rotavirus 
gastro-enteritis      
1st year after birth 1.4% 1.4% 1.4% 1.4% in % per month 
2nd year after birth 0.57% 0.57% 0.57% 0.57% in % per month 
3rd& 4th after birth 0.49% 0.49% 0.49% 0.49% in % per month 
Incidence of moderate 38.7% 38.7% 38.7% 33.1% in % from mild 
Incidence of severe 7.9% 7.9% 7.9% 12.1% in % from 
moderate 
Incidence of death 18.8% 12.5% 6.3% 0.05% in % from severe 
Incidence of nosocomial 
infections 33.3% 33.3% 33.3% 25% 
% from severe 
(on top) 
 
Table 2 Standardized dataset for the cost-effectiveness models in rotavirus vaccination: demography 







 Afr Sear Ams Eur Notes 
Efficacy, assuming a 2-dose schedule at 2 & 3 months (1 dose only between brackets) 
Mild  52% (52%) 52% (52%) 52% (52%) 87% (87%)  
Moderate 55% (54%) 55% (54%) 55% (54%) 92% (90%)  
Severe 60% (54%) 60% (54%) 60% (54%) 100% (90%)  
Waning of efficacy (annual)      
Mild & moderate  0.63 0.63 0.63 0.63 multiply each 
next  
Severe 0.83 0.83 0.83 0.83 multiply each 
next  
Coverage      
Dose 1 50% 50% 50% 50%  
Dose 2 40% 40% 40% 40%  
20 years after introduction 80% 80% 80% 96% for both doses 
Coverage improvement linear linear linear linear  
Per-dose vaccine costs (2 doses)      
2009-2014 7.5 7.5  7.5 45  
2015 & beyond 4 4 4 45  
Table 3: Standardized dataset for the cost-effectiveness models in rotavirus vaccination: vaccine 
characteristics (Sources: [1-5,7,15,20,28], expert opinions) 
 
 Afr Sear Ams Eur Notes 
Average length of hospital stay 4 4 4 4 days 
Cost per hospital day US$35 US$34 US$122 €550  
Cost per outpatient visit (health 
center/GP)  US$10.5 US$9 US$34.50 €40 
Community 
acquired only 
Out-of-pocket costs (comm.-acq. 
only) US$0.50 US$2.5 US$5 €15 Diapers/travel/OTC 
Total direct costs for nosocomial 
cases  
US$15 US$15 US$50 €2,000  
Cost of productivity loss/day US$1 US$5 US$10 €125  
Parents with work loss      
Non-hospitalized 20% 20% 20% 20%  
Hospitalized & nosocomial 75% 75%  75% 75%   
Days of work missed for parents      
Mild  1 1 1 1  
Moderate 1.5 1.5 1.5 1.5  
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Severe 2 2 2 2 Also for nosocomial 
Discount rates  3% 3% 3% 3% Money&health 
Administration costs per dose
  
US$0.53 US$0.46 US$0.46 €5  
 (Note: all mild cases were treated at home, all moderate additionally in an outpatient setting, such as outpatient hospital, GP or health 
centre and all severe cases additionally in hospital; all cases have out-of-pocket costs), plausible assumptions based on literature [29-31] 
and expert opinions (MP & MJ)) 
GP: general practitioner; comm.-acq: community acquired; OTC: over the counter 
Table 4 Standardized dataset for the cost-effectiveness models in rotavirus vaccination: health-care use 
and costs 
 
 Afr Sear Ams Eur Notes 
Disutility      
Mild 0.15 0.15 0.15 0.15 during 4 days 
Moderate 0.25 0.25 0.25  during 4 days 
Severe 0.7 0.7 0.7 0.7 during 4 days 
Nosocomial 0.7 0.7 0.7 0.7 during 4 days 
Death 1 1 1 1 per year 
Age weighting (primarily considered 
for DALYs) off off off off  







Herd effect off off off off  
DALY: disability adjusted life year 
Table 5: Utilities and some remaining issues [4,5,7,20,27] 
 
Key parameters for all analyses were the incidence of rotavirus gastroenteritis (RVGE), the 
corresponding risks of rotavirus-related health-care use, as well as corresponding costs. All cases with 
RVGE were assumed to be treated at home. In particular, moderate cases were assumed to involve 
one additional outpatient visit (GP, health centre or hospital) and severe cases were assumed to 
involve: home treatment, an outpatient visit and a hospitalization. Some models had the additional 
option of severe cases not being hospitalized. Based on data from the clinical trials, vaccine efficacy 
could be specified for different outcomes and for high-income versus other countries.  
Alternatively to what is expressed in Table 1, incidence could be expressed as average annual risks 
over the same 5 years considered in the data and modelling. In particular, the average annual risks at 
population level are 10,440, 4040 and 320 per 100,000 people in all developing regions for mild, 
moderate and severe, respectively. Correspondingly, figures for the Eur region are 10,440; 3460; and 
419 per 100,000 people. Similarly, annual mortality risks are 60, 40, 20 and 0.21 per 100,000 population 





Model developers were requested to present a standardized set of output variables for one single cohort 
(for the multi-cohort model, the coordinating centre estimated the results for one cohort themselves). In 
particular, these were: total number of persons and (person-years if available) followed in the model; 
undiscounted number of mild cases of RVGE; undiscounted number of moderate cases of RVGE; 
undiscounted number of severe cases of RVGE; undiscounted number of outpatient visits (GP, 
outpatient or health centre; typically this would equal the number of moderate and severe cases); 
undiscounted number of hospitalizations (typically equal to the number of severe cases); undiscounted 
number of nosocomial cases (equal to 1/4 or 1/3 of the number of hospitalizations, in the Eur and other 
regions, respectively); undiscounted number of deaths; discounted direct outpatient costs; discounted 
direct inpatient costs; discounted vaccination costs; discounted and undiscounted QALYs due to deaths 
(difference between vaccination and no vaccination is equal to the number of life-years gained); 
discounted and undiscounted QALYs due to morbidity; cost/QALY from the health-care perspective; 
cost/QALY from the societal perspective; a sensitivity analysis was requested by varying parameters 
values through halving and doubling their base case values, except the discount rate which was 
investigated for alternative values of 0% and 4%. 
In particular, cost-effectiveness was expressed in net costs per QALY gained by subtracting discounted 
savings from the reduced need for RVGE treatments from (discounted in the multi-cohort model) 
vaccination costs to provide the numerator and dividing by the QALYs gained (the denominator). 
ZResults 
Results of using the standardized dataset for the various regions in different models are shown in 
Tables 6 through 10 for all three models. In general, cost-effectiveness results are broadly similar and 
comparable. 
 POLYMOD Roxanne CoRoVa 
Health-care perspective 
Afr $ 265* $ 188-367**  $ 233-440** 
Sear $ 358* $ 257-503**  $ 308-591** 
Amr $ 307* $ 200-652**  $ 336-862** 
Eur € 57,897 € 50,999 € 56,656 
Societal perspective 
Afr $ 260* $ 185-364**  $ 231-438** 
Sear $ 328* $ 241-487**  $ 293- 577** 
Amr $ 196* $ 143-595**  $ 282- 809** 
Eur € 49,427 € 40,041 € 44,263 
*Note: based on future reduction of vaccine prices from $7.5 to $4; **Range given for previous upper and lower vaccine prices 
Table 6 Comparative analysis on costs per QALY 
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 POLYMOD Roxanne CoRoVa 
Undiscounted cases 
Mild 92,989 121,312 128,807 
Moderate 49,051 70,126 54,559 
Severe 5,092 9,589 5,277 
Nosocomial 1,680 1,986 2,701 
Death   955 1,789 1,524 
Outpatient  54,143 70,126 54,559 
Inpatient (comm. acq.) 5,092 9,589 5,277 
Discounted savings 
Outpatient  $ 568,502 $ 716,305 $623,977 
Inpatient $ 973,247 $ 1,329,538 $753,884 
Indirect $ 108,916 $ 106,377 $ 81,486 
Discounted net costs** (*1000) $ 6759 $ 8,757-17,094 $ 9,250-17,467 
Discounted QALYs 
 Mortality 24,962 45,817 39,070 
Morbidity  542 762 628 
*Approximations for one cohort from the multi-cohort results; **Health-care perspective & range given for previous upper and lower vaccine 
prices if appropriate 
Table 7 Afr- region, comparative analysis on components of the costs per QALY: cases prevented, 
costs averted and QALYs gained (approximated) for one birth cohort 
 
 POLYMOD Roxanne CoRoVa 
Undiscounted cases 
Mild 216,205 276,861 299,907 
Moderate 114,255 159,129 127,020 
Severe 11,887 22,086 12,325 
Nosocomial 3,92 4,748 6,309 
Death   1,486 2,752 2,366 
Outpatient  126,142 159,129 127,020 
Inpatient (comm. acq.) 11,887 22,086 12,325 
Discounted savings 




Inpatient $ 2,208,959 $ 2,208,959 $1,712,40 
Indirect $ 1,267,227 $ 1,213,598 $ 948,564 
Discounted net costs** (*1000) $ 15,424 $ 19,969-39,083 $ 20,545-39,423 
Discounted QALYs 
 Mortality 41,822 75,969 65,244 
Morbidity 1,261 1,731 1,462 
*Approximations for one cohort from the multi-cohort results; **Health-care perspective & range given for previous upper and lower vaccine 
prices if appropriate 
Table 8 Sear- region, comparative analysis on components of the costs per QALY: cases prevented, 
costs averted and QALys gained (approximated) for one birth cohort 
 
 POLYMOD Roxanne CoRoVa 
Undiscounted cases 
Mild 8989 11,318 12,481 
Moderate 4760 6,471 5,286 
Severe 496 897 514 
Nosocomial 164 193 263 
Death 31 59 50 
Outpatient  5256 6,471 5,286 
Inpatient (comm. acq.) 496 897 514 
Discounted savings 
Outpatient  $ 181,333 $ 216,626 $ 239,534 
Inpatient $ 330,083 $ 432,618 $ 255,186 
Indirect $ 105,467 $ 98,697 $ 78,947 
Discounted net costs** (*1000) $ 293 $ 346-1,127 $ 495-1271 
Discounted QALYs 
 Mortality 900 1,662 1,413 
Morbidity 53 66 61 
*Approximations for one cohort from the multi-cohort results; **Health-care perspective & range given for previous upper and lower vaccine 
prices if appropriate 
Table 9 Amr- region, comparative analysis on components of the costs per QALY: cases prevented, 
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 POLYMOD Roxanne CoRoVa 
Undiscounted cases 
Mild 22,708 32,186 28,680 
Moderate 10,360 14,580 10,430 
Severe 1658 2,324 1,806 
Nosocomial   415 528 452 
Death 1 1 1 
Outpatient 12,019 14,580 10,430 
Inpatient (comm. acq.) 1658 2,324 1,860 
Discounted savings 
Outpatient € 480,745 € 556,984 € 829,111 
Inpatient € 4,643,286 € 5,949,119 € 4,714,920 
Indirect € 1,322,021 € 2,111,857 € 2,088,993 
Discounted net costs** 
(*1000) € 9,032,932 € 9,842,807 € 9,518,208 
Discounted QALYs 
Mortality 25 27 26 
Morbidity 131 166 142 
*Approximations for one cohort from the multi-cohort results; **Health-care perspective 
Table 10 Eur-region, comparative analysis on components of the costs per QALY: cases prevented, 
costs averted and QALys gained (approximated) for one birth cohort 
 
However, there are differences in the building blocks of these cost-effectiveness ratios, for example, 
regarding estimations of QALY losses related to morbidity in the three models. The results for the 
CoRoVa-model were generally in between those for the other two. The Roxanne model generally 
predicts overall higher number of cases, most notably for hospitalized cases. This translates into 
relatively high inpatient savings that are however lowered by discounting and overall dominated by 
vaccination costs to render similar net discounted costs for all three models investigated. However, the 
POLYMOD model gave consistently lower results for these discounted net costs; this might be due to 
the approximation from results for the multiple cohorts to just one. Also, higher vaccination costs in later 
years in the multi-cohort model were offset by a higher number of cases averted in the single-cohort 
model, resulting in the comparable cost-effectiveness ratios between the two types of models. Results 
suggest that rotavirus vaccination could potentially be cost-effective in all regions, particularly in low and 
middle income countries. However, the standardized data set is highly generalised and not specific to 





Figure 1 shows the sensitivity analysis performed on the model results, with the example of CoRoVa 
shown here (other models showed similar patterns). From previous work on cost-effectiveness of 
rotavirus vaccination [5, 7, 15, 19], it is well-known that generally these results are highly sensitive to the 
vaccine price, rotavirus-associated mortality and the discount rate. Our analysis shows the similar 
pattern for all regions investigated. However, there is an interesting shift observed in variables 
influencing the cost-effectiveness results between EU and non-EU countries. In the EU region the 
incidence of the disease is a driver followed by utility weights whereas in the non-EU region mortality is 
essentially driving the result. 
ZDiscussion 
We identified various models used to estimate the cost-effectiveness of rotavirus vaccination. From 
these, results using the standardized dataset could be obtained for three specific applications (the 
POLYMOD, Roxanne and CoRoVa models). Despite differences in the approaches, cost-effectiveness 
results of the models were quite similar. Differences between the outcomes of the specific building 
blocks of the cost-effectiveness (i.e., vaccination costs, savings and QALYs gained) of the models 
currently investigated seem to relate to five  aspects of the models: the multi-cohort nature of the 
POLYMOD model which assumed a step up in vaccination coverage (and hence in vaccination costs as 
well as cases prevented); the exact timing of the waning in the models and in particular the exact 
modulation of between-dose efficacies in the CoRoVa model; assumptions about the distribution of 
cases of different severity levels within the one-year age groups provided (for example, assuming a 
Weibull distribution in the Roxanne model); and the possibility in the models of experiencing subsequent 
episodes of rotavirus infections and/or experiencing episodes with multiple manifestations (for example, 
first moderate progressing to severe) and types of health-care use (for example, inpatient and 
outpatient, rather than just one of both). 
Ergo, differences between the models on the individual components of cost-effectiveness could be 
related to some specific generic features of the models with regards to representing vaccine uptake and 
pricing, within age-group distributions, waning and between-dose efficacies and inclusion of additional 
groups and episodes in the general design of these models. Sensitivity analysis revealed that cost-
effectiveness of rotavirus vaccination is highly sensitive to vaccine prices, rotavirus-associated mortality 
and discount rates, in particular that for effects. This is fully in line with other authors’ findings [32]. 
Unfortunately, we were not able to include a model with a transmission dynamic approach in our model 
comparison, instead of the cohort approach followed in the three models analyzed. Emerging evidence 
that herd immunity effects might be relevant for rotavirus transmission and vaccination enhances the 
relevance of considering populations and transmissions between cohorts [33-35]. Inability to include 
these models was often related to the complexity of these models and the difficulties to adequately 
grasp these complexities in the standardized framework provided on inputs and outputs. However, for 
further work it is important to also analyse such dynamic models given their major advantage of 
incorporating infection dynamics including herd immunity effects and potential age shifts in 
epidemiology [36]. Also, differences in uptake between high-, middle- and low-income countries should 
be analyzed using dynamic models given the different impacts of coverage levels on herd immunity. 
  
 
Figure 1. Sensitivity analyses on the base case cost effectiveness ratio using the CoRoVa model for Afr (a), Sear (b), Amr (c), and Eur (d) regions. Parameters were varied 
through halving and doubling, except for the discount rates which were 0% and 4% for both costs and health effects. Dark bars show the incremental cost effectiveness ratio 
after a 100% decrease in the parameter, whereas light bars show the incremental cost effectiveness ratio after a 100% increase (note that an increase in the incidence or the 
costs resulted in Graphs D for negative cost effectiveness ratios). Note that when the incidence of RVGE was increased or decreased, the total number of deaths was kept 




The three models selected for our analysis were all basically developed for high-income countries. For 
reasons stated previously, other models – inclusive of models developed initially for low- and middle-
income settings – could unfortunately not be considered in our comparison. As one consequence, all 
the publications arising from these models involved costs per QALY gained rather than costs per DALY 
averted. Although not undisputed, for low- and middle income settings DALYs rather than QALYs are 
the common metric used [27,37]. We do note that one specific study showed that results only slightly 
differ if DALYs are used instead of QALYs; in particular, it showed slightly more favourable cost-
effectiveness for DALYs as the outcome [16]. However, it has been demonstrated that the decision 
about whether or not to include caregiver QALYs has a major impact on results [4,7]. The 
appropriateness of including QALYs beyond the index case of disease is being debated; it could be 
argued that caregivers’ QALYs are particularly important for rotavirus as they can be measured directly, 
and hence may be more valid than QALYs in small children with RVGE, where proxy measurements 
have to be used [7,21,22]. 
Our findings for the regions Afr, Sear, Amr and Eur should not be considered as exact representative 
results and policy making should not directly be based on this. For example, it is very unlikely that the 
similarities assumed for the proportion of RVGE cases that are mild, moderate and severe are valid in 
real world. This simplifying assumption was made in order to test the models generically and 
consistently. Nevertheless, our results clearly indicate a general trend of increasingly more favourable 
cost-effectiveness when going from high- to middle and on to low-income countries, respectively. As the 
sensitivity analysis shows, this is obviously primarily related to vaccine pricing and the QALY-impact of 
averted mortality due to rotavirus infection. However for actual policy making, countries will need to 
either further consider the results from existing studies and reviews, or initiate country-specific cost-
effectiveness analyses. For countries that have the capacity and resources to model the cost-
effectiveness of rotavirus vaccine, our comparative analysis can help inform the design of new models 
or selecting existing models to support national-level decision making. 
Hence, although our analysis is not meant to directly inform policy making, it offers considerable 
guidance for design and/or selection of a model for adaptation to individual (low-income) countries who 
want to conduct cost-effectiveness analyses. Scarce resources in these countries may direct the choice 
towards adapting an existing model rather than initiating the development of a new approach. 
Reassuringly, our analysis suggests that different models produce similar cost-effectiveness estimates, 
illustrating that the exact choice of which model to adapt may not be as crucial as the choice of 
assumptions and parameter values to incorporate in the model. 
ZConclusions 
We conclude that our approach is helpful on two specific levels. Firstly, the comparative approach 
followed here is helpful in understanding the various models selected and will thus benefit (low-income) 
countries in designing their own cost-effectiveness analyses using new or adapted existing models. 
Secondly, we find that the communication between the individual researchers involved in the three 
models was helpful in the further development of these individual models and will be so in the future. 
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Therefore, we recommend that this kind of comparative study be extended to other areas of vaccination 
and even other infectious disease interventions, beyond the three areas that have been explored by 
WHO (pneumococcal vaccination, human papilloma virus vaccines and (here) rotavirus) [38-40]. 
Finally, the models reviewed in the exercise gave similar and comparable results which appear to have 
face validity. Hence it appears possible to recommend their use in policy settings, at least for high 
income countries. However, potential users of the models need to consider the specific building blocks 
of the cost-effectiveness models including the nature, scope, design and assumptions made and how 
they affect outcomes. Potential users of the models in low and middle income countries need to 
consider results from existing studies and reviews. There will be a need for contextualisation including 
the use of country specific data inputs. However, given that the underlying biological and 
epidemiological mechanisms do not change between countries, users are likely to be able to adapt 
existing model designs rather than developing completely new approaches. Also, transmission dynamic 
effects are likely to be important, particularly when considering the effect of vaccination (since 
vaccination can affect other cohorts besides those vaccinated). Hence, we would recommend that 
future cost-effectiveness tool comparison exercises include dynamic models. 
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Introduction: Rotavirus is the most common cause of severe diarrhoea worldwide. Vietnam is situated 
in the region of high rotavirus infection incidence and eligible for financial support to introduce rotavirus 
vaccines into the Expanded Program of Immunization (EPI) from the GAVI. This study was designed to 
assess the cost-effectiveness of rotavirus immunization in Vietnam, explicitly the use of Rotateq® and to 
assess the affordability of implementing universal rotavirus immunization based on GAVI-subsidized 
vaccine price in the context of Vietnamese healthcare system for the next 5 years. 
Methodology: An age-structured cohort model was developed for the 2009 birth cohort in Vietnam. 
Two strategies were compared: one being the current situation without vaccination, and the other being 
mass universal rotavirus vaccination. The time horizon of the model was 5 years with time cycles of 1 
month for children less than 1 year of age and annual analysis thereafter. Outcomes included mild, 
moderate, severe cases and death. Multiple outcomes per rotavirus infection are possible in the model. 
Monte Carlo simulations were used to examine the acceptability and affordability of the rotavirus 
vaccination. All costs were expressed in 2009 US$.  
Results: Rotavirus vaccination would not completely protect young children against rotavirus infection 
due to partial nature of vaccine immunity, however, would effectively reduce severe cases of rotavirus 
by roughly 55% during the first 5 years of life. Under GAVI-subsidized vaccine price (US$ 0.3/dose), the 
vaccine cost would amount to US$ 5.5 million per annum for 3-dose of the Rotateq® vaccine. In the 
base-case, the incremental cost per quality-adjusted-life-year (QALY) was US$ 665 from the health 
system perspective, much lower than per-capita GDP of ~ US$ 1,152 in 2009. Affordability results 
showed that at the GAVI-subsidized vaccine price, rotavirus vaccination could be affordable for 
Vietnamese health system. 
Conclusion: Rotavirus vaccination in Vietnam would be a cost-effective health intervention. Vaccination 
only becomes affordable if the country receive GAVI’s financial support due to the current high market 
vaccine price. Given the high mortality rate of under-five-year children, the results showed that rotavirus 
immunization is the “best hope” for prevention of rotavirus-related diarrhoeal disease in Vietnam. In the 
next five years, Vietnam is definitely in debt to financial support from international organizations in 
implementing rotavirus immunization. It is recommended that new rotavirus vaccine candidates be 
developed at cheaper price to speed up the introduction of rotavirus immunization in the developing 
world in general. 




Diarrhoea is a leading cause of child mortality. Globally, around 1.8 million children under the age of five 
die from diarrhoeal-related diseases per year and rotavirus has been identified as the most common 
cause of severe diarrhea [1,2]. Rotavirus infection has been reported to be responsible for more than 2 
million hospitalizations worldwide and roughly 527,000 deaths annually [3]. A large share of the 
mortality and morbidity occurs in developing countries, such as Vietnam [4]. 
Vietnam was one of the two countries in Asia, besides Bangladesh, where the efficacy of the 
pentavalent rotavirus vaccine, RotaTeq®, was assessed in 2009 under a joint partnership between the 
PATH Rotavirus Vaccine Program and Merck [4]. A major outcome of this clinical trial was the 
establishment of vaccine efficacy against severe disease at 48.3% (95% CI 22.3%-66.1%) in Asia [4] or 
63.9% (95% CI 7.6%-90.9%) in Vietnam. This supported the WHO’s expanded immunization 
recommendations to promote the global use of rotavirus vaccines. Notably, Vietnam established 
sentinel hospital surveillance to assess the burden of rotavirus already back in 1998 [5]. This 
surveillance network later served as a model for 8 other countries in the Asian Rotavirus Surveillance 
Network [5,6].  
Up to now, only two cost-effectiveness studies on rotavirus immunization have been conducted in 
Vietnam [7,8], confirming that implementing rotavirus vaccination in the Expanded  Programme on 
Immunization (EPI) would be a cost-effective health-care intervention. However, these studies only 
evaluated the use of the monovalent RotarixTM vaccine while ignoring the possible use of the 
pentavalent rotavirus vaccine in the EPI. Additionally, these previous studies did not account for 
between-dose vaccine efficacies and used vaccine efficacy data, which was done in other countries 
rather than Vietnam. 
Considering the limitations of both studies, we performed a cost-effectiveness analysis on rotavirus 
immunization in Vietnam focusing explicitly on the use of RotaTeq® as one of the recommended 
vaccines to be introduced into countries’ EPI. A major advantage of this approach is that it allows us to 
utilize the most updated and recently released results on RotaTeq® vaccine efficacy, which was 
conducted in Vietnam [4]. We applied a cost-effectiveness model developed by University of Groningen, 
but different from previous studies using this model [9,10], we additionally assessed the affordability of 
implementing universal rotavirus immunization based on the GAVI-subsidized price and market price in 
the context of the Vietnamese healthcare system for the next 5 years [11]. Finally, as a novel data 
source we included publications and reports written in the Vietnamese language, thus incorporating 
literature that is not internationally accessible and was not previously applied in the models. 
ZMethods 
Model 
We applied the CoRoVa model (the Concensus Model on Rotavirus Vaccination) developed by 
University of Groningen for our analysis [10], see Figure 1. This model has been used previously to 
calculate the cost-effectiveness of rotavirus vaccination for both developing and developed countries 




capture more than 1 infection per child and to account for waning immunity, maternal protection against 
infection through breast feeding, and herd immunity [9]. In detail, we populated the Vietnamese 2009 
birth cohort of 1,485,000 [12] in this age-structured cohort model and applied a 5-year time horizon with 
time cycle of 1 month for children less than 1 year of age and annually thereafter. Health outcomes from 
this model were classified by the four levels of severity of rotavirus-related diarrhoea: mild, moderate, 
severe and death. In particular, severe cases refer to rotavirus-related cases that require hospitalization. 
Mild and moderate cases are assumed to require home-treatment and outpatient visits to a health clinic, 
respectively. This classification is in accordance with an earlier published study [2]. The model is 
programmed in Microsoft Excel 2010. For probabilistic sensitivity analysis, the CoRoVa model uses the 
@RISK 4.5.4; Pallisade 2011, Newfield, NY.  
 
Figure 1 Decision analytic model for estimating the cost-effectiveness of universal rotavirus vaccination 
in Vietnam 
Epidemiology 
We obtained data on the cumulative age distribution of severe cases due to rotavirus gastroenteritis in 
Vietnam from the afore-mentioned sentinel surveillance study on disease burden of rotavirus carried out 
in the country [5,6]. Since similar data were not available for rotavirus cases rated as mild, moderate or 
rotavirus-related mortality, we assumed the same cumulative age distribution as for severe cases for the 
exact computation of the estimated number of mild, moderate, and deaths by age groups. 
 
Computation of rotavirus-related deaths 
The total number of rotavirus-associated deaths among children aged < 5 years in 2009 was estimated 
by applying the WHO’s specific data on rotavirus-related mortality among <5-year children to the birth 
cohort in Vietnam [13], see Figure 2. The number of age-specific deaths was computed by applying the 
age distribution to the total rotavirus-associated deaths. Age-specific rotavirus-associated mortality was 
then calculated by dividing the age-specific deaths by the number of children in each different age 
group, see Table 1.  
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Calculation of severe cases 
The age-specific number of rotavirus-associated severe cases was estimated by combining the number 
of deaths and the ratio between rotavirus-related deaths and hospitalizations of 1:31, according to the 
two previous Vietnamese studies [8,14],see Figure 2. The age-specific rate of severe cases was 
calculated by dividing the age-specific severe cases by the number of children in each age group, see 
Table 1. 
 
Calculation of moderate cases 
Numbers of moderate cases among under-5-year Vietnamese children were estimated by applying the 
ratio between rotavirus-related deaths and visits of 1:97 according to earlier studies [7,8], see Figure 2. 
The age-specific rate of moderate cases was calculated by dividing the age-specific moderate cases by 
the number of children in each age group, see Table 1. 
 
Calculation of mild cases 
No data were available on the number of Vietnamese cases among children under five-years with mild 
diarrhoea. Therefore, we estimated rotavirus-related mild episodes using data from an earlier study [2] 
together with information obtained from the Ministry of Health in Vietnam and expert opinions of local 
paediatricians [15]. The rate of age-specific mild cases was calculated similarly as for moderate cases, 
see Table 1. 
 
 




Age in years Age in months Mild Moderate Severe Mortality rate 
- 0 0.08830 0.00996 0.00217 0.000103 
- 1 0.08838 0.00997 0.00217 0.000103 
- 2 0.08847 0.00998 0.00217 0.000103 
- 3 0.30643 0.03458 0.00752 0.000358 
- 4 0.30673 0.03461 0.00752 0.000358 
- 5 0.30703 0.03464 0.00753 0.000359 
- 6 0.64997 0.07334 0.01594 0.000759 
- 7 0.65061 0.07341 0.01596 0.000760 
- 8 0.65125 0.07349 0.01598 0.000761 
- 9 0.75868 0.08561 0.01861 0.000886 
- 10 0.75942 0.08569 0.01863 0.000887 
- 11 0.76017 0.08578 0.01865 0.000888 
1 12 0.34014 0.03838 0.00834 0.000397 
2 24 0.06863 0.00774 0.00168 0.000080 
3 36 0.02718 0.00307 0.00067 0.000032 
4 48 0.00889 0.00100 0.00022 0.000010 
5 60 0.00889 0.00100 0.00022 0.000010 
 
Table 1 Age-specific rotavirus-associated cumulative incidence rate 
 
Vaccine efficacy, waning immunity and between-dose efficacy 
Clinical trials on RotaTeq® vaccine efficacy carried out in Vietnam showed that vaccine efficacy against 
rotavirus-related severe cases was estimated to be  63.9% (95% CI 7.6-90.9) in Vietnam after two-year 
post vaccination [4]. The analysis showed that vaccine efficacy against severe cases was (72.3% (95% 
CI -45.2-97.2) during the first full season after vaccination and 64.6% (95% CI 47.7-93.9%) during the 
second full season [4]. Based on the difference in efficacy between first and second rotavirus seasons 
post-vaccination, we conservatively assumed that vaccine efficacy would exponentially decrease by 
11% per year starting after the first year (waning).  
No specific clinical data on RotaTeq® vaccine efficacy against mild or moderate rotavirus-related cases 
are available for the population living in Asian developing countries.  For moderate cases, we used the 
RotaTeq® vaccine efficacy ratio between clinical visits and hospitalizations as published by Ruiz-
Palacious et al (86% and 95.8%, respectively) [16]. Using this ratio and vaccine efficacy against severe 
cases (63.9%) in Vietnam, we subsequently calculated vaccine efficacy against moderate cases 
Vietnam (57.4%) as: (0.86/0.958)*0.639*100%. Vaccine efficacy against mild cases (52%) was taken 
from the literature [17-23], see Table 2. We conservatively assumed that vaccine efficacy against mild 
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and moderate cases would decrease at the same rate as for severe cases from the first to the second 
season.  
To estimate between dose efficacy for a 3-dose RotaTeq® vaccine, we utilized data from a recent study 
on this subject, where the rates of combined hospitalizations and emergency visits (ED) between doses 
1 and 2, and between doses 2 and 3 were reported at 82% (95% CI: 39-97%) and 84% (95% CI: 54-
96%), respectively [24]. Based on this information, we estimated vaccine efficacy against severe 
disease between doses 1 and 2 at 52.4% (0.82*63.9%) and between doses 2 and 3 at 53.7% 
(0.84*63.9%). Again, we conservatively applied the same rate for estimating between-dose efficacies for 
mild and moderate cases.  
For vaccine coverage, we assumed that RotaTeq® vaccine would be administered at the same time with 
Diptheria-Polio-Tetanus (DPT) vaccine in Vietnam (at 2,4 and 6 months). Therefore, the DPT vaccine 
coverage of 93% would also be applicable for the RotaTeq® vaccine [25], see Table 2. 
QALY losses 
As there are no data available on quality-of-life losses in Vietnam due to rotavirus infection, we applied 
the QALY losses in affected infants and children provided by a number of comparable studies 
[17,19,20,26] (Table 2). A under-5-years-old child normally requires at least one care giver (e.g., one 
parent) to take care when she/he is infected with rotavirus. In severe cases, even two care-givers (e.g., 
two parents) would be needed to take care for the sick child. In the base-case analysis, we did not 
include the QALY loss of caregivers. In sensitivity analysis, the QALY losses by caregivers were taken 
from earlier work [10]. 
 
Sensitivity and scenario analyses 
We performed several sensitivity analyses in the study including univariate, multivariate, scenario-
analytic, probabilistic approaches and affordability analysis. 
 
Univariate sensitivity analyses were performed to explore impacts of different model input parameters 
on cost and health outcomes of rotavirus vaccination. We selected several parameters for examination 
by varying the value of one parameter by 25% while other parameters remained constant at their base-
case value.  
Several scenario analyses were analysed, including (i) base-case analysis where no QALY losses of 
care-giver is considered, (ii) inclusion of QALY losses of one care-giver and (iii) inclusion of QALY 
losses of two care-givers were performed.  
Probabilistic sensitivity analyses (PSA) were performed by running 5000 Monte Carlo simulations using 
@RISK 4.5.4; Pallisade 2011, Newfield, NY. Distributions associated with input parameters are shown 
in Table 2 [27]. The PSA results are subsequently presented in cost-effectiveness acceptability curves 
(CEACs) from a societal perspective for all scenarios. We then evaluated affordability (only shown for 
the base-case analysis) based on the joint distribution of simulated incremental costs and health gains 




financial resources on vaccination. The curve visualizes affordable probabilities for a vaccination 
program given various budgetary levels while also taking into account the uncertainty of all parameters. 
Affordability analyses were performed under the assumption that childhood vaccination programs were 
indivisible, which implies that it could not be performed for a fraction of infants. This is realistic as in 
practice all vaccines implemented in the EPI in Vietnam are given to every child [28].   
Costs 
Direct treatment costs, and indirect costs incurred due to rotavirus-associated mild, moderate and 
severe cases were retrieved from a cost study previously conducted in Vietnam [7]. The analyses were 
carried out from both the healthcare (including only direct medical costs) and the societal (both direct 
medical costs, direct non-medical costs and indirect costs) perspectives. These cost items were 
collected in 2005, and we converted them to 2009 US$ (as reported in Table 2) to reflect current price 
levels, using the underlying growth rate in consumer prices. 
 
Outcome measures 
We calculated the incremental cost-effectiveness ratio (ICER) per QALY for the base-case and various 
scenarios and sensitivity analyses consistently comparing vaccination vs. no vaccination. Additionally, 
we examined the impacts of GAVI-subsidized and market RotaTeq® vaccine prices on ICER values. We 
used the WHO’s definition on cost-effectiveness of health interventions to evaluate results of rotavirus 
vaccination in Vietnam [29]. 
Description Base case value Distribution References 
Vaccine coverage 93% Triangular (90%; 93%; 98%) [25] 
Vaccine Efficacy 
Severe infections hospitalisation (2-
year average, see Methods) 63.9% Lognormal mean 0.639 (SE 0.2125) [4] 
Waning rate per year 
(exponential decrease) 11% NA [4]; calculated 
Moderate infections requiring a clinic 
visit (assumption b, see Methods) 57.4% Lognormal mean 0.574 (SE 0.0819) 
[4; 16]; 
calculated 
Waning rate per year 
(exponential decrease) 11% NA Assumption 
Mild infections treated at home (first 
year) 52% Lognormal mean 0.52 (SE 0.0791) [17-23] 
Waning rate per year 
(exponential decrease) 11% NA Assumption 
Rotavirus-related epidemiological parameters 
Mild 1,318,001 Normalised mean: 1,318,001 (90%CI; 1,317,366-1,318,636)a [2; 15] 
Moderate 148,720 Normalised mean: 148,720 (90%CI; 148,116-149,324) [7; 8] 
Severe 32,331 Normalised mean: 32,331 (90%CI; 32,038-32,624)a [8; 14] 
Deaths 1,540 Not varied [13] 
Age-dependent rotavirus-related proportion 
Mild, Moderate, Severe  Dirichlet  [27] 
QALY losses 









Triangular (using 25% lower and 
upper) 
[17; 19; 20; 
26] 
 
Total direct costs per case (healthcare perspective) 
Mild 4.64 Triangular (4.52; 4.64; 4.77) [7] 
Moderate 5.07 Triangular (4.86; 5.07; 5.27) [7] 
Severe 35.28 Triangular (28.80; 35.28; 41.76) [7] 
Total direct and indirect cost per case (societal perspective) 
Mild 8.65 Triangular (7.51; 8.65; 9.79) [7] 
Moderate 10.68 Triangular (10.29; 10.68; 11.08) [7] 
Severe 44.04 Triangular (40.65; 44.04; 47.43) [7] 
Total vaccination and administration cost per child 
3-dose, GAVI subsidized price 1.11 Alternative scenario [11; 42] 
3-dose, Market price 15.21 Alternative scenario [43] 
Discount rate 3%  Unvaried [30] 
NA: not applicable; SE: standard error 
a Square root transformation was applied. 
b(RotaTeq® EDV efficacy/RotaTeq® hospitalization efficacy (reference)) x RotaTeq® hospitalization efficacy for developing Asian countries) 
= (86%/95.8%)*63.9%= 57.4% 
 




Detailed results of the base-case scenario are presented in Table 3. Assuming 93% coverage, 
vaccination of a birth cohort of 1,485,000 would reduce rotavirus-related mild, moderate, severe cases 
and deaths by 44%, 49%, 54% and 54%, respectively. This reduction corresponds to a gain of 25,825 
discounted QALYs and a saving of US$ 6.4 million in burden cost-of-illness due to rotavirus infection.  
At the per-dose-GAVI-subsidized price of US$ 0.3 for the RotaTeq® vaccine, rotavirus immunization 
would become a cost-saving strategy. Vaccination would always be cost-saving when the RotaTeq® 
vaccine price <= US$ 0.9/dose and <=US$ 1.6/dose from the health system and societal perspectives, 
respectively. In contrast, at the per-dose market price of US$ 5, vaccination is not cost saving and 
results in an ICER per QALY of US$ 665 and US$ 556 from the health system and societal 
perspectives, respectively. These cost-effectiveness values are still less than the 2009 Vietnamese 
GDP-per-capita of US$ 1,159 [12], suggesting that rotavirus immunization is a cost-effective health 
intervention for the Vietnamese healthcare system according to WHO’s definition for cost-effectiveness, 
see Table 3. 
Univariate sensitivity & scenario analyses 
The impacts of parameter changes on the results are presented in a Tornado diagram (Figure 3). Cost-




cases, rotavirus-related mortality. In contrast, total hospitalization cost and outpatient visit cost have 
minimal impact on the cost-effectiveness outcomes. Figure 4 shows that up to US$ 3.5 per dose, there 
were very small changes in the ICER value per QALY from the societal perspective. 
 
 
No vaccination Vaccination a Difference 
Cases b 1,499,052 829,786 669,266 
Mild 1,318,001 738,399 579,602 
Moderate 148,720 76,528 72,193 
Severe 32,331 14,859 17,471 
Deaths 1,540 708 832 
Total QALYs lost c 48,177 22,352 25,825 
Total cost-of-illness a, c $,14,139,897 $,7,699,471 $,6,440,426 
 
Vaccine pricing scenarios GAVI-subsidized price ($0.3/dose) Market price ($5/dose) 
ICER per QALY (healthcare perspective) c cost-saving $665 
ICER per QALY (societal perspective) c cost-saving $556 
a





Table 3 Results from the base-case analysis 
 
 
Figure 3 Results of univariate sensitivity analyses showing the ranges of ICERs for universal newborn 
vaccination against rotavirus compared to no vaccination in Vietnam (societal perspective) 





Figure 4 Diagram showing how vaccine pricing impacts on the ICER value under different assumptions 
for QALY-losses from the societal perspective  
 
 
Probabilistic sensitivity analyses 
Cost-effectiveness acceptability curves (CEACs) 
Results of probabilistic sensitivity analyses from societal perspective are presented in Figure 5. The 
CEACs showed that at the threshold ICER per QALY of US$ 556 (the base-case value of ICER per 
QALY from the societal perspective), the probability for the vaccination program to be cost-effective 
would be 67.7%, 70.2% and 73.7% for scenarios with no care giver, one care giver and two care givers, 
respectively. If a US$ 1,000 threshold per QALY was applied (<1x per-capita-GDP), still >90% of 
simulations resulted in acceptable ICERs for all scenarios. If a threshold of US$ 3,000 per QALY was 
applied (<3x per-capita-GDP), >98% of simulations resulted in acceptable ICERs for all scenarios. 
Although the CEACs help to summarize the uncertainty surrounded the cost-effectiveness possibility of 
a rotavirus vaccination program, the curve is unable to inform the decision-makers regarding resources 
to fund vaccination programs, which remains a crucial factor for the Vietnamese healthcare sector and 





Figure 5 Cost-effectiveness (C-E) acceptability curve showing the probability that universal newborn 
rotavirus vaccination in Vietnam is cost-effective at different cost-effective threshold values (societal 
perspective)  
Affordability curve 
Figure 6 presents affordable scenarios where rotavirus vaccine is subsidized by the GAVI and when it is 
purchased at the market price of US$ 5 per dose. The results show that under GAVI-subsidy, rotavirus 
vaccination would always be fully implementable when the budget exceeds US$ 5.5 million. In contrast, 
vaccination would not be affordable with a budget ≤ US$ 1.5 million. Under the market scenario, 
vaccination would only be implementable at the minimum budget of US$ 10 million, which is almost 2 
times higher than the needed budget for full vaccination under the GAVI-subsidy scenario. Rotavirus 
vaccination would always be implementable when the budget exceeds US$ 22 million. 
 
 
Figure 6 Affordability curves showing the probability that rotavirus vaccination is affordable (for birth 
cohort of 1,485,000) as a function of budget constraint (societal perspective and no care giver QALY-
losses assumed) 




Our economic analysis indicates that inclusion of rotavirus vaccination in the EPI in Vietnam would be 
cost-effective or even cost-saving depending on the cost of the vaccine. At the base-case GAVI-
subsidized price of US$ 0.3 per dose, rotavirus vaccination would be cost-saving from both analyzed 
perspectives (health care and societal). Rotavirus vaccination would reduce the number of rotavirus-
related cases and deaths by approximately 50%.  
 
From the societal perspective, at the current market price of US$ 5 per dose, rotavirus vaccination 
would be a cost-effective intervention according to the WHO’s criteria for cost-effectiveness [29]. 
However, being cost-effective does not automatically mean that the intervention would be affordable for 
the Vietnamese healthcare. Indeed, when parameter uncertainties are taken into account, affordability 
analyses revealed that there was a big difference in required funds for rotavirus vaccination in Vietnam 
under the GAVI-subsidized and market situations. In particular, at the market vaccine price of US$ 5 per 
dose, a fully implemented vaccination program would cost US$ 22 million, while it would only cost US$ 
5.5 million under the GAVI-subsidized price of US$ 0.3 per dose. Practically speaking, in 2009, total 
government spending in Vietnam on EPI activities was approximately US$ 8 million [30]. Compared to 
the total government health budget, the required investment by the government for universal rotavirus 
vaccination in case of no GAVI support would be more than triple. This implies that if the Vietnamese 
government has to fully finance vaccination by itself, implementation would be highly unrealistic. A 
possible solution would be to reduce rotavirus vaccine price either through the development of new 
generations of less expensive rotavirus vaccines or through subsidy by international organizations for 
developing countries like Vietnam. Next to possibilities of GAVI-subsidized programs, in fact, the 
Vietnamese Ministry of Health is testing a vaccine against rotavirus, which is domestically 
manufactured. Clinical trials are being carried out in Vietnam [31-36].   
Our study confirms that rotavirus vaccination using the Rotateq® brand is cost-effective in Vietnam from 
both societal and health system perspectives. This is congruent with other studies in high-endemic and 
intermediate-endemic countries [8,37-41]. Our study also emphasizes the important role of donors such 
as the GAVI in financing vaccination programs. Indeed, Vietnam is still a developing country and relies 
heavily on external financial support. To assist a high-endemic country in implementing vaccination 
programs, financial support is indispensable. Our results may be useful to help Vietnamese government 
to apply for further financial support from the GAVI. 
Compared to other studies conducted in Vietnam on the same subject [7,8], our results are similar by 
concluding that rotavirus vaccination is a cost-effective public health intervention. The results support 
the WHO’s recommendations on universal rotavirus immunization worldwide. However, our study also 
differs from previous studies in Vietnam. Firstly, we used RotaTeq® vaccine instead of Rotarix™ vaccine 
in the analysis. The advantage of this was the utilization of the most updated local RotaTeq® vaccine 
efficacy data on severe cases, which was just completed in Vietnam. Using these data instead of the 
general efficacy data from other regions of the world probably gives more reliable estimates.  Another 




ability to capture multiple infections per infected child, waning immunity as well as the impacts of breast 
feeding though the latter was not yet considered in our current analysis due to data availability. 
Additionally, the application of this model was supportive of another study initiated by the WHO, which 
offers guidance for design and/or selection of a model for adaptation to individual (low-income) 
countries who want to conduct cost-effectiveness analyses [9]. Finally, our study explored the impact of 
caregivers by considering scenarios where QALY losses of caregivers were included. This was not 
done in any earlier studies on the same subjects in Vietnam. The importance of including QALY losses 
of caregivers into our study was because a sick child normally is cared by a caregiver (e.g., parents, or 
family members). Other studies tend to ignore the impacts of caregivers. Carrying such type of analysis, 
we explored the important role of care-givers.  
Our study, however, does encounter some limitations. The first limitation is the application of a static, 
step-wise model of the disease instead of applying a dynamic continuous model. In particular, the latter 
type of models allows the inclusion of herd immunity effects in the analysis. In the lack of data and 
information, herd immunity was not considered in the study. However, had herd immunity been included 
in the analysis, impacts of rotavirus vaccination would have been greater and favorable cost-
effectiveness or even cost-saving would only have been further strengthened. The second limitation is 
the lack of data on vaccine efficacy for mild and moderate cases. We used data from various studies 
conducted in developed countries, thus the vaccine efficacy might be overestimated for a developing 
country. However, if the vaccine efficacy would be lower, rotavirus vaccination would prove to be even 
more cost effective. The third limitation is the lack of rotavirus epidemiology data in Vietnam. There was 
much estimation in different stages of rotavirus in the study. However, even at this high epidemiology, 
rotavirus vaccination was proved to be cost-effective. The fourth limitation is the utilization of treatment 
costs. The treatment cost of rotavirus-related diarrhoea was collected in 2005 and the cost must have 
changed in 2009. To overcome this, we have adjusted the cost by using the CPI to make it more 
updated. Indeed, rotavirus vaccination would be more cost-effective when the treatment cost of the 
disease was higher.  
Our study shows that vaccine price was a crucial factor on the cost-effectiveness results and a heavy 
burden for any developing country’s government in introducing a new vaccine. The current available 
market price (US$ 5 per dose) appears to be very expensive for the Vietnamese government 
suggesting that new generations of less costly rotavirus vaccines be developed or financial supports 
from the GAVI a decisive factor for the Vietnamese health system at least in the next 5 years.  
The results of our cost-effectiveness analysis on the use of RotaTeq® vaccination in Vietnam should 
encourage health policy makers as well international donors, who are committed in supporting 
developing countries in combating infectious diseases in children as well as of supportive of the WHO’s 
recommendation on universal rotavirus vaccination.  
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General Discussion, Conclusions and Future Perspectives 
ZDiscussion 
The emphasis of this thesis is on economic evaluations of universal childhood immunization strategies 
against infectious diseases implemented within the Expanded Programme on Immunization EPI in 
developing countries with the focus on Vietnam. Two infectious diseases, hepatitis B and rotavirus were 
selected as examples. The former represents the current immunization strategy within the EPI and the 
latter represents the recommended vaccination strategy for the future. Adding new vaccines to routine 
infant immunization schedules is a financial challenge for Vietnam, requiring institutional and policy 
changes at the national level. In the context of the scarcity of resources, there is a need for prioritization 
of vaccines, planning to secure their sustainable supply, information on their affordability, assessment of 
their cost-effectiveness, and support from international organizations in providing funding for vaccination 
programs. 
The research presented in this thesis explores the contribution of economic evaluations and provides 
tools to address some of the afore-mentioned issues. Analyses of this sort are still limited for developing 
countries and therefore considered valuable for the progress in the field. Hence, findings of this 
research may be useful for developing countries in formulating appropriate public health policies, 
mobilizing financial resources for vaccination programs and making plans for vaccines sustainability.  
The detailed findings are summarized and discussed below.  
 
Cost-effectiveness analyses   
In this thesis, the overall emphasis is on the different modeling techniques, which can be used to 
estimate the cost-effectiveness of (preventive) interventions against infectious diseases. In particular, 
the cost-effectiveness analyses against hepatitis B and rotavirus consist of both epidemiological and 
economic aspects and modeling of incidence numbers and costs are discussed in detail in Chapters 4 
and 7, respectively. In Chapter 4, a Markov model for chronic hepatitis B infection was designed and in 
Chapter 7, an existing age-structured cohort model was adopted for the Vietnamese birth cohort. 
Though the applied models were static and did not yet account for the benefit of herd immunity of 
vaccination, such analyses are very useful in developing countries, in particular in view of their current 
scarcity. In fact, the cost-effectiveness analysis on universal childhood hepatitis B immunization 
presented in Chapter 4 was the first study ever carried out in Vietnam. It provides useful information for 
the Vietnamese health policy-makers on the performance of hepatitis B vaccination in the country. The 
modeling technique applied in that study could eventually be applied for economic evaluations of other 
vaccination programs within the EPI in Vietnam and in other (neighboring) countries. Chapter 7 presents 
a comparable assessment for the recommended rotavirus immunization in Vietnam. However, we did 
not design a disease Markov model ourselves for this study but applied an existing age-structured 
cohort model for the Vietnamese birth cohort that had been specially designed by our research group to 
be applied for developed countries. The overall aim was to explore the benefit for developing countries 
in utilizing existing disease models for their future research. This matter has been discussed in a 
comparative study on cost-effectiveness models designed for rotavirus vaccination in developed 
countries in Chapter 6. One of the strengths of the study in Chapter 7 is the utilization of the most 
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updated data on vaccine efficacy, which was actually carried out in Vietnam. This enabled us to provide 
more rigorous cost-effectiveness results on rotavirus vaccination than other similar studies on the same 
subject ever done in Vietnam (1, 2).  
 
Budget impacts and affordability analyses 
To assist health policy makers in budget preparation for various vaccination programs in Vietnam, 
besides conducting cost-effectiveness analyses of respective vaccination strategies, we performed 
budget impact and affordability analyses. The argument for doing this was that many healthcare 
interventions could be cost-effective but might not be affordable due to high expenses (e.g., high 
vaccine price). Indeed, for a developing country such as Vietnam, one of the most crucial factors for the 
government to decide whether to introduce a new vaccine or to extend vaccination to a larger 
population depends heavily on the budget availability. Hence, we presented a financial tool to assist 
health decision-making processes by running Monte Carlo simulations to account for uncertainty of all 
input factors of a vaccination program. The results of simulated iterations are presented in affordability 
curves and cost-effectiveness affordability curves based on the theory by Sendi & Briggs [3]. This 
methodology was applied in the studies described in Chapters 4 and 7. Budget impact and affordability 
analyses will definitely help inform decision makers on the level of required budgets for vaccination 
while facing the scarcity of resources. This methodology was, however, done under the assumption that 
a vaccination program was indivisible, meaning that vaccination cannot be administered to only a 
fraction of infants based on the arguments that this would be inequitable. This was reasonable in 
Vietnam as vaccination within the EPI is given free to every child. Results of our analyses will inform 
health managers of the minimum required budget for a vaccination program to be implementable and 
the maximum budget level at which vaccination would be fully implemented. The findings from the 
affordability analyses will be useful for governments in developing countries in making appropriate 
financial plans for different vaccination strategies and applying for additional funds from international 
organizations, such as the Global Alliance of Vaccines and Immunization (GAVI), that are committed to 
promote universal vaccination in the developing world.  
 
Cost-of-illness 
Treatment cost of a disease is, one of the two most important components for any cost-effectiveness 
analysis beside epidemiological data. However, data on this issue are still not yet available for almost all 
diseases in Vietnam and in most developing countries. To overcome this limitation, we carried out a 
cost-of-illness study to estimate the burden of chronic hepatitis B in Vietnam as an example, which is 
the subject of Chapter 3. The overall aim was to provide a methodology in estimating the burden of 
disease in the context of limited data available and to inform health policy-makers of the economic 
burden of the chronic hepatitis B to the Vietnamese society. Indeed, cost-of-illness research on hepatitis 
B has been done in various Asian countries and different methodologies were introduced [4-7]. 
However, these studies were conducted in countries, where an established recording system of patients 
and costs had been developed. In contrast, data recording is still an emerging and serious issue in 
Vietnam due to the poor facilities and infrastructure. By conducting the cost-of-illness of chronic 




estimation. We also tried to provide plausible explanations for the uncertainty surrounded cost 
estimations by conducting various sensitivity analyses (e.g., one way, two-way sensitivity analyses) to 
give a range within which the cost could be varied. This approach could potentially be applied for 
estimating the burden of many other diseases in countries where there is limited available data like 
Vietnam. 
Regarding the treatment cost of rotavirus, we fortunately could make use of cost data derived from an 
existing study carried out in Vietnam [1]. However, to make the cost up-to-date, we adjusted the 
treatment cost of rotavirus infection by using the consumer price index.  
The role of the GAVI and the international community 
Throughout the research, the important role of the GAVI in providing financial support is indispensable. 
This is mentioned in Chapters 1 and 5 where hepatitis B and rotavirus immunization in developing 
countries were extensively reviewed. The crucial role of the GAVI is furthered explored in the 
consequential Chapters 3 and 7 where cost-effectiveness analyses of vaccination in Vietnam were 
carried out. In particular Chapter 7 went further to compare the required budget for rotavirus vaccination 
based on market vaccine and GAVI-subsidized prices. It was concluded that without the GAVI support 
the government of Vietnam might have to spend up to US$ 25 million for a full immunization program 
against rotavirus, while under the GAVI support, this necessary budget goes down to US$ 6 million. 
This is significant for Vietnam where healthcare programs are competing among limited resources. 
Indeed, statistical data from the Ministry of Health show that in 2009 the total expenditure for all EPI 
activities in Vietnam was approximately US$ 8 million [8]. Budget analyses revealed that the necessary 
funding for universal vaccination against hepatitis B and rotavirus in Vietnam would exceed the total 
budget given for all EPI activities. The results of our research would justify the support from the GAVI 
and provide positive health-economic evidences for international organizations, which are committed to 
help developing countries. 
 
Strength of our research 
Our research has embarked on different types of economic evaluations such as cohort-based, Markov-
based cost-effectiveness analyses, affordability analyses, which as previously mentioned are still very 
limited in Vietnam. The application of advanced modeling techniques such as the application of Monte 
Carlo simulations, one-way or multivariate sensitivity analyses in our research helped clarify and 
understand the uncertainty in health economic evaluations and provide a reasonable explanation for the 
results obtained. The techniques applied may become useful tools for economic evaluations of other 
public health interventions in Vietnam and other developing countries, where the epidemiology of 
diseases is similar. They are discussed in details in Chapters 3, 4, 6 and 7.  
Notably, health economics is still a new research area in Vietnam though it has been well recognized in 
developed countries. The embarkment of our research on this topic should provide insightful information 
for Vietnamese policy makers on assessing current and future public health programs and encouraging 
research institutions to promote health economic research. It eventually could become a strong and 
efficient evaluation tool for health care decision makers in evaluating the outcomes and making financial 
plans for health care programs.  
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Weaknesses of our research 
While working on this research, one the most challenging and difficult issues we encountered was the 
poor quality and availability of both epidemiology and economic data, which might have affected the 
outcome of our research. However, this limitation cannot be circumvented, but should be coped with as 
good as possible. In reality, epidemiological data on hepatitis B infections has not yet been well 
recorded in Vietnamese hospitals due to the infrastructure. We could not retrieve data on disease 
progressions among different stages of chronic hepatitis B, thus, we had to use epidemiological data 
from other countries, where the hepatitis B epidemiology is more or less similar to Vietnam [9-13]. This 
is justified because disease progression rates appear to be stable across populations. The same 
situation was encountered for rotavirus disease. Though the rotavirus surveillance system was 
established in Vietnam in 1998 [14], there was no formal system to report rotavirus-related cases (e.g., 
mild, moderate, severe) nationally or regionally. These limitations suggest a better established 
surveillance system for diseases to be established in the country. This will not only benefit research but 
also provide the Ministry of Health with more updated disease burden information for the purpose of 
prevention and control. Additionally, better epidemiological surveillance would enable more rigorous 
estimation of the treatment cost of diseases.  
The use of static models instead of dynamic models in the modeling studies (Chapters 4 and 7) resulted 
in the negligence of herd-immunity effects and consequently leads to the underestimation of cost-
effectiveness of vaccination. However, this can be justified by the lack of epidemiological data in 
Vietnam in particular and in developing countries in general. It would be arguable that if dynamic models 
were applied for health economic evaluations and herd immunity were accounted in our studies, 
vaccination against hepatitis B and rotavirus would become even more cost-effective. 
ZConclusions 
In this thesis, various types of economic evaluations were carried out to assess the impacts of 
vaccination strategies in Vietnam. Besides cost-effectiveness analyses to assess the cost and 
outcomes of universal vaccination against hepatitis B and rotavirus, affordable analyses to estimate the 
budget impacts on the implementation of vaccination and cost-of-illness to estimate the burden of 
disease were also implemented. These types of economic evaluations are very important in Vietnam as 
they are still rarely available especially in the health sector.  Overall, our results show that universal 
childhood immunization in Vietnam is a cost-effective and a “must-do” public health intervention for 
countries, where the epidemiology of hepatitis B and rotavirus is similar and as high like in Vietnam 
(Chapter 4 and 7). The results of this thesis are in line with results that have been carried out in other 
developing countries. These have been discussed and summarized in Chapters 2 and 5. Results of our 
research also strongly support the WHO’s recommendation on universal vaccination against hepatitis B 
and rotavirus [r15].  Additionally, the data generated would assist Vietnamese health policy makers in 
making appropriate financial arrangement and making proper plans on healthcare prioritization. Our 
research also explored different tools and techniques (cost-effectiveness, affordability analyses, cost-of-
illness, static modeling based on Markov- and cohort-based models) in economic evaluations in order to 




Vietnamese EPI (e.g., pertussis, polio, Hib, and so on). This would definitely assist health managers in 
making financial, management plans for healthcare activities. Moreover, the methodologies we 
introduced in this thesis may be useful for health researchers in Vietnamese academic institutions, who 
want to conduct health economic research for other healthcare interventions in Vietnam.  These 
techniques have been discussed in detail in Chapters 3, 4, and 7. Specifically, in Chapter 6 a 
comparative study of several models for evaluating rotavirus vaccination would enables modelers not 
only in Vietnam but also in developing countries to apply existing models in their research. It would 
tremendously save energy, time and resources for researchers in the developing world in carrying out 
high-quality economic evaluations and to quickly learn from experience which has been done in 
developed countries. 
Finally, the findings of the thesis emphasize the important role of international donors in continuously 
providing support to developing countries’ governments in implementing childhood immunization. The 
important support from the international community, among which the GAVI is an active player would 
assist developing countries to achieve the Millennium Development Goals by bring down the under-five 
mortality rate and in combating against infectious diseases (16, 17).  
ZFuture perspectives 
Results of our studies have illuminated new directions for future research. Dynamic modeling of 
vaccination against infectious diseases that provide more rigorous results of vaccination strategies is 
considered to be very important for developing countries. In addition to universal childhood vaccination, 
possible cost-effectiveness analyses of vaccination strategies, which are targeted not only at children 
but also at adolescents and at-risk population, will show to be very useful for Vietnam. Economic results 
on targeted vaccination may assist the Vietnamese government to consider extending vaccination to 
larger populations such as adolescents in the future. Finally, the use of the economic evaluation tools 
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w SUMMARY y 
Vietnam is a country, where universal childhood immunization has been successfully accomplished 
through the Expanded Programme on Immunization (EPI). Currently, nine routine childhood vaccines 
have been included into the EPI and in the future new vaccines will be added to the program. Vietnam 
has received substantial technical support from the World Health Organization (WHO) and financial 
support from international organizations such as the Global Alliance on Vaccines and Immunization 
(GAVI) for the EPI activities. Thus far, very few cost-effectiveness analyses or economic evaluations on 
childhood vaccination have been conducted in Vietnam despite the importance of health economic 
evaluations in assessing health care interventions. Motivated by this, we decided to carry out cost-
effectiveness analyses on hepatitis B and rotavirus vaccination, representing for under-used and new 
vaccines, respectively. The former is an existing vaccine in the EPI and the latter a newly recommended 
vaccine by the WHO. The goal is to provide concrete health economic evidence to the government and 
to international organizations who commit to provide support to immunization in the developing world. 
In-depth and advanced analyses were carried out on hepatitis B and rotavirus vaccination and are 
described in Part I and Part II of this thesis, respectively. 
In Part I, a comprehensive picture of the cost-effectiveness of hepatitis B vaccination in developing 
countries is presented in a review (Chapter 2). Hepatitis B vaccination was found cost-effective and a 
crucial strategy to prevent hepatitis B infection in the developing world. Further economic evaluations on 
hepatitis B are described in the subsequent two chapters with the focus on Vietnam. Chapter 3 presents 
a cost-of-illness study aiming to estimate the disease burden of chronic hepatitis B infection to the 
Vietnamese society. The study presents a methodology for the cost estimation of a disease in countries 
where underlying data are not always readily available. It was shown that the treatment cost of chronic 
hepatitis B in Vietnam poses a very high financial burden for an average Vietnamese citizen and for the 
country as a whole, where healthcare programs strongly compete among the limited resources. 
Challenged by the economic burden of chronic hepatitis B infection, a cost-effectiveness analysis on the 
vaccination against hepatitis B in Vietnam was subsequently performed (Chapter 4). We applied a 
Markov model and advanced modeling techniques in order to estimate the health impact of vaccination. 
It became obvious that childhood vaccination against hepatitis B is always cost-effective for a high-
endemic country of hepatitis B infection like Vietnam. Budget affordability revealed that hepatitis B 
vaccination is a necessary intervention in Vietnam to hedge expensive treatment costs of chronic 
hepatitis B and to reduce the morbidity and mortality of the disease. 
In Part II, the possibility of introducing the rotavirus vaccine into the Vietnam’s EPI was explored. 
Chapter 5 reviews the results of rotavirus immunization in the developing world. It was concluded that 
rotavirus immunization in developing countries is cost-effective and even potentially cost-saving, 
depending on the rotavirus vaccine price. All countries had expressed the need for external financial 
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support in implementing rotavirus vaccination. However, a major limitation (as presented in the review) 
was the application of simple decision tree models of rotavirus infection, which underestimate the real 
impact of vaccination. To assist developing countries with better but more complex and sophisticated 
models for economic evaluations, we carried out a comparative study on a number of existing disease 
models of rotavirus infection, which have been developed for use in the developed world (Chapter 6). 
The overall aim was to assist modelers in developing countries with adopting adequate existing models 
in order to obtain more rigorous and robust health economic results. For the purpose of illustration, in 
Chapter 7 we applied the CoRoVa model as specified in Chapter 6, by conducting a cost-effectiveness 
analysis on rotavirus immunization for children under five years of age in Vietnam. The  results showed 
that rotavirus immunization could even become a cost-saving strategy in the country, depending on the 
vaccine price, and a rational prevention against diarrhoea-related diseases among children younger 
than five years. We explicitly compared the budget impacts on vaccination based on the market prices 
as well as on the GAVI-subsidized vaccine prices. 
Overall, vaccination against hepatitis B and rotavirus in Vietnam is cost-effective and a crucial strategy 
to prevent hepatitis B and rotavirus infection. The analyses also emphasize the important role of the 
GAVI and other international organizations in expediting vaccination strategies in developing countries 
such as Vietnam where coping with the limited financial resources are a real challenge.  
In conclusion, cost-of-illness, cost-effectiveness and affordability analyses are very useful health 
economic tools to guide decision makers in where to invest the scarce resources. For developing 
countries, where healthcare programs even more strongly compete for the limited resources, it is 
important to make choices based on evidence-based cost-effectiveness analyses. Ultimately, people 




w SAMENVATTING y 
Vietnam heeft middels het Expanded Programme on Immunization (EPI) een succesvol 
vaccinatieprogramma opgezet. Momenteel zijn negen vaccins in het EPI opgenomen en in de toekomst 
zullen nieuw ontwikkelde vaccins worden toegevoegd. Vietnam heeft hier technische ondersteuning 
voor gekregen van de Wereldgezondheidsorganisatie (WHO) en financiële ondersteuning van de Global 
Alliance on Vaccines and Immunization (GAVI). Tot nu toe zijn er nauwelijks economische evaluaties of 
kosteneffectiviteitsanalyses uitgevoerd naar vaccinaties bij kinderen in Vietnam, ondanks het belang 
hiervan. Dit motiveerde ons om kosteneffectiviteitsanalyses uit te voeren voor vaccinaties tegen 
hepatitis B en het rotavirus. Hepatitis B vaccins worden mogelijk te weinig gebruikt, terwijl het rotavirus 
vaccin een nieuw vaccin is. Hepatitis B vaccininatie is een reeds bestaand programma binnen het EPI, 
rotavirus is een voorbeeld van een door de WHO nieuw aanbevolen vaccin om in het EPI op te nemen. 
Ons doel is om concreet bewijs te leveren aan de overheid en aan internationale organisaties die zich 
commiteren aan het steunen van immunisatie in ontwikkelingslanden. Uitgebreide analyses zijn 
uitgevoerd voor hepatitis B en rotavirus vaccinatie en deze zijn beschreven in respectievelijk deel I en 
deel II van dit proefschrift. 
In deel I wordt eerst een compleet beeld van de kosteneffectiviteit van het hepatitis B vaccin gegeven in 
de vorm van een systematisch review (hoofdstuk 2). Hepatitis B vaccinatie werd kosteneffectief 
bevonden en is een strategie gebleken om hepatitis B infecties te voorkomen in ontwikkelingslanden. 
Verdere economische evaluaties voor hepatitis B zijn beschreven in de volgende twee hoofdstukken, 
waarbij we ons richtten op Vietnam. In hoofdstuk 3 wordt een kosten van ziekten studie gepresenteerd 
om de ziektelast van chronische hepatitis B infectie te schatten voor de Vietnamese samenleving. We 
beschrijven een bruikbare methodologie voor de kostenraming van een ziekte in landen waar 
onderliggende data niet altijd direct beschikbaar zijn. De behandelkosten van chronische hepatitis B in 
Vietnam blijken een zeer hoge last te vormen voor de gemiddelde Vietnamees, maar ook voor Vietnam 
als land, waar de programma’s in de gezondheidszorg sterk concurreren om de beperkt aanwezige 
middelen. Uitgedaagd door de economische last die chronische hepatitis B infectie met zich meedraagt, 
hebben we vervolgens een kosteneffectiviteitsanalyse van de vaccinatie tegen hepatitis B in Vietnam 
uitgevoerd. We hebben een Markov-model ontwikkeld en geavanceerde modelleringstechnieken 
toegepast om de impact van de vaccinatie in te kunnen schatten. De resultaten tonen aan dat 
vaccinatie van kinderen tegen hepatitis B altijd rendabel is voor een hoog-endemisch land met hepatitis 
B infectie, zoals Vietnam. De budget-impact analyse liet zien dat hepatitis B vaccinatie ook een 
haalbare interventie is in Vietnam, om hoge behandelkosten van chronische hepatitis B te voorkomen, 
en de morbiditeit en mortaliteit van de ziekte te beperken. 
In deel II van het proefschrift is de mogelijkheid onderzocht om het rotavirus vaccin in Vietnam’s EPI in 
te voeren. Hoofdstuk 5 geeft een overzicht van de resultaten van rotavirus immunisatie in 
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ontwikkelingslanden. De conclusie is dat rotavirus vaccinatie in ontwikkelingslanden kosteneffectief is 
en zelfs potentieel kosten besparend, afhankelijk van de vaccinprijs. Al deze landen hebben echter 
aangegeven financiële steun nodig te hebben voor de implementatie van rotavirusvaccinatie. Een van 
de beperkingen in de studies die tot dusver zijn uitgevoerd is de toepassing van een mogelijk te recht-
toe-rechtaan beslisboommodel voor rotavirusinfectie, waardoor de impact van vaccinatie wordt 
onderschat. Om ontwikkelingslanden te helpen met betere, complexere en meer geavanceerde 
modellen voor economische evaluaties, is een vergelijkende studie naar verschillende bestaande 
ziektemodellen van rotavirus infectie uitgevoerd. Deze modellen zijn ontwikkeld voor gebruik in 
ontwikkelde landen. Het doel is om de gezondheidsautoriteiten in ontwikkelingslanden te helpen met het 
gebruiken van geschikte bestaande modellen om meer valide en robuuste gezondheidseconomische  
resultaten te verkrijgen. Om dit te illustreren hebben we in hoofdstuk 7 het CoRoVa model, zoals 
beschreven in hoofdstuk 6, toegepast door het uitvoeren van een kosteneffectiviteitsanalyse van 
rotavirusvaccinatie voor kinderen jonger dan vijf jaar in Vietnam. Uit de studieresultaten blijkt dat 
rotavirus immunisatie zelfs een kostenbesparende strategie in Vietnam zou zijn, afhankelijk van de 
vaccinprijs en de exacte ziektelast. We hebben expliciet de kosten voor de vaccinatie op basis van de 
marktprijzen vergeleken met die op basis van de door het GAVI-gesubsidieerde vaccinprijzen. 
Vaccinaties tegen hepatitis B en rotavirus in Vietnam zijn mogelijk kosteneffectieve en haalbare 
strategieën om hepatitis B en rotavirusinfectie te voorkomen. De analyses benadrukken ook de 
belangrijke rol van de GAVI en andere internationale organisaties bij het versnellen van de ontwikkeling 
van vaccinatiestrategieën in ontwikkelingslanden zoals Vietnam, waar de beperkte financiële middelen 
de echte uitdaging vormen. 
We concluderen dat analyses naar de kosten van ziekten, kosteneffectiviteitsanalyses en 
haalbaarheidsanalyses zeer nuttige gezondheidseconomische hulpmiddelen zijn voor het adviseren van 
beleidsmakers bij hun keuzes waar de schaarse middelen in te investeren. Voor ontwikkelingslanden, 
waar de gezondheidszorgprogramma's nog sterker concurreren voor de beperkte middelen, zijn keuzes 
op basis van dergelijke evidence-based economische analyses van cruciaal belang. Uiteindelijk zullen 
mensen in ontwikkelingslanden baat hebben bij een dergelijke rationele besluitvorming. 
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